Patent application title: HUMANIZED ANTIBODIES TO LIV-1 AND USE OF SAME TO TREAT CANCER
Inventors:
IPC8 Class: AC07K1628FI
USPC Class:
1 1
Class name:
Publication date: 2020-05-28
Patent application number: 20200165335
Abstract:
The invention provides humanized antibodies that specifically bind to
LIV-1. The antibodies are useful for treatment and diagnoses of various
cancers as well as detecting LIV-1.Claims:
1. A humanized antibody comprising a mature heavy chain variable region
having an amino acid sequence at least 90% identical to SEQ ID NO:53
provided that position H27 is occupied by L, position H29 is occupied by
I, H30 by E and H94 by V and a mature light chain variable region at
least 90% identical to SEQ ID NO:60 provided position L36 is occupied by
Y and position L46 by P.
2. The humanized antibody of claim 1, comprising three CDRs of SEQ ID NO:53 and three CDRs of SEQ ID NO:60.
3. The humanized antibody of claim 1 or 2, further provided position H76 is occupied by N.
4. The humanized antibody of any of claims 1-3, comprising a mature heavy chain variable region having an amino acid sequence at least 95% identical to SEQ ID NO:53 and a mature light chain variable region at least 95% identical to SEQ ID NO:60.
5. The humanized antibody of any of claims 1-4 wherein the mature heavy chain variable region is fused to a heavy chain constant region and the mature light chain variable region is fused to a light chain constant region.
6. The humanized antibody of any of claims 1-5, wherein the heavy chain constant region is a mutant form of natural human constant region which has reduced binding to an Fcgamma receptor relative to the natural human constant region.
7. The humanized antibody of any of claims 1-6, wherein the heavy chain constant region is of IgG1 isotype.
8. The humanized antibody of any of claims 1-5 or 7, wherein the heavy chain constant region has an amino acid sequence comprising SEQ ID NO:44 and the light chain constant region has an amino acid sequence comprising SEQ ID NO:42.
9. The humanized antibody of any of claims 1-7, wherein the heavy chain constant region has an amino acid sequence comprising SEQ ID NO:46 (S239C) and the light chain constant region has an amino acid sequence comprising SEQ ID NO:42.
10. The humanized antibody of any of claims 1-9, provided any differences in CDRs of the mature heavy chain variable region and mature light variable region from SEQ ID NOS. 52 and 60 respectively reside in positions H60-H65.
11. The humanized antibody of any of claim 1-10, wherein the mature heavy chain variable region has an amino acid sequence designated SEQ ID NO:52 or 53 and the mature light chain variable region has an amino acid sequence designated SEQ ID NO: 59 or 60.
12. The humanized antibody of any of claims 1-11, wherein the mature heavy chain variable region has an amino acid sequence designated SEQ ID NO:53 and the mature light chain variable region has an amino acid sequence designated SEQ ID NO:60.
13. The humanized antibody of any of claims 1-12, wherein the antibody is conjugated to a cytotoxic or cytostatic agent.
14. The humanized antibody of any of claims 1-13 having an association constant for human or cynomolgus monkey LIV-1 of 0.5 to 2.times.10.sup.9 M.sup.-1.
15. A humanized antibody comprising a mature heavy chain variable region comprising the three Kabat CDRs of SEQ ID NO:52, wherein position H27 is occupied by L, position H29 is occupied by 1, H30 by E, H76 by N, and H94 by V and a mature light chain variable region comprising the three Kabat CDRs of SEQ ID NO:60 provided position L36 is occupied by Y and position L46 by P.
16. A nucleic acid encoding a mature heavy chain variable region and/or a mature light chain variable region as defined by any of claims 1-15.
17. A method of treating a patient having or at risk of cancer, comprising administering to the patient an effective regime of a humanized antibody of any of claims 1-15.
18. The method of claim 17, wherein the cancer is a breast cancer, a prostate cancer, a cervical cancer or a melanoma.
19. A pharmaceutical composition comprising a humanized antibody of any of claims 1-5.
20. A humanized antibody comprising a mature heavy chain variable region having an amino acid sequence at least 90% identical to HB (SEQ ID NO:10) and a mature light chain variable region at least 90% identical to LB (SEQ ID NO:5).
21. The humanized antibody of claim 20, comprising a mature heavy chain variable region having an amino acid sequence at least 95% identical to HB and a mature light chain variable region at least 95% identical to LB.
22. The humanized antibody of claim 20 or 21, provided that position H29, H30 and H76 are occupied by I, E and N, and L36 is occupied by Y.
23. The humanized antibody of any of claims 20-22, provided that any difference in the variable region frameworks of the mature heavy chain variable region and SEQ ID NO:10 are selected from the group consisting of H27 occupied by F, H28 occupied by N, H48 occupied by I, H66 occupied by K, H67 occupied by A, H71 occupied by A, H76 occupied by N, H93 occupied by N, H94 occupied by V, L37 occupied by L, L39 occupied by K, LA5 occupied by K, and L46 occupied by L.
24. The humanized antibody of any of claims 20-23, wherein the 3 CDRs of the mature heavy chain variable region are those of SEQ ID NO. 10 and the 3 CDRs of the mature light chain variable region are those of SEQ ID NO:15.
25. The humanized antibody of any of claims 20-24, wherein the mature heavy chain variable region is fused to a heavy chain constant region and the mature light chain variable region is fused to a light chain constant region.
26. The humanized antibody of any of claims 20-25, wherein the heavy chain constant region is a mutant form of natural human constant region which has reduced binding to an Fcgamma receptor relative to the natural human constant region.
27. The humanized antibody of any of claims 20-26, wherein the heavy chain constant region is of IgG1 isotype.
28. The humanized antibody of any of claims 20-25 or 27, wherein the heavy chain constant region has an amino acid sequence comprising SEQ ID NO:6 and the light chain constant region has an amino acid sequence comprising SEQ ID NO:4.
29. The humanized antibody of any of claims 20-26, wherein the heavy chain constant region has an amino acid sequence comprising SEQ ID NO:8 (S239C) and the light chain constant region has an amino acid sequence comprising SEQ ID NO:4.
30. The humanized antibody of any of claims 20-29 provided any differences in CDRs of the mature heavy chain variable region and mature light variable region from SEQ ID NOS. 10 and 15 respectively reside in positions H60-H65.
31. The humanized antibody of any of claims 20-30, wherein the mature heavy chain variable region has an amino acid sequence comprising SEQ ID NO:10 and the mature light chain variable region has an amino acid sequence comprising SEQ ID NO: 15.
32. The humanized antibody of any of claims 20-31, wherein the antibody is conjugated to a cytotoxic or cytostatic agent.
33. A humanized antibody comprising a mature heavy chain variable region comprising the 3 CDRs of SEQ ID NO:10 and wherein positions H29, H30 and H76 are occupied by I, E and N respectively, and a mature light chain variable region comprising the 3 CDRs of SEQ ID NO:15, and wherein position L36 is occupied by Y.
34. The humanized antibody of any of claims 20-33 having greater affinity for human LIV-1 than the antibody BR2-14a.
35. The humanized antibody of any of claims 20-33, having an association constant for human or cynomolgus monkey LIV-1 of 0.5 to 2.times.10.sup.9 M.sup.-1.
36. A nucleic acid encoding a mature heavy chain variable region and/or a mature light chain variable region as defined by any of claims 20-35.
37. A method of treating a patient having or at risk of cancer, comprising administering to the patient an effective regime of a humanized antibody of any of claims 20-35.
38. The method of claim 37, wherein the cancer is breast cancer, prostate cancer, cervical cancer, or melanoma.
39. A pharmaceutical composition comprising a humanized antibody of any preceding claim.
40. A method of treating a patient having or at risk of triple negative breast cancer, comprising administering to the patient an effective regime of an antibody that specifically binds to LIV-1.
41. The method of claim 20, wherein the antibody is conjugated to a cytotoxic or cytostatic agent.
42. An isolated polypeptide having an amino acid sequence comprising SEQ ID NO:85 provided residues 1-28 can be omitted, or a nucleic acid encoding the same.
Description:
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation of U.S. application Ser. No. 14/948,183 filed Nov. 20, 2015, which is a continuation of U.S. application Ser. No. 13/990,778, filed May 30, 2013, which is a nonprovisional and claims the benefit of US Provisional Application Nos. 61/420,291 filed Dec. 6, 2010, and 61/446,990 filed Feb. 25, 2011, each incorporated by reference in its entirety for all purposes.
REFERENCE TO A SEQUENCE LISTING
[0002] This application includes an electronic sequence listing in a file named "503385_SEQLST.txt" created on Aug. 30, 2017, and having a size of 100,932 bytes. The information in this file is hereby incorporated by reference.
BACKGROUND
[0003] LIV-1 is a member of the LZT (LIV-1-ZIP Zinc Transporters) subfamily of zinc transporter proteins. Taylor et al., Biochim. Biophys. Acta 1611:16-30 (2003). Computer analysis of the LIV-1 protein reveals a potential metalloprotease motif, fitting the consensus sequence for the catalytic zinc-binding site motif of the zinc metalloprotease. LIV-1 mRNA is primarily expressed in breast, prostate, pituitary gland and brain tissue.
[0004] The LIV-1 protein has also been implicated in certain cancerous conditions, e.g. breast cancer and prostate cancer. The detection of LIV-1 is associated with estrogen receptor-positive breast cancer, McClelland et al., Br. J. Cancer 77:1653-1656 (1998), and the metastatic spread of these cancers to the regional lymph nodes. Manning et al., Eur. J. Cancer 30A:675-678 (1994).
SUMMARY OF THE CLAIMED INVENTION
[0005] The invention provides a humanized antibody comprising a mature heavy chain variable region having an amino acid sequence at least 90% identical to SEQ ID NO:53 provided that position H27 is occupied by L, position H29 is occupied by I, H30 by E and H94 by V and a mature light chain variable region at least 90% identical to SEQ ID NO:60 provided position L36 is occupied by Y and position L46 by P. Optionally, the humanized antibody comprises three CDRs of SEQ ID NO:53 and three CDRs of SEQ ID NO:60. Those CDRs are shown in FIG. 16. Optionally, position H76 is occupied by N. Optionally, the humanized comprises a mature heavy chain variable region having an amino acid sequence at least 95% identical to SEQ ID NO:53 and a mature light chain variable region at least 95% identical to SEQ ID NO:60. Optionally, the mature heavy chain variable region is fused to a heavy chain constant region and the mature light chain constant region is fused to a light chain constant region. Optionally, the heavy chain constant region is a mutant form of natural human constant region which has reduced binding to an Fcgamma receptor relative to the natural human constant region. Optionally, the heavy chain constant region is of IgG1 isotype. Optionally, the heavy chain constant region has an amino acid sequence comprising SEQ ID NO:44 and the light chain constant region has an amino acid sequence comprising SEQ ID NO:42. Optionally, the heavy chain constant region has an amino acid sequence comprising SEQ ID NO:46 (S239C) and the light chain constant region has an amino acid sequence comprising SEQ ID NO:42. In some such humanized antibodies, any differences in CDRs of the mature heavy chain variable region and mature light variable region from SEQ ID NOS. 52 and 60 respectively reside in positions H60-H65. In some such humanized antibodies, the mature heavy chain variable region has an amino acid sequence designated SEQ ID NO:52 or 53 and the mature light chain variable region has an amino acid sequence designated SEQ ID NO: 59 or 60. In some such humanized antibodies, the mature heavy chain variable region has an amino acid sequence designated SEQ ID NO:53 and the mature light chain variable region has an amino acid sequence designated SEQ ID NO:60. Some such humanized antibodies are conjugated to a cytotoxic or cytostatic agent. Some such humanized antibodies have an association constant for human or cynomolgus monkey LIV-1 of 0.5 to 2.times.10.sup.9 M.sup.-1.
[0006] The invention also provides a humanized antibody comprising a mature heavy chain variable region comprising the three Kabat CDRs of SEQ ID NO:52, wherein position H27 is occupied by L, position H29 is occupied by I, H30 by E, H76 by N, and H94 by V and a mature light chain variable region comprising the three Kabat CDRs of SEQ ID NO:60 provided position L36 is occupied by Y and position L46 by P. The invention also provides a nucleic acid encoding a mature heavy chain variable region and/or a mature light chain variable region of any of the above defined humanized antibodies.
[0007] The invention further provides a method of treating a patient having or at risk of cancer, comprising administering to the patient an effective regime of any of the above defined humanized antibodies. The cancer can be for example a breast cancer, cervical cancer, melanoma, or a prostate cancer.
[0008] The invention further provides a pharmaceutical composition comprising a humanized antibody as defined above.
[0009] The invention further provides methods of treating a subject afflicted with a melanoma that expresses the LIV-1 protein by administering to the subject a LIV-1 specific antibody or a LIV-1 antibody drug conjugate, in an amount sufficient to inhibit growth of the melanoma cancer cells.
[0010] The invention further provides methods of treating a subject afflicted with a cervical cancer that expresses the LIV-1 protein by administering to the subject a LIV-1 specific antibody or a LIV-1 antibody drug conjugate, in an amount sufficient to inhibit growth of the cervical cancer cells.
[0011] The invention further provides a humanized antibody comprising a mature heavy chain variable region having an amino acid sequence at least 90% identical to HB (SEQ ID NO:10) and a mature light chain variable region at least 90% identical to LB (SEQ ID NO:15). Optionally, the antibody comprises a mature heavy chain variable region having an amino acid sequence at least 95% identical to HB and a mature light chain variable region at least 95% identical to LB. Optionally, in any such antibody, positions H29, H30 and H76 are occupied by I, E and N, and L36 is occupied by Y. Optionally, any difference in the variable region frameworks of the mature heavy chain variable region and SEQ ID NO: 10 is/are selected from the group consisting of H27 occupied by F, H28 occupied by N, H48 occupied by I, H66 occupied by K, H67 occupied by A, H71 occupied by A, H76 occupied by N, H93 occupied by N, H94 occupied by V, L37 occupied by L, L39 occupied by K, L45 occupied by K, and L46 occupied by L. Optionally, the 3 CDRs of the mature heavy chain variable region are those of SEQ ID NO. 10 and the 3 CDRs of the mature light chain variable region are those of SEQ ID NO: 15. The CDRs are shown in FIG. 1. Optionally, the mature heavy chain variable region is fused to a heavy chain constant region and the mature light chain constant region is fused to a light chain constant region. Optionally, the heavy chain constant region is a mutant form of natural human constant region which has reduced binding to an Fcgamma receptor relative to the natural human constant region. Optionally, the heavy chain constant region is of IgG1 isotype. Optionally, the heavy chain constant region has an amino acid sequence comprising SEQ ID NO:6 and the light chain constant region has an amino acid sequence comprising SEQ ID NO:4. Optionally, the heavy chain constant region has an amino acid sequence comprising SEQ ID NO:8 (S239C) and the light chain constant region has an amino acid sequence comprising SEQ ID NO:4. Optionally, any differences in CDRs of the mature heavy chain variable region and mature light variable region from SEQ ID NOS. 10 and 15 respectively reside in positions H60-H65. Optionally, the mature heavy chain variable region has an amino acid sequence comprising SEQ ID NO:10 and the mature light chain variable region has an amino acid sequence comprising SEQ ID NO:15. Optionally, the antibody is conjugated to a cytotoxic or cytostatic agent. Preferred humanized antibodies having greater affinity for LIV-1 than the antibody BR2-14a In another embodiment, the humanized antibody has an association constant for human or cynomolgus monkey LIV-1 of 0.5 to 2.times.10.sup.9 M.sup.-1.
[0012] The invention further provides a humanized antibody comprising a mature heavy chain variable region comprising the 3 CDRs of SEQ ID NO:10 and wherein positions H29, H30 and H76 are occupied by I, E and N respectively, and a mature light chain variable region comprising the 3 CDRs of SEQ ID NO: 15, and wherein position L36 is occupied by Y.
[0013] The invention further provides a nucleic acid encoding a mature heavy chain variable region and/or a mature light chain variable region of any of the humanized antibodies described above.
[0014] The invention further provides a method of treating a patient having or at risk of cancer, comprising administering to the patient an effective regime of a humanized antibody as described above. Optionally, the cancer is breast cancer, cervical cancer, melanoma, or a prostate cancer.
[0015] The invention further provides a pharmaceutical composition comprising a humanized antibody as described above.
[0016] The invention further provides a method of treating a patient having or at risk of triple negative breast cancer, comprising administering to the patient an effective regime of an antibody that specifically binds to LIV-1. Optionally, in such methods, the antibody is conjugated to a cytotoxic or cytostatic agent.
BRIEF DESCRIPTION OF THE FIGURES
[0017] FIG. 1 shows an alignment of the amino acid sequences of of humanized LIV-1 heavy chain variable regions for hLIV-1 HA (SEQ ID NO:9), hLIV-1 HB (SEQ ID NO:10), hLIV-1 HC (SEQ ID NO: 11), hLIV-1 HD (SEQ ID NO:12), and hLIV-1 HE (SEQ ID NO:13) with the heavy chain variable region of the parental murine mAb (referred to as BR2-14a) (SEQ ID NO:86) (upper two panesl). FIG. 1 further shows an alignment of the amino acid sequences of humanized light chain variable regions for hLIV-1 LA (SEQ ID NO:14), hLIV-1 LB (SEQ ID NO:15), hLIV-1 LC (SEQ ID NO:16), hLIV-1 LD (SEQ ID NO:17), hLIV-1 LE (SEQ ID NO:18), and hLIV-1 LF (SEQ ID NO:19) with the light chain variable region of the parental murine mAb (referred to as BR2-14a) (SEQ ID NO:87) (lower two panels).
[0018] FIG. 2 shows the binding curves for the humanized LIV-1 mAbs and the parental murine antibody (referred to as BR2-14a).
[0019] FIG. 3 shows the results of competition binding studies of the humanized LIV-1 mAbs and the parental murine antibody (referred to as BR2-14a). The numbers in parentheses after each variant indicate the number of back mutations.
[0020] FIG. 4 shows the results of saturation binding studies on MCF7 cells. BR2-14a-AF refers to AF-labeled parental murine antibody. hLIV-14 refers to AF-labeled HBLB antibody, a humanized antibody that specifically binds to LIV-1.
[0021] FIG. 5 shows the results of competition binding studies on CHO cells expressing recombinant LIV-1 protein. BR2-14a refers to the parental murine antibody. hLIV-14 HBLB WT refers to the HBLB antibody. hLIV-14 HBLB S239C refers to the HBLB antibody having serine to cysteine substitutions at each position in the heavy chain.
[0022] FIG. 6 shows an analysis of LIV-1 protein expression by IHC on post-hormone treated breast cancer patient samples.
[0023] FIG. 7 shows an analysis of LIV-1 protein expression by IHC on hormone-refractory metastatic prostate cancer patient samples.
[0024] FIG. 8 shows an analysis of LIV-1 protein expression by IHC on triple negative breast cancer patient samples.
[0025] FIG. 9 shows the results of cytotoxicity assays on hLIV-14 antibody drug conjugates, i.e., the HBLB mAb conjugated to vcMMAE (1006) or mcMMAF (1269), as well as conjugates of control murine (mIgG) and human (hIgG) antibodies. hLIV-14-SEA-1006 refers to a non-fucosylated form of the HBLB mAb conjugated to vcMMAE (1006).
[0026] FIG. 10 shows the results of an in vitro ADCC assay on MCF7 cells using human NK cells (donor 1; V/V). hLIV-14 WT refers to the HBLB mAb. hLIV-14 SEA refers to the non-fucosylated form of the HBLB mAb. hLIV-14 mcMMAF refers to an antibody drug conjugate of the HBLB mAb conjugated to mcMMAF. hLIV-14 vcMMAE refers to an antibody drug conjugate of the HBLB mAb conjugated to vcMMAE. hLIV-14 SEA vcMMAE refers to a non-fucosylated form of the HBLB mAb-vcMMAE antibody drug conjugate.
[0027] FIG. 11 shows the results of an in vitro ADCC assay on MCF7 cells using human NK cells (donor 2). hLIV-14 WT refers to the HBLB mAb. hLIV-14 SEA refers to the non-fucosylated form of the HBLB mAb. cLIV-14 SEA refers to the non-fucosylated form of the chimeric parental murine antibody. hLIV-14 mcF(4) refers to an antibody drug conjugate of the HBLB mAb with an average of 4 mcMMAF drug linker molecules per antibody. hLIV-14 vcE(4) refers to an antibody drug conjugate of the HBLB mAb with an average of 4 vcMMAE drug linker molecules per antibody. hLIV-14 vcE(4) SEA refers to a non-fucosylated form of the HBLB mAb-vcMMAE antibody drug conjugate having an average of four vcMMAE drug linker molecules per antibody. hIgG refers to control human IgG. H00-mcF(4) refers to a control antibody drug conjugate of a nonbinding antibody with an average of 4 mcMMAF drug linker molecules per antibody. H00-vcE(4) refers to 9 control antibody drug conjugate of a nonbinding antibody with an average of 4 vcMMAE drug linker molecules per antibody.
[0028] FIG. 12 shows the results of a xenograft study of the MCF7 breast cancer line in nude mice. cLIV-14-mcMMAF(4) refers to an antibody drug conjugate of the chimeric form of the parental murine antibody having an average of 4 mcMMAF drug linker molecules per antibody. cLIV-14-vcMMAE(4) refers to an antibody drug conjugate of the chimeric form of the parent murine antibody having an average of 4 vcMMAE drug linker molecules per antibody. H00-mcMMAF(4) refers to an antibody drug conjugate of a nonbinding control antibody having an average of 4 mcMMAF drug linker molecules per antibody. HOO-vcMMAE(4) refers to an antibody drug conjugate of a nonbinding control antibody having an average of 4 vcMMAE drug linker molecules per antibody. The dose and time of administration of indicated on the figure.
[0029] FIG. 13 shows the results of a xenograft study of the PC3 prostate cancer line in male nude mice. cLIV-14-vcMMAE(4) refers to an antibody drug conjugate of the chimeric form of the parent murine antibody having an average of 4 vcMMAE drug linker molecules per antibody. hBU12-vcMMAE(4) refers to an antibody drug conjugate of an anti-CD19 antibody having an average of 4 vcMMAE drug linker molecules per antibody. The dose and time of administration of indicated on the figure.
[0030] FIG. 14 shows the results of a xenograft study of the MCF7 breast cancer line in nude mice. hLIV-14-vcMMAE (4) refers to an antibody drug conjugate of the HBLB antibody having an average of 4 vcMMAE drug linker molecules per antibody. hLIV-14d-vcMMAE (2) refers to an antibody drug conjugate of the HBLB antibody having an average of 2 vcMMAE drug linker molecules per antibody, each conjugated at the S239C position of each heavy chain. H00-vcMMAE(4) refers to an antibody drug conjugate of a nonbinding control antibody having an average of 4 vcMMAE drug linker molecules per antibody. The dose and time of administration of indicated on the figure.
[0031] FIG. 15 shows the results of a xenograft study of the PC3 prostate cancer line in male nude mice. hLIV-14-vcMMAE (4) refers to an antibody drug conjugate of the HBLB antibody having an average of 4 vcMMAE drug linker molecules per antibody. hLIV-14-mcMMAF(4) refers to an antibody drug conjugate of the HBLB antibody having an average of 4 mcMMAF drug linker molecules per antibody. hLIV-14d-vcMMAE(2) refers to an antibody drug conjugate of the HBLB antibody having an average of 2 vcMMAE drug linker molecules per antibody, each conjugated at the S239C position of each heavy chain. hLIV-14d-mcMMAF(2) refers to an antibody drug conjugate of the HBLB antibody having an average of 2 mcMMAF drug linker molecules per antibody, each conjugated at the S239C position of each heavy chain. H00-vcMMAE(4) refers to an antibody drug conjugate of a nonbinding control antibody having an average of 4 vcMMAE drug linker molecules per antibody. H00-mcMMAF(4) refers to an antibody drug conjugate of a nonbinding control antibody having an average of 4 mcMMAF drug linker molecules per antibody. The dose and time of administration of indicated on the figure.
[0032] FIGS. 16A and 16B show alignments of humanized heavy chain (FIG. 16A) and light chain (FIG. 16B) mature variable regions with those of the mouse BR2-22a. FIG. 16A shows an alignment of the amino acid sequences of humanized heavy chain variable regions for hLIV-22 HA (SEQ ID NO:47), hLIV-22 HB (SEQ ID NO:48), hLIV-22 HC (SEQ ID NO:49), hLIV-22 HD (SEQ ID NO:50), hLIV-22 HE (SEQ ID NO:51), hLIV-22 HF (SEQ ID NO:52), and hLIV-22 HG (SEQ ID NO:53) with the heavy chain variable region of the parental murine mAb (referred to as BR2-22a) (SEQ ID NO:88). FIG. 16B shows an alignment of the amino acid sequences of humanized light chain variable regions for hLIV-22 LA (SEQ ID NO:54), hLIV-22 LB (SEQ ID NO:55), hLIV-22 LC (SEQ ID NO:56), hLIV-22 LD (SEQ ID NO:57), hLIV-22 LE (SEQ ID NO:58), hLIV-22 LF (SEQ ID NO:59), and hLIV-22 LG (SEQ ID NO:60) with the light chain variable region of the parental murine mAb (referred to as BR2-22a) (SEQ ID NO:89).
[0033] FIG. 17 shows competition binding assays of different permutations of humanized heavy chains HA-HF and humanized light chains LA-LF derived from the murine monoclonal anti LIV-1 antibody BR2-22a. The total number of murine back mutations in each light or heavy chain is shown in parentheses. Only HELF showed sufficient retention of binding.
[0034] FIG. 18 shows systematic variation of the HE and LF chains to test contribution of individual backmutations to antigen binding. Sites of potential somatic hypermutation are in parentheses. Mouse residues are underlined. The remaining residues are human germline residues.
[0035] FIG. 19 shows competition binding of the LF variants on the top of the figure. The tested back mutations are shown in the bottom of the figure. Mouse residues are underlined. The remaining residues are human germline residues.
[0036] FIG. 20 shows competition binding of the HE variants on the top of the figure. The tested back mutations are shown in the bottom of the figure. Mouse residues are underlined. The remaining residues are human germline residues.
[0037] FIG. 21 shows competition binding of different permutations of HE, HF, HG and LF and LG.
[0038] FIG. 22 shows saturation binding of humanized LIV14 antibody and humanized LIV22 antibody on human and cynomolgus LIV-1 expressed from CHO cells.
[0039] FIG. 23 shows cytotoxic activity of humanized LIV22-vcMMAE on MCF-7 cells after 144 hr of treatment. h00-1006 is a control drug-conjugated antibody.
[0040] FIG. 24 shows cytotoxic activity of hLIV22-mcMMAF on MCF-7 cells after 144 hr of treatment. h00-1269 is a control drug-conjugated antibody.
[0041] FIG. 25 shows the activity of hLIV22 antibody on PC3 (DSMZ) prostate carcinoma model in nude female mice. Dose days are indicated by triangles on the X-axis.
[0042] FIG. 26 shows that activity of hLIV22 antibody on MCF7 (NCI) breast carcinoma tumors in nude mice.
[0043] FIG. 27 compares the activity of hLIV22 and hLIV14 in the same model as FIG. 26.
[0044] FIG. 28 shows an analysis of LIV-1 protein expression by IHC on melanoma cancer patient samples.
DEFINITIONS
[0045] Monoclonal antibodies are typically provided in isolated form. This means that an antibody is typically at least 50% w/w pure of interfering proteins and other contaminants arising from its production or purification but does not exclude the possibility that the monoclonal antibody is combined with an excess of pharmaceutical acceptable carrier(s) or other vehicle intended to facilitate its use. Sometimes monoclonal antibodies are at least 60%, 70%, 80%, 90%, 95 or 99% w/w pure of interfering proteins and contaminants from production or purification.
[0046] Specific binding of a monoclonal antibody to its target antigen means an affinity of at least 10.sup.6, 10.sup.7, 10.sup.8, 10.sup.9, or 10.sup.10 M.sup.-1. Specific binding is detectably higher in magnitude and distinguishable from non-specific binding occurring to at least one unrelated target. Specific binding can be the result of formation of bonds between particular functional groups or particular spatial fit (e.g., lock and key type) whereas nonspecific binding is usually the result of van der Waals forces. Specific binding does not however necessarily imply that a monoclonal antibody binds one and only one target.
[0047] The basic antibody structural unit is a tetramer of subunits. Each tetramer includes two identical pairs of polypeptide chains, each pair having one "light" (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. This variable region is initially expressed linked to a cleavable signal peptide. The variable region without the signal peptide is sometimes referred to as a mature variable region. Thus, for example, a light chain mature variable region, means a light chain variable region without the light chain signal peptide. The carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function.
[0048] Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, and define the antibody's isotype as IgG, IgM, IgA, IgD and IgE, respectively. Within light and heavy chains, the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 10 or more amino acids. (See generally, Fundamental Immunology (Paul, W., ed., 2nd ed. Raven Press, N.Y., 1989, Ch. 7, incorporated by reference in its entirety for all purposes).
[0049] The mature variable regions of each light/heavy chain pair form the antibody binding site. Thus, an intact antibody has two binding sites. Except in bifunctional or bispecific antibodies, the two binding sites are the same. The chains all exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called complementarity determining regions or CDRs. The CDRs from the two chains of each pair are aligned by the framework regions, enabling binding to a specific epitope. From N-terminal to C-terminal, both light and heavy chains comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each domain is in accordance with the definitions of Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md., 1987 and 1991), or Chothia & Lesk, J. Mol. Biol. 196:901-917 (1987); Chothia et al., Nature 342:878-883 (1989). Kabat also provides a widely used numbering convention (Kabat numbering) in which corresponding residues between different heavy chains or between different light chains are assigned the same number.
[0050] The term "antibody" includes intact antibodies and binding fragments thereof. Typically, antibody fragments compete with the intact antibody from which they were derived for specific binding to the target including separate heavy chains, light chains Fab, Fab', F(ab').sub.2, F(ab)c, diabodies, Dabs, nanobodies, and Fv. Fragments can be produced by recombinant DNA techniques, or by enzymatic or chemical separation of intact immunoglobulins. The term "antibody" also includes a diabody (homodimeric Fv fragment) or a minibody (V.sub.L-V.sub.H-C.sub.H3), a bispecific antibody or the like. A bispecific or bifunctional antibody is an artificial hybrid antibody having two different heavy/light chain pairs and two different binding sites (see, e.g., Songsivilai and Lachmann, Clin. Exp. Immunol., 79:315-321 (1990); Kostelny et al., J. Immunol., 148:1547-53 (1992)). The term "antibody" includes an antibody by itself (naked antibody) or an antibody conjugated to a cytotoxic or cytostatic drug.
[0051] The term "epitope" refers to a site on an antigen to which an antibody binds. An epitope can be formed from contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of one or more proteins. Epitopes formed from contiguous amino acids are typically retained on exposure to denaturing solvents whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents. An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation. Methods of determining spatial conformation of epitopes include, for example, x-ray crystallography and 2-dimensional nuclear magnetic resonance. See, e.g., Epitope Mapping Protocols, in Methods in Molecular Biology, Vol. 66, Glenn E. Morris, Ed. (1996).
[0052] Antibodies that recognize the same or overlapping epitopes can be identified in a simple immunoassay showing the ability of one antibody to compete with the binding of another antibody to a target antigen. The epitope of an antibody can also be defined by X-ray crystallography of the antibody bound to its antigen to identify contact residues. Alternatively, two antibodies have the same epitope if all amino acid mutations in the antigen that reduce or eliminate binding of one antibody reduce or eliminate binding of the other. Two antibodies have overlapping epitopes if some amino acid mutations that reduce or eliminate binding of one antibody reduce or eliminate binding of the other.
[0053] Competition between antibodies is determined by an assay in which an antibody under test inhibits specific binding of a reference antibody to a common antigen (see, e.g., Junghans et al., Cancer Res. 50:1495, 1990). A test antibody competes with a reference antibody if an excess of a test antibody (e.g., at least 2.times., 5.times., 10.times., 20.times. or 100.times.) inhibits binding of the reference antibody by at least 50% but preferably 75%, 90% or 99% as measured in a competitive binding assay. Antibodies identified by competition assay (competing antibodies) include antibodies binding to the same epitope as the reference antibody and antibodies binding to an adjacent epitope sufficiently proximal to the epitope bound by the reference antibody for steric hindrance to occur.
[0054] The term "patient" includes human and other mammalian subjects that receive either prophylactic or therapeutic treatment.
[0055] For purposes of classifying amino acids substitutions as conservative or nonconservative, amino acids are grouped as follows: Group I (hydrophobic side chains): met, ala, val, leu, ile; Group II (neutral hydrophilic side chains): cys, ser, thr, Group III (acidic side chains): asp, glu; Group IV (basic side chains): asn, gin, his, lys, arg; Group V (residues influencing chain orientation): gly, pro; and Group VI (aromatic side chains): trp, tyr, phe. Conservative substitutions involve substitutions between amino acids in the same class. Non-conservative substitutions constitute exchanging a member of one of these classes for a member of another.
[0056] Percentage sequence identities are determined with antibody sequences maximally aligned by the Kabat numbering convention. After alignment, if a subject antibody region (e.g., the entire mature variable region of a heavy or light chain) is being compared with the same region of a reference antibody, the percentage sequence identity between the subject and reference antibody regions is the number of positions occupied by the same amino acid in both the subject and reference antibody region divided by the total number of aligned positions of the two regions, with gaps not counted, multiplied by 100 to convert to percentage.
[0057] Compositions or methods "comprising" one or more recited elements may include other elements not specifically recited. For example, a composition that comprises antibody may contain the antibody alone or in combination with other ingredients.
[0058] Designation of a range of values includes all integers within or defining the range.
[0059] An antibody effector function refers to a function contributed by an Fc domain(s) of an Ig. Such functions can be, for example, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis or complement-dependent cytotoxicity. Such function can be effected by, for example, binding of an Fc effector domain(s) to an Fc receptor on an immune cell with phagocytic or lytic activity or by binding of an Fc effector domain(s) to components of the complement system. Typically, the effect(s) mediated by the Fc-binding cells or complement components result in inhibition and/or depletion of the LIV-1 targeted cell. Fc regions of antibodies can recruit Fc receptor (FcR)-expressing cells and juxtapose them with antibody-coated target cells. Cells expressing surface FcR for IgGs including Fc.gamma.RIII (CD16), Fc.gamma.RII (CD32) and Fc.gamma.RIII (CD64) can act as effector cells for the destruction of IgG-coated cells. Such effector cells include monocytes, macrophages, natural killer (NK) cells, neutrophils and eosinophils. Engagement of Fc.gamma.R by IgG activates antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent cellular phagocytosis (ADCP). ADCC is mediated by CD16.sup.+ effector cells through the secretion of membrane pore-forming proteins and proteases, while phagocytosis is mediated by CD32.sup.+ and CD64.sup.+ effector cells (see Fundamental Immunology, 4.sup.th ed., Paul ed., Lippincott-Raven, N.Y., 1997, Chapters 3, 17 and 30; Uchida et al., 2004, J. Exp. Med. 199:1659-69; Akewanlop et al., 2001, Cancer Res. 61:4061-65; Watanabe et al., 1999, Breast Cancer Res. Treat. 53:199-207). In addition to ADCC and ADCP, Fc regions of cell-bound antibodies can also activate the complement classical pathway to elicit complement-dependent cytotoxicity (CDC). C1q of the complement system binds to the Fc regions of antibodies when they are complexed with antigens. Binding of C1q to cell-bound antibodies can initiate a cascade of events involving the proteolytic activation of C4 and C2 to generate the C3 convertase. Cleavage of C3 to C3b by C3 convertase enables the activation of terminal complement components including C5b, C6, C7, C8 and C9. Collectively, these proteins form membrane-attack complex pores on the antibody-coated cells. These pores disrupt the cell membrane integrity, killing the target cell (see Immunobiology, 6.sup.th ed., Janeway et al., Garland Science, N. Y., 2005, Chapter 2).
[0060] The term "antibody-dependent cellular cytotoxicity", or ADCC, is a mechanism for inducing cell death that depends upon the interaction of antibody-coated target cells with immune cells possessing lytic activity (also referred to as effector cells). Such effector cells include natural killer cells, monocytes/macrophages and neutrophils. The effector cells attach to an Fc effector domain(s) of Ig bound to target cells via their antigen-combining sites. Death of the antibody-coated target cell occurs as a result of effector cell activity.
[0061] The term "antibody-dependent cellular phagocytosis", or ADCP, refers to the process by which antibody-coated cells are internalized, either in whole or in part, by phagocytic immune cells (e.g., macrophages, neutrophils and dendritic cells) that bind to an Fc effector domain(s) of Ig.
[0062] The term "complement-dependent cytotoxicity", or CDC, refers to a mechanism for inducing cell death in which an Fc effector domain(s) of a target-bound antibody activates a series of enzymatic reactions culminating in the formation of holes in the target cell membrane. Typically, antigen-antibody complexes such as those on antibody-coated target cells bind and activate complement component C1q which in turn activates the complement cascade leading to target cell death. Activation of complement may also result in deposition of complement components on the target cell surface that facilitate ADCC by binding complement receptors (e.g., CR3) on leukocytes.
[0063] A "cytotoxic effect" refers to the depletion, elimination and/or the killing of a target cell. A "cytotoxic agent" refers to an agent that has a cytotoxic effect on a cell. Cytotoxic agents can be conjugated to an antibody or administered in combination with an antibody.
[0064] A "cytostatic effect" refers to the inhibition of cell proliferation. A "cytostatic agent" refers to an agent that has a cytostatic effect on a cell, thereby inhibiting the growth and/or expansion of a specific subset of cells. Cytostatic agents can be conjugated to an antibody or administered in combination with an antibody.
[0065] The term "pharmaceutically acceptable" means approved or approvable by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "pharmaceutically compatible ingredient" refers to a pharmaceutically acceptable diluent, adjuvant, excipient, or vehicle with which an anti-LIV-1 antibody.
[0066] The phrase "pharmaceutically acceptable salt," refers to pharmaceutically acceptable organic or inorganic salts of an anti-LIV-1 antibody or conjugate thereof or agent administered with an anti-LIV-1 antibody. Exemplary salts include sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p toluenesulfonate, and pamoate (i.e., 1,1' methylene bis-(2 hydroxy 3 naphthoate)) salts. A pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counterion. The counterion may be any organic or inorganic moiety that stabilizes the charge on the parent compound. Furthermore, a pharmaceutically acceptable salt may have more than one charged atom in its structure. Instances where multiple charged atoms are part of the pharmaceutically acceptable salt can have multiple counter ions. Hence, a pharmaceutically acceptable salt can have one or more charged atoms and/or one or more counterion.
[0067] Unless otherwise apparent from the context, the term "about" encompasses values within a standard deviation of a stated value.
DETAILED DESCRIPTION
I. General
[0068] The invention provides monoclonal antibodies that specifically bind to LIV-1. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting LIV-1.
II. Target Molecules
[0069] Unless otherwise indicated, LIV-1 means a human LIV-1. An exemplary human sequence is assigned Swiss Prot accession number Q13433. Q13433 is included herein as SEQ ID NO:83. Three variant isoforms and one polymorphism are known. A second version of the human LIV-1 protein, accession number AAA96258.2, is included herein as SEQ ID NO:84. Four extracellular domains are bounded by residues 29-325, 377-423, 679-686 and 746-755 of Q13433 respectively.
[0070] Unless otherwise apparent from the context reference LIV-1 means at least an extracellular domain of the protein and usually the complete protein other than a cleavable signal peptide (amino acids 1-28 of Q13433).
III. Antibodies of the Invention
A. Binding Specificity and Functional Properties
[0071] The invention provides humanized antibodies derived from two mouse antibodies, BR2-14a and BR2-22a. Unless specifically indicated otherwise, the present disclosures relate to both antibodies. The two mouse antibodies show 94% and 91% sequence identity to one another in the mature heavy and light chain variable regions. The two antibodies bind to the same or overlapping epitopes on human LIV-1. However, the BR2-22a antibody has about ten-fold higher affinity for human LIV-1 and about 3-fold higher affinity for cynomolgus monkey LIV-1 than BR2-14a as shown in FIG. 22.
[0072] The affinity of humanized forms of the mouse BR2-14a antibody (i.e., Ka) is preferably within a factor of five or or a factor of two of that of the mouse antibody BR2-14a for human LIV-1. Humanized BR2-14a antibodies specifically bind to human LIV-1 in native form and/or recombinantly expressed from CHO cells as does the mouse antibody from which they were derived. Preferred humanized BR2-14a antibodies have an affinity the same as or greater than (i.e., greater than beyond margin of error in measurement) that of BR2-14a for human LIV-1 (e.g., 1.1-5 fold, 1.1 to 3 fold, 1.5 to 3-fold, 1.7 to 2.3-fold or 1.7-2.1-fold the affinity or about twice the affinity of BR2-14a). Preferred humanized BR2-14a antibodies bind to the same epitope and/or compete with BR2-14a for binding to human LIV-1. Preferred humanized BR2-14a antibodies also bind to the cyno-homolog of LIV-1 thus permitting preclinical testing in nonhuman primates.
[0073] The affinity of humanized forms of the mouse BR2-22a antibody (i.e., Ka) for human LIV-1, natively expressed or expressed from CHO cells, is preferably within a factor of five or a factor of two of that of the mouse antibody BR2-22. Some humanized BR2-22a antibodies have an association constant that is essentially the same as that of BR2-22a (i.e., within experimental error). Some humanized BR2-22a antibodies have an association constant within a range of 0.5 to 1 or 0.5-1.5 that of the association constant of the BR2-22a antibody. Preferred humanized BR2-22a antibodies have an association constant greater than 5.times.10.sup.8 M.sup.-1, or in a range of 0.5 to 2.times.10.sup.9 M.sup.-1 or about 0.8.times.10.sup.9 M.sup.-1 (+/-error in measurement) for human LIV-1 expressed from CHO cells. Here as elsewhere in this application, affinities can be measured in accordance with the methods of the Examples. Preferred humanized BR2-22a antibodies bind to the same epitope and/or compete with BR2-22a for binding to human LIV-1. Humanized BR2-22a antibodies bind to the cyno-homolog of LIV-1 as well as human LIV-1. Preferred humanized BR2-22a antibodies bind with essentially the same association constant to human and cynomolgus monkey LIV-1 both expressed from CHO cells (within experimental error) thus permitting and increasing the predictive accuracy of preclinical testing in nonhuman primates.
[0074] Preferred antibodies (both humanized BR2-14a and humanized BR2-22a) inhibit cancer (e.g., growth of cells, metastasis and/or lethality to the organisms) as shown on cancerous cells propagating in culture, in an animal model or clinical trial. Animal models can be formed by implanting LIV-1-expressing human tumor cell lines into appropriate immunodeficient rodent strains, e.g., athymic nude mice or SCID mice. These tumor cell lines can be established in immunodeficient rodent hosts either as solid tumor by subcutaneous injections or as disseminated tumors by intravenous injections. Once established within a host, these tumor models can be applied to evaluate the therapeutic efficacies of the anti-LIV-1 antibodies or conjugated forms thereof as described in the Examples.
B. Humanized Antibodies
[0075] A humanized antibody is a genetically engineered antibody in which the CDRs from a non-human "donor" antibody are grafted into human "acceptor" antibody sequences (see, e.g., Queen, U.S. Pat. Nos. 5,530,101 and 5,585,089; Winter, U.S. Pat. No. 5,225,539; Carter, U.S. Pat. No. 6,407,213; Adair, U.S. Pat. No. 5,859,205; and Foote, U.S. Pat. No. 6,881,557). The acceptor antibody sequences can be, for example, a mature human antibody sequence, a composite of such sequences, a consensus sequence of human antibody sequences, or a germline region sequence. A preferred acceptor sequence for the heavy chain is the germline V.sub.H exon V.sub.H1-2 (also referred to in the literature as HV1-2) (Shin et al., 1991, EMBO J. 10:3641-3645) and for the hinge region (J.sub.H), exon J.sub.H-6 (Mattila et al., 1995, Eur. J. Immunol. 25:2578-2582). For the light chain, a preferred acceptor sequence is exon VK2-30 (also referred to in the literature as KV2-30) and for the hinge region exon J.sub..kappa.-4 (Hieter et al., 1982, J. Biol. Chem. 257:1516-1522). Thus, a humanized antibody is an antibody having some or all CDRs entirely or substantially from a donor antibody and variable region framework sequences and constant regions, if present, entirely or substantially from human antibody sequences. Similarly a humanized heavy chain has at least one, two and usually all three CDRs entirely or substantially from a donor antibody heavy chain, and a heavy chain variable region framework sequence and heavy chain constant region, if present, substantially from human heavy chain variable region framework and constant region sequences. Similarly a humanized light chain has at least one, two and usually all three CDRs entirely or substantially from a donor antibody light chain, and a light chain variable region framework sequence and light chain constant region, if present, substantially from human light chain variable region framework and constant region sequences. Other than nanobodies and dAbs, a humanized antibody comprises a humanized heavy chain and a humanized light chain. A CDR in a humanized antibody is substantially from a corresponding CDR in a non-human antibody when at least 60%, 85%, 90%, 95% or 100% of corresponding residues (as defined by Kabat) are identical between the respective CDRs. The variable region framework sequences of an antibody chain or the constant region of an antibody chain are substantially from a human variable region framework sequence or human constant region respectively when at least 85%, 90%, 95% or 100% of corresponding residues defined by Kabat are identical.
[0076] Although humanized antibodies often incorporate all six CDRs (preferably as defined by Kabat) from a mouse antibody, they can also be made with less than all CDRs (e.g., at least 3, 4, or 5) CDRs from a mouse antibody (e.g., Pascalis et al., J. Immunol. 169:3076, 2002; Vajdos et al., Journal of Molecular Biology, 320: 415-428, 2002; Iwahashi et al., Mol. Immunol. 36:1079-1091, 1999; Tamura et al, Journal of Immunology, 164:1432-1441, 2000).
[0077] Certain amino acids from the human variable region framework residues can be selected for substitution based on their possible influence on CDR conformation and/or binding to antigen. Investigation of such possible influences is by modeling, examination of the characteristics of the amino acids at particular locations, or empirical observation of the effects of substitution or mutagenesis of particular amino acids.
[0078] For example, when an amino acid differs between a murine variable region framework residue and a selected human variable region framework residue, the human framework amino acid can be substituted by the equivalent framework amino acid from the mouse antibody when it is reasonably expected that the amino acid:
[0079] (1) noncovalently binds antigen directly,
[0080] (2) is adjacent to a CDR region,
[0081] (3) otherwise interacts with a CDR region (e.g. is within about 6 .ANG. of a CDR region); or
[0082] (4) mediates interaction between the heavy and light chains.
[0083] The invention provides humanized forms of the mouse BR2-14a antibody including five exemplified humanized heavy chain mature variable regions (HA-HE) and six exemplified humanized light chain mature variable regions (LA-LF). The permutations of these chains having the strongest binding (lowest EC50) are HBLB, HBLF, HCLB, HCLF, HDLB, HDLF, HELE and HELF. Of these permutations, HBLB (also known as hLIV14) is preferred because it has the strongest binding, about 2 fold stronger than the mouse donor antibody, and has the fewest back mutations (four).
[0084] The invention provides variants of the HBLB humanized antibody in which the humanized heavy chain mature variable region shows at least 90%, 95% or 99% identity to SEQ ID NO:10 and the humanized light chain mature variable region shows at least 90%, 95% or 99% sequence identity to SEQ ID NO: 15. Preferably, in such antibodies some or all of the backmutations in HBLB are retained. In other words, at least 1, 2 or preferably all 3 of heavy chain positions H29, H30 and H76 are occupied by I and E and N, respectively. Likewise position L36 is preferably occupied by Y. The CDR regions of such humanized antibodies are preferably substantially identical to the CDR regions of HBLB, which are the same as those of the mouse donor antibody. The CDR regions can be defined by any conventional definition (e.g., Chothia) but are preferably as defined by Kabat. In one embodiment, the humanized antibody comprises a heavy chain comprising the 3 CDRs of SEQ ID NO:10 and variable region frameworks with at least 95% identity to the variable region frameworks of SEQ ID NO: 10. In another embodiment, the humanized antibody comprises a light chain comprising the 3 CDRs of SEQ ID NO: 15 and variable region frameworks with at least 95% identity to variable region frameworks of SEQ ID NO: 15. In a further embodiment, the humanized antibody comprises a heavy chain comprising the 3 CDRs of SEQ ID NO:10 and variable region frameworks with at least 95% identity to the variable region frameworks of SEQ ID NO:10, and a light chain comprising the 3 CDRs of SEQ ID NO: 15, and variable region frameworks with at least 95% identity to the variable region frameworks of SEQ ID NO:15.
[0085] Insofar as humanized antibodies show any variation from the exemplified HBLB humanized antibody, one possibility for such additional variation is additional backmutations in the variable region frameworks. Any or all of the positions backmutated in other exemplified humanized heavy or light chain mature variable regions can also be made (i.e., 1, 2, 3, 4, 5, 6, 7, 8 or all 9 of H27 occupied by F, H28 occupied by N, H48 occupied by I, H66 occupied by K, H67 occupied by A, H71 occupied by A, H76 occupied by N, H93 occupied by N and H94 occupied by V in the heavy chain and 1, 2, 3, 4 or all 5 of L37 occupied by L, L39 occupied by K, L45 occupied by K, and L46 occupied by L in the light chain. However, such additional backmutations are not preferred because they in general do not improve affinity and introducing more mouse residues may give increased risk of immunogenicity.
[0086] The invention provides humanized forms of the mouse BR2-22a antibody including three exemplified humanized heavy chain mature variable regions (HE, HF and HG) and two exemplified humanized light chain (LF and LG) which can be combined in different permutations with adequate binding (see FIG. 21). Of these permutations, HGLG (also known as hLIV22) is preferred because it has the best combination of binding properties (essentially the same as the mouse BR2-22a antibody within experimental error) and fewest back mutations (seven).
[0087] The invention provides variants of the HGLG humanized antibody in which the humanized heavy chain mature variable region shows at least 90%, 95%, 98% or 99% identity to SEQ ID NO:53 and the humanized light chain mature variable region shows at least 90%, 95%, 98% or 99% sequence identity to SEQ ID NO:60. Preferably, in such antibodies some or all of the backmutations in HGLG are retained. In other words, at least 1, 2, 3, 4 or preferably all 5 of heavy chain positions H27, H29, H30, H76, and H94 are occupied by L, I, E, N and V (here, as elsewhere in this application Kabat numbering is used to describe positions in the mature variable heavy and light chain variable regions). Of these backmutations, H94 contributes the most to retention of binding affinity and H76 the least. Likewise positions L36 and L46 are preferably occupied by Y and P respectively. The CDR regions of such humanized antibodies are preferably substantially identical to the CDR regions of HGLG, which are the same as those of the mouse donor antibody. The CDR regions can be defined by any conventional definition (e.g., Chothia) but are preferably as defined by Kabat. In one embodiment, the humanized antibody comprises a heavy chain comprising the 3 CDRs of SEQ ID NO:53 and variable region frameworks with at least 95% identity to the variable region frameworks of SEQ ID NO:53. In another embodiment, the humanized antibody comprises a light chain comprising the 3 CDR's of SEQ ID NO:60 and variable region frameworks with at least 95% identity to the variable region frameworks of SEQ ID NO:60. In a further embodiment, the humanized antibody comprises a heavy chain comprising the 3 CDRs of SEQ ID NO:53 and variable region frameworks with at least 95% identity to the variable region frameworks of SEQ ID NO:53, and a light chain comprising the 3 CDRs of SEQ ID NO:60, and variable region frameworks with at least 95% identity to the variable region frameworks of SEQ ID NO:60.
[0088] Insofar as humanized BR2-22a antibodies show any variation from the exemplified HGLG humanized antibody, one possibility for such additional variation is additional backmutations in the variable region frameworks. Any or all of the positions backmutated in other exemplified humanized heavy or light chain mature variable regions can also be made (i.e., 1, 2, 3, 4, 5, or all 6, of H28 occupied by N, H48 occupied by I, H66 occupied by K, H67 occupied by A, H71 occupied by A, H93 occupied by T in the heavy chain and 1 or, 2 of L37 occupied by L37 occupied by L, and L45 occupied by K. However, such additional backmutations are not preferred because they in general do not improve affinity and introducing more mouse residues may give increased risk of immunogenicity.
[0089] Another possible variation is to substitute certain residues in the CDRs of the mouse antibody with corresponding residues from human CDRs sequences, typically from the CDRs of the human acceptor sequences used in designing the exemplified humanized antibodies. In some antibodies only part of the CDRs, namely the subset of CDR residues required for binding, termed the SDRs, are needed to retain binding in a humanized antibody. CDR residues not contacting antigen and not in the SDRs can be identified based on previous studies (for example residues H60-H65 in CDR H2 are often not required), from regions of Kabat CDRs lying outside Chothia hypervariable loops (Chothia, J. Mol. Biol. 196:901, 1987), by molecular modeling and/or empirically, or as described in Gonzales et al., Mol. Immunol. 41: 863 (2004). In such humanized antibodies at positions in which one or more donor CDR residues is absent or in which an entire donor CDR is omitted, the amino acid occupying the position can be an amino acid occupying the corresponding position (by Kabat numbering) in the acceptor antibody sequence. The number of such substitutions of acceptor for donor amino acids in the CDRs to include reflects a balance of competing considerations. Such substitutions are potentially advantageous in decreasing the number of mouse amino acids in a humanized antibody and consequently decreasing potential immunogenicity. However, substitutions can also cause changes of affinity, and significant reductions in affinity are preferably avoided. In a further variation, one or more residues in a CDR of a humanized BR2-22a antibody (which would otherwise be the same as the CDR of the mouse BR2-22a antibody) can be replaced by corresponding residues from a CDR from the mouse BR2-14a antibody (or vice versa). Positions for substitution within CDRs and amino acids to substitute can also be selected empirically.
[0090] Although not preferred other amino acid substitutions can be made, for example, in framework residues not in contact with the CDRs, or even some potential CDR-contact residues amino acids within the CDRs. Often the replacements made in the variant humanized sequences are conservative with respect to the replaced HBLB amino acids (in the case of humanized BR2-14a) or HGLG amino acids (in the case of humanized BR2-22). Preferably, replacements relative to HBLB or HGLG (whether or not conservative) have no substantial effect on the binding affinity or potency of the humanized mAb, that is, its ability to bind human LIV-1 and inhibit growth of cancer cells.
[0091] Variants typically differ from the heavy and light chain mature variable region sequences of HBLB (hLIV14) or HGLG (hLIV22) by a small number (e.g., typically no more than 1, 2, 3, 5 or 10 in either the light chain or heavy chain mature variable region, or both) of replacements, deletions or insertions.
[0092] C. Selection of Constant Region
[0093] The heavy and light chain variable regions of humanized antibodies can be linked to at least a portion of a human constant region. The choice of constant region depends, in part, whether antibody-dependent cell-mediated cytotoxicity, antibody dependent cellular phagocytosis and/or complement dependent cytotoxicity are desired. For example, human isotopes IgG1 and IgG3 have strong complement-dependent cytotoxicity, human isotype IgG2 weak complement-dependent cytotoxicity and human IgG4 lacks complement-dependent cytotoxicity. Human IgG1 and IgG3 also induce stronger cell mediated effector functions than human IgG2 and IgG4. Light chain constant regions can be lambda or kappa. Antibodies can be expressed as tetramers containing two light and two heavy chains, as separate heavy chains, light chains, as Fab, Fab', F(ab')2, and Fv, or as single chain antibodies in which heavy and light chain variable domains are linked through a spacer.
[0094] Human constant regions show allotypic variation and isoallotypic variation between different individuals, that is, the constant regions can differ in different individuals at one or more polymorphic positions. Isoallotypes differ from allotypes in that sera recognizing an isoallotype binds to a non-polymorphic region of a one or more other isotypes.
[0095] One or several amino acids at the amino or carboxy terminus of the light and/or heavy chain, such as the C-terminal lysine of the heavy chain, may be missing or derivatized in a proportion or all of the molecules. Substitutions can be made in the constant regions to reduce or increase effector function such as complement-mediated cytotoxicity or ADCC (see, e.g., Winter et al., U.S. Pat. No. 5,624,821; Tso et al., U.S. Pat. No. 5,834,597; and Lazar et al., Proc. Natl. Acad. Sci. USA 103:4005, 2006), or to prolong half-life in humans (see, e.g., Hinton et al., J. Biol. Chem. 279:6213, 2004).
[0096] Exemplary substitution include the amino acid substitution of the native amino acid to a cysteine residue is introduced at amino acid position 234, 235, 237, 239, 267, 298, 299, 326, 330, or 332, preferably an S239C mutation in a human IgG1 isotype (US 20100158909). The presence of an additional cysteine residue allows interchain disulfide bond formation. Such interchain disulfide bond formation can cause steric hindrance, thereby reducing the affinity of the Fc region-Fc.gamma.R binding interaction. The cysteine residue(s) introduced in or in proximity to the Fc region of an IgG constant region can also serve as sites for conjugation to therapeutic agents (i.e., coupling cytotoxic drugs using thiol specific reagents such as maleimide derivatives of drugs. The presence of a therapeutic agent causes steric hindrance, thereby further reducing the affinity of the Fc region-Fc.gamma.R binding interaction. Other substitutions at any of positions 234, 235, 236 and/or 237 reduce affinity for Fc.gamma. receptors, particularly Fc.gamma.RI receptor (see, e.g., U.S. Pat. Nos. 6,624,821, 5,624,821.)
[0097] The in vivo half-life of an antibody can also impact on its effector functions. The half-life of an antibody can be increased or decreased to modify its therapeutic activities. FcRn is a receptor that is structurally similar to MHC Class I antigen that non-covalently associates with P2-microglobulin. FcRn regulates the catabolism of IgGs and their transcytosis across tissues (Ghetie and Ward, 2000, Annu. Rev. Immunol. 18:739-766; Ghetie and Ward, 2002, Immunol. Res. 25:97-113). The IgG-FcRn interaction takes place at pH 6.0 (pH of intracellular vesicles) but not at pH 7.4 (pH of blood); this interaction enables IgGs to be recycled back to the circulation (Ghetie and Ward, 2000, Ann. Rev. Immunol. 18:739-766; Ghetie and Ward, 2002, Immunol. Res. 25:97-113). The region on human IgG1 involved in FcRn binding has been mapped (Shields et al., 2001, J. Biol. Chem. 276:6591-604). Alanine substitutions at positions Pro238, Thr256, Thr307, Gln311, Asp312, Glu380, Glu382, or Asn434 of human IgG1 enhance FcRn binding (Shields et al., 2001, J. Biol. Chem. 276:6591-604). IgG1 molecules harboring these substitutions have longer serum half-lives. Consequently, these modified IgG1 molecules may be able to carry out their effector functions, and hence exert their therapeutic efficacies, over a longer period of time compared to unmodified IgG1. Other exemplary substitutions for increasing binding to FcRn include a Gin at position 250 and/or a Leu at position 428. EU numbering is used for all position in the constant region.
[0098] Oligosaccharides covalently attached to the conserved Asn297 are involved in the ability of the Fc region of an IgG to bind Fc.gamma.R (Lund et al., 1996, J. Immunol. 157:4963-69; Wright and Morrison, 1997, Trends Biotechnol. 15:26-31). Engineering of this glycoform on IgG can significantly improve IgG-mediated ADCC. Addition of bisecting N-acetylglucosamine modifications (Umana et al., 1999, Nat. Biotechnol. 17:176-180; Davies et al., 2001, Biotech. Bioeng. 74:288-94) to this glycoform or removal of fucose (Shields et al., 2002, J. Biol. Chem. 277:26733-40; Shinkawa et al., 2003, J. Biol. Chem. 278:6591-604; Niwa et al., 2004, Cancer Res. 64:2127-33) from this glycoform are two examples of IgG Fc engineering that improves the binding between IgG Fc and Fc.gamma.R, thereby enhancing Ig-mediated ADCC activity.
[0099] A systemic substitution of solvent-exposed amino acids of human IgG1 Fc region has generated IgG variants with altered Fc.gamma.R binding affinities (Shields et al., 2001, J. Biol. Chem. 276:6591-604). When compared to parental IgG1, a subset of these variants involving substitutions at Thr256/Ser298, Ser298/Glu333, Ser298/Lys334, or Ser298/Glu333/Lys334 to Ala demonstrate increased in both binding affinity toward Fc.gamma.R and ADCC activity (Shields et al., 2001, J. Biol. Chem. 276:6591-604; Okazaki et al., 2004, J. Mol. Biol. 336:1239-49).
[0100] Complement fixation activity of antibodies (both C1q binding and CDC activity) can be improved by substitutions at Lys326 and Glu333 (Idusogie et al., 2001, J. Immunol. 166:2571-2575). The same substitutions on a human IgG2 backbone can convert an antibody isotype that binds poorly to C1q and is severely deficient in complement activation activity to one that can both bind C1q and mediate CDC (Idusogie et al., 2001, J. Immunol. 166:2571-75). Several other methods have also been applied to improve complement fixation activity of antibodies. For example, the grafting of an 18-amino acid carboxyl-terminal tail piece of IgM to the carboxyl-termini of IgG greatly enhances their CDC activity. This is observed even with IgG4, which normally has no detectable CDC activity (Smith et al., 1995, J. Immunol. 154:2226-36). Also, substituting Ser444 located close to the carboxy-terminal of IgG1 heavy chain with Cys induced tail-to-tail dimerization of IgG1 with a 200-fold increase of CDC activity over monomeric IgG1 (Shopes et al., 1992, J. Immunol. 148:2918-22). In addition, a bispecific diabody construct with specificity for C1q also confers CDC activity (Kontermann et al., 1997, Nat. Biotech. 15:629-31).
[0101] Complement activity can be reduced by mutating at least one of the amino acid residues 318, 320, and 322 of the heavy chain to a residue having a different side chain, such as Ala. Other alkyl-substituted non-ionic residues, such as Gly, Ile, Leu, or Val, or such aromatic non-polar residues as Phe, Tyr, Trp and Pro in place of any one of the three residues also reduce or abolish C1q binding. Ser, Thr, Cys, and Met can be used at residues 320 and 322, but not 318, to reduce or abolish C1q binding activity. Replacement of the 318 (Glu) residue by a polar residue may modify but not abolish C1 q binding activity. Replacing residue 297 (Asn) with Ala results in removal of lytic activity but only slightly reduces (about three fold weaker) affinity for C1q. This alteration destroys the glycosylation site and the presence of carbohydrate that is required for complement activation. Any other substitution at this site also destroys the glycosylation site. The following mutations and any combination thereof also reduce C1q binding: D270A, K322A, P329A, and P311S (see WO 06/036291).
[0102] Reference to a human constant region includes a constant region with any natural allotype or any permutation of residues occupying polymorphic positions in natural allotypes. Also, up to 1, 2, 5, or 10 mutations may be present relative to a natural human constant region, such as those indicated above to reduce Fcgamma receptor binding or increase binding to FcRN.
[0103] D. Expression of Recombinant Antibodies
[0104] Humanized antibodies are typically produced by recombinant expression. Recombinant polynucleotide constructs typically include an expression control sequence operably linked to the coding sequences of antibody chains, including naturally-associated or heterologous promoter regions. Preferably, the expression control sequences are eukaryotic promoter systems in vectors capable of transforming or transfecting eukaryotic host cells. Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences, and the collection and purification of the crossreacting antibodies.
[0105] Mammalian cells are a preferred host for expressing nucleotide segments encoding immunoglobulins or fragments thereof. See Winnacker, From Genes to Clones, (VCH Publishers, N Y, 1987). A number of suitable host cell lines capable of secreting intact heterologous proteins have been developed in the art, and include CHO cell lines (e.g., DG44), various COS cell lines, HeLa cells, HEK293 cells, L cells, and non-antibody-producing myelomas including Sp2/0 and NS0. Preferably, the cells are nonhuman. Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter, an enhancer (Queen et al., Immunol. Rev. 89:49 (1986)), and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. Preferred expression control sequences are promoters derived from endogenous genes, cytomegalovirus, SV40, adenovirus, bovine papillomavirus, and the like. See Co et al., J. Immunol. 148:1149 (1992).
[0106] Once expressed, antibodies can be purified according to standard procedures of the art, including HPLC purification, column chromatography, gel electrophoresis and the like (see generally, Scopes, Protein Purification (Springer-Verlag, NY, 1982)).
IV. Nucleic Acids
[0107] The invention further provides nucleic acids encoding any of the humanized heavy and light chains described above. Typically, the nucleic acids also encode a signal peptide fused to the mature heavy and light chains. Coding sequences on nucleic acids can be in operable linkage with regulatory sequences to ensure expression of the coding sequences, such as a promoter, enhancer, ribosome binding site, transcription termination signal and the like. The nucleic acids encoding heavy and light chains can occur in isolated form or can be cloned into one or more vectors. The nucleic acids can be synthesized by for example, solid state synthesis or PCR of overlapping oligonucleotides. Nucleic acids encoding heavy and light chains can be joined as one contiguous nucleic acid, e.g., within an expression vector, or can be separate, e.g., each cloned into its own expression vector.
V. Antibody Drug Conjugates
[0108] Anti-LIV-1 antibodies can be conjugated to cytotoxic or cytostatic moieties (including pharmaceutically compatible salts thereof) to form an antibody drug conjugate (ADC). Particularly suitable moieties for conjugation to antibodies are cytotoxic agents (e.g., chemotherapeutic agents), prodrug converting enzymes, radioactive isotopes or compounds, or toxins (these moieties being collectively referred to as a therapeutic agent). For example, an anti-LIV-1 antibody can be conjugated to a cytotoxic agent such as a chemotherapeutic agent, or a toxin (e.g., a cytostatic or cytocidal agent such as, e.g., abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin).
[0109] An anti-LIV-1 antibody can be conjugated to a pro-drug converting enzyme. The pro-drug converting enzyme can be recombinantly fused to the antibody or chemically conjugated thereto using known methods. Exemplary pro-drug converting enzymes are carboxypeptidase G2, beta-glucuronidase, penicillin-V-amidase, penicillin-G-amidase, .beta.-lactamase, .beta.-glucosidase, nitroreductase and carboxypeptidase A.
[0110] Techniques for conjugating therapeutic agents to proteins, and in particular to antibodies, are well-known. (See, e.g., Amon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy," in Monoclonal Antibodies And Cancer Therapy (Reisfeld et al. eds., Alan R. Liss, Inc., 1985); Hellstrom et al., "Antibodies For Drug Delivery," in Controlled Drug Delivery (Robinson et al. eds., Marcel Dekker, Inc., 2nd ed. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review," in Monoclonal Antibodies '84: Biological And Clinical Applications (Pinchera et al. eds., 1985); "Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolabeled Antibody In Cancer Therapy," in Monoclonal Antibodies For Cancer Detection And Therapy (Baldwin et al. eds., Academic Press, 1985); and Thorpe et al., 1982, Immunol. Rev. 62:119-58. See also, e.g., PCT publication WO 89/12624.)
[0111] The therapeutic agent can be conjugated in a manner that reduces its activity unless it is cleaved off the antibody (e.g., by hydrolysis, by antibody degradation or by a cleaving agent). Such therapeutic agent is attached to the antibody with a cleavable linker that is sensitive to cleavage in the intracellular environment of the LIV-1-expressing cancer cell but is not substantially sensitive to the extracellular environment, such that the conjugate is cleaved from the antibody when it is internalized by the LIV-1-expressing cancer cell (e.g., in the endosomal or, for example by virtue of pH sensitivity or protease sensitivity, in the lysosomal environment or in the caveolear environment).
[0112] Typically the ADC comprises a linker region between the therapeutic agent and the anti-LIV-1 antibody. As noted supra, typically, the linker is cleavable under intracellular conditions, such that cleavage of the linker releases the therapeutic agent from the antibody in the intracellular environment (e.g., within a lysosome or endosome or caveolea). The linker can be, e.g., a peptidyl linker that is cleaved by an intracellular peptidase or protease enzyme, including a lysosomal or endosomal protease. Typically, the peptidyl linker is at least two amino acids long or at least three amino acids long. Cleaving agents can include cathepsins B and D and plasmin (see, e.g., Dubowchik and Walker, 1999, Pharm. Therapeutics 83:67-123). Most typical are peptidyl linkers that are cleavable by enzymes that are present in LIV-1-expressing cells. For example, a peptidyl linker that is cleavable by the thiol-dependent protease cathepsin-B, which is highly expressed in cancerous tissue, can be used (e.g., a linker comprising a Phe-Leu or a Gly-Phe-Leu-Gly (SEQ ID NO:90) peptide). Other such linkers are described, e.g., in U.S. Pat. No. 6,214,345. In specific embodiments, the peptidyl linker cleavable by an intracellular protease comprises a Val-Cit linker or a Phe-Lys dipeptide (see, e.g., U.S. Pat. No. 6,214,345, which describes the synthesis of doxorubicin with the Val-Cit linker). One advantage of using intracellular proteolytic release of the therapeutic agent is that the agent is typically attenuated when conjugated and the serum stabilities of the conjugates are typically high.
[0113] The cleavable linker can be pH-sensitive, i.e., sensitive to hydrolysis at certain pH values. Typically, the pH-sensitive linker is hydrolyzable under acidic conditions. For example, an acid-labile linker that is hydrolyzable in the lysosome (e.g., a hydrazone, semicarbazone, thiosemicarbazone, cis-aconitic amide, orthoester, acetal, ketal, or the like) can be used. (See, e.g., U.S. Pat. Nos. 5,122,368; 5,824,805; 5,622,929; Dubowchik and Walker, 1999, Pharm. Therapeutics 83:67-123; Neville et al., 1989, Biol. Chem. 264:14653-14661.) Such linkers are relatively stable under neutral pH conditions, such as those in the blood, but are unstable at below pH 5.5 or 5.0, the approximate pH of the lysosome. In certain embodiments, the hydrolyzable linker is a thioether linker (such as, e.g., a thioether attached to the therapeutic agent via an acylhydrazone bond (see, e.g., U.S. Pat. No. 5,622,929)).
[0114] Other linkers are cleavable under reducing conditions (e.g., a disulfide linker). Disulfide linkers include those that can be formed using SATA (N-succinimidyl-S-acetylthioacetate), SPDP (N-succinimidyl-3-(2-pyridyldithio)propionate), SPDB (N-succinimidyl-3-(2-pyridyldithio)butyrate) and SMPT (N-succinimidyl-oxycarbonyl-alpha-methyl-alpha-(2-pyridyl-dithio)toluene)- , SPDB and SMPT. (See, e.g., Thorpe et al., 1987, Cancer Res. 47:5924-5931; Wawrzynczak et al., In Immunoconjugates: Antibody Conjugates in Radioimagery and Therapy of Cancer (C. W. Vogel ed., Oxford U. Press, 1987. See also U.S. Pat. No. 4,880,935.)
[0115] The linker can also be a malonate linker (Johnson et al., 1995, Anticancer Res. 15:1387-93), a maleimidobenzoyl linker (Lau et al., 1995, Bioorg-Med-Chem. 3(10):1299-1304), or a 3'-N-amide analog (Lau et al., 1995, Bioorg-Med-Chem. 3(10):1305-12).
[0116] The linker also can be a non-cleavable linker, such as an maleimido-alkylene- or maleimide-aryl linker that is directly attached to the therapeutic agent (e.g., a drug). An active drug-linker is released by degradation of the antibody.
[0117] Typically, the linker is not substantially sensitive to the extracellular environment meaning that no more than about 20%, typically no more than about 15%, more typically no more than about 10%, and even more typically no more than about 5%, no more than about 3%, or no more than about 1% of the linkers in a sample of the ADC is cleaved when the ADC present in an extracellular environment (e.g., in plasma). Whether a linker is not substantially sensitive to the extracellular environment can be determined, for example, by incubating independently with plasma both (a) the ADC (the "ADC sample") and (b) an equal molar amount of unconjugated antibody or therapeutic agent (the "control sample") for a predetermined time period (e.g., 2, 4, 8, 16, or 24 hours) and then comparing the amount of unconjugated antibody or therapeutic agent present in the ADC sample with that present in control sample, as measured, for example, by high performance liquid chromatography.
[0118] The linker can also promote cellular internalization. The linker can promote cellular internalization when conjugated to the therapeutic agent (i.e., in the milieu of the linker-therapeutic agent moiety of the ADC or ADC derivative as described herein). Alternatively, the linker can promote cellular internalization when conjugated to both the therapeutic agent and the anti-LIV-1 antibody (i.e., in the milieu of the ADC as described herein).
[0119] A variety of linkers that can be used with the present compositions are described in WO 2004-010957 and have the form
##STR00001##
[0120] wherein:
[0121] -A- is a stretcher unit;
[0122] a is 0 or 1;
[0123] each --W-- is independently an amino acid unit;
[0124] w is independently an integer ranging from 0 to 12;
[0125] --Y-- is a spacer unit; and
[0126] y is 0, 1 or 2.
[0127] Representative stretcher units are depicted within the square brackets of Formulas (Ia) and (Ib; see infra), wherein A-, --W--, --Y--, -D, w and y are as defined above and R.sup.1 is selected from --C.sub.1-C.sub.10 alkylene-, --C.sub.3-C.sub.8 carbocyclo-, --O--(C.sub.1-C.sub.8 alkyl)-, -arylene-, --C.sub.1-C.sub.10 alkylene-arylene-, -arylene-C.sub.1-C.sub.10 alkylene-, --C.sub.1-C.sub.10 alkylene-(C.sub.3-C.sub.8 carbocyclo)-, --(C.sub.3-C.sub.8 carbocyclo)-C.sub.1-C.sub.10 alkylene-, --C.sub.3-C.sub.8 heterocyclo-, --C.sub.1-C.sub.10 alkylene-(C.sub.3-C.sub.8 heterocyclo)-, --(C.sub.3-C.sub.8 heterocyclo)-C.sub.1-C.sub.10 alkylene-, --(CH.sub.2CH.sub.2O).sub.r--, and --(CH.sub.2CH.sub.2O).sub.r--CH.sub.2--; and r is an integer ranging from 1-10. Ab is antibody.
##STR00002##
[0128] The drug loading is represented by p, the number of drug-linker molecules per antibody. Depending on the context, p can represent the average number of drug-linker molecules per antibody, also referred to the average drug loading. P ranges from 1 to 20 and is preferably from 1 to 8. In some preferred embodiments, when p represents the average drug loading, p ranges from about 2 to about 5. In some embodiments, p is about 2, about 3, about 4, or about 5. The average number of drugs per antibody in a preparation may be characterized by conventional means such as mass spectroscopy, ELISA assay, and HPLC.
[0129] The Amino Acid unit (--W--), if present, links the Stretcher unit (-A-) to the Spacer unit (--Y--) if the Spacer unit is present, and links the Stretcher unit to the cytotoxic or cytostatic agent (Drug unit; D) if the spacer unit is absent.
[0130] If present, --W.sub.w-- is preferably a dipeptide, tripeptide, tetrapeptide, pentapeptide, hexapeptide, heptapeptide, octapeptide, nonapeptide, decapeptide, undecapeptide or dodecapeptide unit.
[0131] The Spacer unit (--Y--), when present, links an Amino Acid unit to the Drug unit. Spacer units are of two general types: self-immolative and non self-immolative. A non self-immolative spacer unit is one in which part or all of the Spacer unit remains bound to the Drug unit after enzymatic cleavage of an amino acid unit from the anti-LIV-1 antibody-linker-drug conjugate or the drug-linker compound. Examples of a non self-immolative Spacer unit include a (glycine-glycine) spacer unit and a glycine spacer unit. When an anti-LIV-1 antibody-linker-drug conjugate containing a glycine-glycine spacer unit or a glycine spacer unit undergoes enzymatic cleavage via a tumor-cell associated-protease, a cancer-cell-associated protease or a lymphocyte-associated protease, a glycine-glycine-drug moiety or a glycine-drug moiety is cleaved from Ab-A.sub.a-W.sub.w--. To liberate the drug, an independent hydrolysis reaction should take place within the target cell to cleave the glycine-drug unit bond.
[0132] Alternatively, an anti-LIV-1 antibody drug conjugate containing a self-immolative spacer unit can release the drug (D) without the need for a separate hydrolysis step. In some of these embodiments, --Y-- is a p-aminobenzyl alcohol (PAB) unit that is linked to --W.sub.w-- via the nitrogen atom of the PAB group, and connected directly to -D via a carbonate, carbamate or ether group. Other examples of self-immolative spacers include aromatic compounds that are electronically equivalent to the PAB group such as 2-aminoimidazol-5-methanol derivatives (see Hay et al., 1999, Bioorg. Med Chem. Lett. 9:2237 for examples) and ortho or para-aminobenzylacetals. Spacers can be used that undergo facile cyclization upon amide bond hydrolysis, such as substituted and unsubstituted 4-aminobutyric acid amides (Rodrigues et al., 1995, Chemistry Biology 2:223), appropriately substituted bicyclo[2.2.1] and bicyclo[2.2.2] ring systems (Storm et al., 1972, J. Amer. Chem. Soc. 94:5815) and 2-aminophenylpropionic acid amides (Amsberry el al., 1990, J. Org. Chem. 55:5867). Elimination of amine-containing drugs that are substituted at the .alpha.-position of glycine (Kingsbury, et al., 1984, J. Med. Chem. 27:1447) are also examples of self-immolative spacer strategies that can be applied to the anti-LIV-1 antibody-linker-drug conjugates. Alternatively, the spacer unit is a branched bis(hydroxymethyl)styrene (BHMS) unit, which can be used to incorporate additional drugs.
[0133] Useful classes of cytotoxic agents to conjugate to anti-LIV-1 antibodies include, for example, antitubulin agents, DNA minor groove binding agents, DNA replication inhibitors, chemotherapy sensitizers, or the like. Other exemplary classes of cytotoxic agents include anthracyclines, auristatins, camptothecins, duocarmycins, etoposides, maytansinoids and vinca alkaloids. Some exemplary cytotoxic agents include auristatins (e.g., auristatin E, AFP, MMAF, MMAE), DNA minor groove binders (e.g., enediynes and lexitropsins), duocarmycins, taxanes (e.g., paclitaxel and docetaxel), vinca alkaloids, doxorubicin, morpholino-doxorubicin, and cyanomorpholino-doxorubicin.
[0134] The cytotoxic agent can be a chemotherapeutic such as, for example, doxorubicin, paclitaxel, melphalan, vinca alkaloids, methotrexate, mitomycin C or etoposide. The agent can also be a CC-1065 analogue, calicheamicin, maytansine, an analog of dolastatin 10, rhizoxin, or palytoxin.
[0135] The cytotoxic agent can also be an auristatin. The auristatin can be an auristatin E derivative is, e.g., an ester formed between auristatin E and a keto acid. For example, auristatin E can be reacted with paraacetyl benzoic acid or benzoylvaleric acid to produce AEB and AEVB, respectively. Other typical auristatins include AFP, MMAF, and MMAE. The synthesis and structure of various auristatins are described in, for example, US 2005-0238649 and US2006-0074008.
[0136] The cytotoxic agent can be a DNA minor groove binding agent. (See, e.g., U.S. Pat. No. 6,130,237.) For example, the minor groove binding agent can be a CBI compound or an enediyne (e.g., calicheamicin).
[0137] The cytotoxic or cytostatic agent can be an anti-tubulin agent. Examples of anti-tubulin agents include taxanes (e.g., Taxol.RTM. (paclitaxel), Taxotere.RTM. (docetaxel)), T67 (Tularik), vinca alkyloids (e.g., vincristine, vinblastine, vindesine, and vinorelbine), and auristatins (e.g., auristatin E, AFP, MMAF, MMAE, AEB, AEVB). (Exemplary auristatins are shown below in formulae III-XIII. Other suitable antitubulin agents include, for example, baccatin derivatives, taxane analogs (e.g., epothilone A and B), nocodazole, colchicine and colcimid, estramustine, cryptophysins, cemadotin, maytansinoids, combretastatins, discodermolide, and eleutherobin.
##STR00003##
[0138] The cytotoxic agent can be a maytansinoid, another group of anti-tubulin agents. For example, the maytansinoid can be maytansine or a maytansine containing drug linker such as DM-1 or DM-4 (ImmunoGen, Inc.; see also Chari et al., 1992, Cancer Res. 52:127-131).
[0139] Exemplary antibody drug conjugates include vcMMAE and mcMMAF antibody drug conjugates as follows wherein p and Ab are as previously described herein:
##STR00004##
or a pharmaceutically acceptable salt thereof.
VI. Other Antibodies to LIV-1
[0140] As well as humanized forms of the BR2-14a and BR2-22a antibodies discussed above, other antibodies binding to an extracellular domain of LIV-1 can be used in some of the methods of the invention, particularly the treatment of triple negative breast cancers. A collection of mouse antibodies to LIV-1 is described in US20080175839. These antibodies include 1.1F10, 1.7A4, BR2-10b, BR2-11a, BR2-13a, BR2-14a, BR2-15a, BR2-16a, BR2-17a, BR2-18a, BR2-19a, BR2-20a, BR2-21a, BR2-22a, BR2-23a, BR2-24a, and BR2-25a, of which BR2-19a produced by the hybridoma ATCC Accession No. PTA-5706 or BR2-23a produced by the hybridoma ATCC Accession No. PTA-5707 in addition to BR2-14a and BR2-22a are preferred. Humanized, chimeric or veneered forms of these antibodies can be made by conventional methods summarized below.
[0141] Other antibodies to LIV-1 can be made de novo by immunizing with LIV-1 or one or more extracellular domains thereof. The production of other non-human monoclonal antibodies, e.g., murine, guinea pig, primate, rabbit or rat, against an immunogen can be performed by as described by Harlow & Lane, Antibodies, A Laboratory Manual (CSHP NY, 1988) (incorporated by reference for all purposes). Such an immunogen can be obtained from a natural source, by peptide synthesis or by recombinant expression.
[0142] Humanized, chimeric or veneered forms of non-human antibodies can be made. General methodology for producing humanized antibodies is described by Queen, U.S. Pat. Nos. 5,530,101 and 5,585,089; Winter, U.S. Pat. No. 5,225,539; Carter, U.S. Pat. No. 6,407,213; Adair, U.S. Pat. No. 5,859,205; and Foote, U.S. Pat. No. 6,881,557). A chimeric antibody is an antibody in which the mature variable regions of light and heavy chains of a non-human antibody (e.g., a mouse) are combined with human light and heavy chain constant regions. Such antibodies substantially or entirely retain the binding specificity of the mouse antibody, and are about two-thirds human sequence. A veneered antibody is a type of humanized antibody that retains some and usually all of the CDRs and some of the non-human variable region framework residues of a non-human antibody but replaces other variable region framework residues that may contribute to B- or T-cell epitopes, for example exposed residues (Padlan, Mol. Immunol. 28:489, 1991) with residues from the corresponding positions of a human antibody sequence. The result is an antibody in which the CDRs are entirely or substantially from a non-human antibody and the variable region frameworks of the non-human antibody are made more human-like by the substitutions.
[0143] Human antibodies against LIV-1 can be provided by a variety of techniques described below. Methods for producing human antibodies include the trioma method of Oestberg et al., Hybridoma 2:361-367 (1983); Oestberg, U.S. Pat. No. 4,634,664; and Engleman et al., U.S. Pat. No. 4,634,666; use of transgenic mice including human immunoglobulin genes (see, e.g., Lonberg et al., WO93/12227 (1993); U.S. Pat. Nos. 5,877,397, 5,874,299, 5,814,318, 5,789,650, 5,770,429, 5,661,016, 5,633,425, 5,625,126, 5,569,825, 5,545,806, Nature 148, 1547-1553 (1994), Nature Biotechnology 14, 826 (1996), Kucherlapati, WO 91/10741 (1991) and phage display methods (see, e.g. Dower et al., WO 91/17271 and McCafferty et al., WO 92/01047, U.S. Pat. Nos. 5,877,218, 5,871,907, 5,858,657, 5,837,242, 5,733,743 and 5,565,332.
[0144] Any of the antibodies can be selected to have the same or overlapping epitope specificity as an exemplar antibody, such as the BR2-14a antibody, by a competitive binding assay or otherwise.
VII. Therapeutic Applications
[0145] The humanized antibodies of the invention, alone or as LIV-1 antibody drug conjugates thereof, can be used to treat cancer. Some such cancers show detectable levels of LIV-1 measured at either the protein (e.g., by immunoassay using one of the exemplified antibodies) or mRNA level. Some such cancers show elevated levels of LIV-1 relative to noncancerous tissue of the same type, preferably from the same patient. An exemplary level of LIV-1 on cancer cells amenable to treatment is 5000-150000 LIV-1 molecules per cell, although higher or lower levels can be treated. Optionally, a level of LIV-1 in a cancer is measured before performing treatment.
[0146] Examples of cancers associated with LIV-1 expression and amenable to treatment include breast cancer, prostate cancer, ovarian cancer, endometrial cancer, cervical, liver, gastric, kidney, and squamous cell carcinomas (e.g., bladder, head, neck and lung), skin cancers, e.g., melanoma, small lung cell carcinoma or lung carcinoid. The treatment can be applied to patients having primary or metastatic tumors of these kinds. The treatment can also be applied to patients who are refractory to conventional treatments (e.g., hormones, tamoxifen, herceptin), or who have relapsed following a response to such treatments. The methods can also be used on triple negative breast cancers. A triple negative breast cancer is a term of art for a cancer lacking detectable estrogen and progesterone receptors and lacking overexpression of HER2/neu when stained with an antibody to any of these receptors, such as described in the examples. Staining can be performed relative to an irrelevant control antibody and lack of expression shown from a background level of straining the same or similar to that of the control within experimental error. Likewise lack of overexpression is shown by staining at the same or similar level within experimental error of noncancerous breast tissue, preferably obtained from the same patient. Alternatively or additionally, triple native breast cancers are characterized by lack of responsiveness to hormones interacting with these receptors, aggressive behavior and a distinct pattern of metastasis. hLIV14 antibodies can be used to treat cancers that express LIV-1. In one embodiment, an hLIV14 antibody is used treat a subject with a LIV-1-expressing breast cancer. In another embodiment, an hLIV14 antibody is used treat a subject with a LIV-1-expressing prostate cancer. In another embodiment, an hLIV14 antibody is used treat a subject with a LIV-1-expressing melanoma. In another embodiment, an hLIV14 antibody is used treat a subject with a LIV-1-expressing ovarian cancer. In another embodiment, an hLIV14 antibody is used treat a subject with a LIV-1-expressing endometrial cancer. In another embodiment, an hLIV14 antibody is used treat a subject with a LIV-1-expressing cervical cancer. In another embodiment, an hLIV14 antibody is used treat a subject with a LIV-1-expressing liver cancer. In another embodiment, an hLIV14 antibody is used treat a subject with a LIV-1-expressing gastric cancer. In another embodiment, an hLIV14 antibody is used treat a subject with a LIV-1-expressing kidney cancer. In another embodiment, an hLIV14 antibody is used treat a subject with a LIV-1-expressing squamous cell carcinomas (e.g., bladder, head, neck and lung cancer). In another embodiment, an hLIV14 antibody is used treat a subject with a LIV-1-expressing breast cancer. In another embodiment, an hLIV14 antibody is used treat a subject with a LIV-1-expressing skin cancer. In another embodiment, an hLIV14 antibody is used treat a subject with a LIV-1-expressing small lung cell carcinoma or lung carcinoid. hLIV22 antibodies can be used to treat cancers that express LIV-1. In one embodiment, an hLIV22 antibody is used treat a subject with a LIV-1-expressing breast cancer. In another embodiment, an hLIV22 antibody is used treat a subject with a LIV-1-expressing prostate cancer. In another embodiment, an hLIV22 antibody is used treat a subject with a LIV-1-expressing melanoma. In another embodiment, an hLIV22 antibody is used treat a subject with a LIV-1-expressing ovarian cancer. In another embodiment, an hLIV22 antibody is used treat a subject with a LIV-1-expressing endometrial cancer. In another embodiment, an hLIV22 antibody is used treat a subject with a LIV-1-expressing cervical cancer. In another embodiment, an hLIV22 antibody is used treat a subject with a LIV-1-expressing liver cancer. In another embodiment, an hLIV22 antibody is used treat a subject with a LIV-1-expressing gastric cancer. In another embodiment, an hLIV22 antibody is used treat a subject with a LIV-1-expressing kidney cancer. In another embodiment, an hLIV22 antibody is used treat a subject with a LIV-1-expressing squamous cell carcinomas (e.g., bladder, head, neck and lung cancer). In another embodiment, an hLIV22 antibody is used treat a subject with a LIV-1-expressing breast cancer. In another embodiment, an hLIV22 antibody is used treat a subject with a LIV-1-expressing skin cancer. In another embodiment, an hLIV22 antibody is used treat a subject with a LIV-1-expressing small lung cell carcinoma or lung carcinoid. This application provides the first disclosure that LIV-1 protein is expressed on the surface of melanoma cells. Thus, antibodies that bind to LIV-1 can be used to treat patients that are afflicted with melanomas that express LIV-1. Such antibodies include antibodies disclosed herein, e.g., hLIV14 and hLIV22, but are not limited to the antibodies disclosed herein.
[0147] Humanized antibodies, alone or as conjugates thereof, are administered in an effective regime meaning a dosage, route of administration and frequency of administration that delays the onset, reduces the severity, inhibits further deterioration, and/or ameliorates at least one sign or symptom of cancer. If a patient is already suffering from cancer, the regime can be referred to as a therapeutically effective regime. If the patient is at elevated risk of the cancer relative to the general population but is not yet experiencing symptoms, the regime can be referred to as a prophylactically effective regime. In some instances, therapeutic or prophylactic efficacy can be observed in an individual patient relative to historical controls or past experience in the same patient. In other instances, therapeutic or prophylactic efficacy can be demonstrated in a preclinical or clinical trial in a population of treated patients relative to a control population of untreated patients.
[0148] Exemplary dosages for a monoclonal antibody are 0.1 mg/kg to 50 mg/kg of the patient's body weight, more typically 1 mg/kg to 30 mg/kg, 1 mg/kg to 20 mg/kg, 1 mg/kg to 15 mg/kg, 1 mg/kg to 12 mg/kg, or 1 mg/kg to 10 mg/kg1, or 2 mg/kg to 30 mg/kg, 2 mg/kg to 20 mg/kg, 2 mg/kg to 15 mg/kg, 2 mg/kg to 12 mg/kg, or 2 mg/kg to 10 mg/kg, or 3 mg/kg to 30 mg/kg, 3 mg/kg to 20 mg/kg, 3 mg/kg to 15 mg/kg, 3 mg/kg to 12 mg/kg, or 3 mg/kg to 10 mg/kg. Exemplary dosages for a monoclonal antibody or antibody drug conjugates thereof are 1 mg/kg to 7.5 mg/kg, or 2 mg/kg to 7.5 mg/kg or 3 mg/kg to 7.5 mg/kg of the subject's body weight, or 0.1-20, or 0.5-5 mg/kg body weight (e.g., 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mg/kg) or 10-1500 or 200-1500 mg as a fixed dosage. In some methods, the patient is administered a dose of at least 1.5 mg/kg, at least 2 mg/kg or at least 3 mg/kg, administered once every three weeks or greater. The dosage depends on the frequency of administration, condition of the patient and response to prior treatment, if any, whether the treatment is prophylactic or therapeutic and whether the disorder is acute or chronic, among other factors.
[0149] Administration can be parenteral, intravenous, oral, subcutaneous, intra-arterial, intracranial, intrathecal, intraperitoneal, topical, intranasal or intramuscular. Administration can also be localized directly into a tumor. Administration into the systemic circulation by intravenous or subcutaneous administration is preferred. Intravenous administration can be, for example, by infusion over a period such as 30-90 min or by a single bolus injection.
[0150] The frequency of administration depends on the half-life of the antibody or conjugate in the circulation, the condition of the patient and the route of administration among other factors. The frequency can be daily, weekly, monthly, quarterly, or at irregular intervals in response to changes in the patient's condition or progression of the cancer being treated. An exemplary frequency for intravenous administration is between twice a week and quarterly over a continuous course of treatment, although more or less frequent dosing is also possible. Other exemplary frequencies for intravenous administration are between weekly or three out of every four weeks over a continuous course of treatment, although more or less frequent dosing is also possible. For subcutaneous administration, an exemplary dosing frequency is daily to monthly, although more or less frequent dosing is also possible.
[0151] The number of dosages administered depends on the nature of the cancer (e.g., whether presenting acute or chronic symptoms) and the response of the disorder to the treatment. For acute disorders or acute exacerbations of a chronic disorder between 1 and 10 doses are often sufficient. Sometimes a single bolus dose, optionally in divided form, is sufficient for an acute disorder or acute exacerbation of a chronic disorder. Treatment can be repeated for recurrence of an acute disorder or acute exacerbation. For chronic disorders, an antibody can be administered at regular intervals, e.g., weekly, fortnightly, monthly, quarterly, every six months for at least 1, 5 or 10 years, or the life of the patient.
[0152] Pharmaceutical compositions for parenteral administration are preferably sterile and substantially isotonic and manufactured under GMP conditions. Pharmaceutical compositions can be provided in unit dosage form (i.e., the dosage for a single administration). Pharmaceutical compositions can be formulated using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries. The formulation depends on the route of administration chosen. For injection, antibodies can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline or acetate buffer (to reduce discomfort at the site of injection). The solution can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively antibodies can be in lyophilized form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. The concentration of antibody in a liquid formulation can be e.g., 1-100 mg/ml, such as 10 mg/ml.
[0153] Treatment with antibodies of the invention can be combined with chemotherapy, radiation, stem cell treatment, surgery other treatments effective against the disorder being treated. Useful classes of other agents that can be administered with humanized antibodies to LIV-1 include, for example, antibodies to other receptors expressed on cancerous cells, antitubulin agents (e.g., auristatins), DNA minor groove binders, DNA replication inhibitors, alkylating agents (e.g., platinum complexes such as cis-platin, mono(platinum), bis(platinum) and tri-nuclear platinum complexes and carboplatin), anthracyclines, antibiotics, antifolates, antimetabolites, chemotherapy sensitizers, duocarmycins, etoposides, fluorinated pyrimidines, ionophores, lexitropsins, nitrosoureas, platinols, pre-forming compounds, purine antimetabolites, puromycins, radiation sensitizers, steroids, taxanes, topoisomerase inhibitors, vinca alkaloids, and the like.
[0154] Treatment with the humanized anti-LIV-1 antibody, optionally in combination with any of the other agents or regimes described above alone or as an antibody drug conjugate, can increase the median progression-free survival or overall survival time of patients with tumors (e.g., breast, prostate, melanoma), especially when relapsed or refractory, by at least 30% or 40% but preferably 50%, 60% to 70% or even 100% or longer, compared to the same treatment (e.g., chemotherapy) but without an anti-LIV-1 antibody alone or as a conjugate. In addition or alternatively, treatment (e.g., standard chemotherapy) including the anti-LIV-1 antibody alone or as a conjugate can increase the complete response rate, partial response rate, or objective response rate (complete+partial) of patients with tumors by at least 30% or 40% but preferably 50%, 60% to 70% or even 100% compared to the same treatment (e.g., chemotherapy) but without the anti-LIV-1 antibody.
[0155] Typically, in a clinical trial (e.g., a phase II, phase II/III or phase III trial), the aforementioned increases in median progression-free survival and/or response rate of the patients treated with standard therapy plus the humanized anti-LIV-1 antibody, relative to the control group of patients receiving standard therapy alone (or plus placebo), are statistically significant, for example at the p=0.05 or 0.01 or even 0.001 level. The complete and partial response rates are determined by objective criteria commonly used in clinical trials for cancer, e.g., as listed or accepted by the National Cancer Institute and/or Food and Drug Administration.
VIII. Other Applications
[0156] The anti-LIV-1 humanized antibodies can be used for detecting LIV-1 in the context of clinical diagnosis or treatment or in research. Expression of LIV-1 on a cancer provides an indication that the cancer is amenable to treatment with the antibodies of the present invention. The antibodies can also be sold as research reagents for laboratory research in detecting cells bearing LIV-1 and their response to various stimuli. In such uses, monoclonal antibodies can be labeled with fluorescent molecules, spin-labeled molecules, enzymes or radioisotypes, and can be provided in the form of kit with all the necessary reagents to perform the assay for LIV-1. The antibodies described herein, BR2-14a, BR2-22a and humanized versions thereof, e.g., hLIV14 and hLIV22, can be used to detect LIV-1 protein expression and determine whether a cancer is amenable to treatment with LIV-1 ADCs. As an example, BR2-14a, BR2-22a and humanized versions thereof, e.g., hLIV14 and hLIV22 can be used to detect LIV-1 expression on breast cancer cells, melanoma cells, cervical cancer cells, or prostate cancer cells. The antibodies can also be used to purify LIV-1, e.g., by affinity chromatography.
IX. Cynomolgus Monkey LIV-1
[0157] The invention further provides an amino acid sequence for LIV-1 (CY LIV-1) from cynomolgus monkeys at SEQ ID NO:85 with or without a signal peptide, which occupies approximately residues 1-28 of SEQ ID NO:85, as well as nucleic acids that encode that amino acid sequences. Variants differing by up to 1, 2, 3, 4, or 5 substitutions, deletions or insertions are also included provided CY variants do not include a natural human LIV-1 sequence. Analogous to human LIV-1, reference to CY-LIV-1 means at least an extracellular domain of the protein and usually the complete protein other than a cleavable signal peptide (amino acids 1-28). The invention further provides antibodies that specifically bind to SEQ ID NO:85 with or without specifically binding to human LIV-1 (i.e., binding to human LIV-1 at level of negative control irrelevant antibody). The invention further provides antibodies that preferentially bind CY-LIV-1 over human LIV-1 and vice versa. Preferential binding means an association higher beyond experimental error and preferably at least 2, 3 or 4 fold higher. The invention further provides antibodies that show the same binding profile to human and CY LIV-1 within experimental error as any of the exemplified antibodies described below. The invention further provides methods of analyzing binding of an antibody to CY LIV-1. Such methods involve contacting an antibody with CY LIV-1, determining whether the antibody specifically binds to CY LIV-1 and optionally determining a measure of binding strength, such as an association constant.
[0158] All patent filings, website, other publications, accession numbers and the like cited above or below are incorporated by reference in their entirety for all purposes to the same extent as if each individual item were specifically and individually indicated to be so incorporated by reference. If different versions of a sequence are associated with an accession number at different times, the version associated with the accession number at the effective filing date of this application is meant. The effective filing date means the earlier of the actual filing date or filing date of a priority application referring to the accession number if applicable. Likewise if different versions of a publication, website or the like are published at different times, the version most recently published at the effective filing date of the application is meant unless otherwise indicated. Any feature, step, element, embodiment, or aspect of the invention can be used in combination with any other unless specifically indicated otherwise. Although the present invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.
EXAMPLES
I. Humanization of BR2-14a
Materials
[0159] Cell lines described in the following examples were maintained in culture according to the conditions specified by the American Type Culture Collection (ATCC), the National Cancer Institute (NCI) or the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany (DMSZ). Cell culture reagents were obtained from Invitrogen Corp. (Carlsbad, Calif.) or other suppliers.
Methodologies:
Saturation Binding Assays
[0160] 1.times.10.sup.5 antigen expressing cells (either MCF7 cells (ATCC) expressing human LIV-1, a transfected CHO cell line expressing human LIV-1 or a transfected CHO cell line expressing cyno LIV-1) were aliquoted per well of a 96-well v-bottom plates. AlexaFluor-647 labeled murine LIV-1 mAb, e.g., BR2-14a, was added in concentrations ranging from 0.66 pM to 690 nM and incubated on ice for 30 minutes. Cells were pelleted and washed 3.times. with PBS/BSA. The cells were then pelleted and resuspended in 125 .mu.L of PBS/BSA. Fluorescence was analyzed by flow cytometry, using percent of saturated fluorescent signal to determine percent bound and to subsequently calculate apparent Kd.
Competition Binding Assays
[0161] 1.times.10.sup.5 CHO cells expressing recombinant human LIV-1 in PBS/BSA were aliquoted into each well of a 96-well v-bottom plates on ice. The cells were incubated for 1 hour with 5 nM AlexaFluor-647 (AF) labeled parental murine LIV-1 mAb and increasing concentrations (from 0.038 nM to 600 nM) of unlabeled humanized LIV-1 mAb, combinations of humanized light chains LA-LF and humanized heavy chains HA-HE. Cells were pelleted and washed 3 times with PBS/BSA. The cells were pelleted and resuspended in 125 .mu.L of PBS/BSA. Fluorescence was analyzed by flow cytometry, using percent of saturated fluorescent signal to determine percent labeled murine LIV-1 mAb bound and to subsequently extrapolate the EC50 by fitting the data to a sigmoidal dose-response curve with variable slope.
[0162] 1.times.10.sup.5 MCF7 cells expressing LIV-1 in PBS/BSA were aliquoted in each well of a 96-well v-bottom plates on ice. The cells were incubated for 1 hour with 5 nM AlexaFluor-647 labeled murine LIV-1 mAb and increasing concentrations (from 0.038 nM to 600 nM) of unlabeled humanized LIV-1 mAb, combinations of humanized light chains LA-LF and humanized heavy chains HA-HE. Cells were pelleted and washed 3 times with PBS. The cells were pelleted and resuspended in 125 .mu.L of PBS/BSA. Fluorescence was analyzed by flow cytometery, using percent of saturated fluorescent signal to determine percent labeled murine LIV-1 mAb bound and to subsequently extrapolate the EC50 by fitting the data to a sigmoidal dose-response curve with variable slope.
[0163] 1.times.10.sup.5 CHO cells expressing recombinant cyno LIV-1 in PBS were aliquoted in each well of a 96-well v-bottom plates on ice. The cells were incubated for 1 hour with 5 nM AlexaFluor-647 labeled murine LIV-1 mAb and increasing concentrations (from 0.038 nM to 600 nM) of unlabeled humanized LIV-1 mAb, combinations of humanized light chains LA-LF and humanized heavy chains HA-HE. Cells were pelleted and washed 3 times with PBS. The cells were pelleted and resuspended in 125 .mu.L of PBS/BSA. Fluorescence was analyzed by flow cytometry, using percent of saturated fluorescent signal to determine percent labeled murine LIV-1 mAb bound and to subsequently extrapolate the EC50 by fitting the data to a sigmoidal dose-response curve with variable slope.
Quantitative Flow Cytometric Analysis
[0164] Quantification of LIV-1 copy number on the cell surfaces was determined using murine LIV-1 mAb as primary antibody and the DAKO QiFiKit flow cytometric indirect assay as described by the manufacturer (DAKO A/S, Glostrup, Denmark) and evaluated with a Becton Dickinson FACS.RTM.can flow cytometer.
Cytotoxicity Assay
[0165] Tumor cells were incubated with LIV-1 antibody drug conjugates for 96-144 hours at 37.degree. C. A non-binding (H00) ADC was used as a negative control. Cell viability was measured by resazurin (Sigma) at the final concentration of 50 pM. Cells were incubated for four to six hours at 37.degree.. Fluorescent signal was measured on a Fusion HT fluorescent plate reader (Perkin Elmer, Waltham, Mass.). Results are reported as IC.sub.50, the concentration of compound needed to yield a 50% reduction in viability compared to vehicle-treated cells (control=100%).
Production of Antibody Drug Conjugates
[0166] Antibody drug conjugates of the LIV-1 antibodies were prepared as described in US20050238649. The drug linkers vcMMAE (also referred to as 1006) and mcMMAF (referred to as 1269) are both described in US20050238649. Preparation of cysteine mutants of IgG1 antibodies is generally described in US20100158919. US20050238649 and US20100158919 are herein incorporated by reference for all purposes.
Production of Non-Fucosylated Anti-LIV-1 mAb
[0167] A CHO DG44 cell line producing the humanized IgG1 anti-LIV-1 monoclonal antibody, HBLB mAb (hLIV-14), was cultured at 3.0.times.10.sup.5 cells per mL in 30 mL of CHO culture media at 37', 5% CO.sub.2 and shaking at 100 RPM in a 125 mL shake flask. Media was supplemented with insulin like growth factor (IGF), penicillin, streptomycin and 65 pM 2-fluorofucose peracetate (SGD-2084) (see US20090317869). Cultures were fed on day 3 with 2% volume of feed media. On day four, the culture was split 1:4 into fresh culture media. Cultures were fed with a 6% volume of production feed media on days 5, 7, 9 and 10. Conditioned media was collected on day 13 by passing the culture through a 0.2 .mu.m filter. Antibody purification was performed by applying the conditioned media to a protein A column pre-equilibrated with IX phosphate buffered saline (PBS), pH 7.4.
[0168] After washing column with 20 column volumes of IX PBS, antibodies were eluted with 5 column volumes of Immunopure IgG elution buffer (Pierce Biotechnology, Rockford, Ill.). A 10% volume of 1M Tris pH 8.0 was added to eluted fraction. Sample was dialyzed overnight into Ix PBS.
Antibody-Dependent Cellular Cytotoxicity (ADCC)
[0169] ADCC activity was measured using the standard .sup.51Cr-release assay. Briefly, the MCF-7 target tumor cells were labeled with 100 .mu.Ci Na.sup.51CrO.sub.4, washed, and pre-incubated with test antibodies prior to addition of effector (natural killer, NK) cells. NK (CD16.sup.+ CD56.sup.+) cells were prepared from non-adherent peripheral blood mononuclear cells (PBMCs) obtained from normal Fc.gamma.RIIIA 158V/V donors (Lifeblood, Memphis, Tenn.) with immunomagnetic beads (EasySep, StemCell Technologies, Vancouver, BC, Canada). Viable NK cells were added to target cells at an effector to target cell ratio of 10:1. A human IgG1.kappa. (Ancell, Bayport, Minn.) was used as negative control in this assay. After 4 hours of incubation, supernatants were collected and dried overnight on Luma plates. Gamma radiation emitted from lysed MCF-7 cells was then detected using the TopCount Microplate Scintillation and Luminescence Counter (Perkin Elmer, Waltham, Mass.). ADCC activity is reported as % specific lysis.
In Vivo Activity Study
[0170] Nude (nu/nu) mice (7-8 animals/group) were implanted with tumor cells grown in culture: MCF-7 from NCI (5.times.10.sup.6 cells in 25% matrigel), PC3 from ATCC (2.5.times.10.sup.6 cells in 25% matrigel), and PC3 from DSMZ (5.times.10.sup.5 in 25% matrigel). For in vivo growth of MCF-7 cells, female mice also received estrogen supplementation by implanting a slow-release estrogen pellet (90 day release). Dosing with either chimeric or humanized LIV-1 ADC or nonbinding control ADC (3 mg/kg) started when tumors reached 100 mm.sup.3 (q4d.times.4 intraperitoneal injections). Tumor volumes were monitored using calipers and animals were euthanized when tumor volume reached .about.800 mm.sup.3. Median tumor volume plots were continued for each group until one or more animals were euthanized. All animal procedures were performed under a protocol approved by the Institutional Animal Care and Use Committee in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care.
LIV-1 Immunohistochemical (IHC) Staining
Method
[0171] Tumor microarrays (TMAs) and individual tumor samples were obtained from commercial sources. Tissue microarrays from normal or tumor formalin fixed and paraffin embedded (FFPE) tissues were purchased either from US Biomax Inc. or Cybrdi. A frozen array was purchased from BioChain. Single sections were purchased from NDRI, Asterand, Tissue Solution or CHTN. A set of 25 paraffin-embedded samples of metastatic hormone refractory prostate cancer (corresponding bone and soft tissue metastatic sites) was provided by Dr. R. Vessella, University of Washington, Genitourinary Cancer Department. All samples were processed on Bond-Max.TM. auto-stainer (Leica).
IHC Staining of FFPE Tissues:
[0172] FFPE slides or TMAs sectioned on glass slides were de-paraffinized using Bond.TM. Dewax solution (Leica, cat # AR9222) at 72.degree. C. and rehydrated. Antigen retrieval was performed using EDTA based Bond.TM. Epitope Retrieval Solution 2 (Leica, cat #AR9640) for 20 min at 95-100.degree. C. before incubation with the primary murine LIV-1 mAb (1-2 .mu.g/ml for 30-45 minutes at 25.degree. C.). Isotype-matched murine IgG1 (Sigma; cat # M5284) was used as negative control for background staining. For automated IHC staining we used either a Refine DAB kit or an alkaline phosphatase based detection kit: Bond.TM. Polymer AP Red Detection kit (Leica, cat # DS9305). Slides were incubated with murine monoclonal primary antibodies against murine LIV-1 mAb for 45 min at 1 .mu.g/ml with a preliminary 30 min protein block (DAKO cat # X0909). After chromogen development, sections were counterstained with hematoxylin and coverslipped. Slides were evaluated and scored by a pathologist and images were taken using a Zeiss Axiovert 200M microscope (Carl Zeiss, Inc., Thornwood, N.Y.).
IHC of Frozen Tissues:
[0173] 5 .mu.m sections of frozen/OCT samples were acetone fixed for 10 min., air dried for 30 min, and pretreated 20 min with 1.times.Morphosave at room temperature. The slides were loaded into Bond-Max.TM. auto-stainer (Leica) and stained for 45 min with primary antibody with preliminary 30 min protein block (DAKO cat # X0909). Mouse IgG1 (BD Pharmingen cat #550878) was used as negative control. For detection we used DAB-based Bond Polymer Refine kit (Leica, cat # DS9800). After chromogen development, sections were counterstained with hematoxylin and coverslipped. Slides were evaluated and scored by pathologist.
Results
1. Binding of Mouse Antibody
[0174] The K.sub.D for the murine LIV-1 monoclonal antibody BR2-14a antibody (US2004141983) was determined for human LIV-1 expressed as an endogenous protein in a human breast cancer cell line or as a recombinant protein in a CHO cell line. The K.sub.D for the murine LIV-1 antibody BR2-14a was also determined for cyno LIV-1 expressed as a recombinant protein in a CHO cell line. MCF7 is a human breast cancer cell line. 293F is a human embryonic kidney cell line. Table 1 shows that the antibody had about 5-fold lower dissociation constant for non-recombinant LIV-1 expressed from a human cell line than recombinant LIV-1, whether human (hLIV-1) or from cynomolgus monkeys (cyLIV-1).
TABLE-US-00001 TABLE 1 Cell line Antigen Kd (nM) MCF-7 (ATCC) hLIV-1 2.4 293F (hLIV-1) hLIV-1 2.7 CHO (hLIV-1) hLIV-1 12.5 CHO (cyLIV-1) cLIV-1 14.0
2. Design and Testing of Humanized Antibodies
[0175] The starting point or donor antibody for humanization in this Example is the mouse antibody BR2-14a produced by the hybridoma having ATCC Accession No. PTA-5705A and described in US2004141983. Suitable human acceptor sequences are genomic sequences provided by VH1-02 and JH5 for the heavy chain and by VK2-30 and Jk4 for the light chain. The human acceptor sequences show 68 and 85 percentage identity to the donor sequences in the variable region frameworks. The light chain CDRs of the human acceptor sequences are of the same canonical type as the CDRs of the donor sequences. In contrast, the heavy chain CDRs of the human acceptor sequences differed in their canonical type (the germline was 1-3 versus 1-2 for the murine donor).
[0176] Alignment of the donor sequences identified eleven positions in the heavy chain (H27, H28, H29, H30, H48, H66, H67, H71, H76, H93 and H94) and five positions in the light chain (L36, L37, L45, L46 and L39) at which the human acceptor sequence differed from the donor sequence and that may affect antibody binding as a result of contacting antigen directly, affecting conformation of CDRs or affecting packing between heavy and light chains. Five humanized heavy chains and six humanized light chains were made incorporating back mutations at different permutations of these positions (FIG. 1 (sequence alignment) and Table 2).
TABLE-US-00002 TABLE 2 Backmutations VH exon acceptor sequence donor framework residues V.sub.H variant hV.sub.H A VH1-02 none hV.sub.H B VH1-02 H29, H30, H76 hV.sub.H C VH1-02 H66, H67, H71 hV.sub.H D VH1-02 H27, H93, H94 hV.sub.H E VH1-02 H27, H28, H29, H30, H48, H76, H66, H67, H71, H93, H94 V.sub.L variant hV.sub.K A VK2-30 none hV.sub.K B VK2-30 L36 hV.sub.K C VK2-30 L37 hV.sub.K D VK2-30 L45 hV.sub.K E VK2-30 L46 hV.sub.K F VK2-30 L36, L37, L39, L45, L46
[0177] Humanized antibodies were then expressed representing every permutation of these chains (30 possibilities) of the humanized heavy and light chains. The binding curves for recombinant human LIV-1 expressed from CHO cells are shown in FIG. 2. The EC50's are summarized in the Table 3 below.
TABLE-US-00003 TABLE 3 EC.sub.50s for humanized LIV-1 mAb antibodies, derived from BR2-14a, on human LIV-1 expressed in CHO cells Ab EC50 (.mu.g/mL) HALA DNB HALB 37.8 HALC 25.5 HALD 4.9 HALE DNB HALF 8.8 HBLA 19.9 HBLB 0.3 HBLC 44.0 HBLD 17.4 HBLE DNB HBLF 0.7 HCLA DNB HCLB 1.8 HCLC DNB HCLD 66.6 HCLE DNB HCLF 1.3 HDLA DNB HDLB 2.3 HDLC DNB HDLD 67.9 HDLE DNB HDLF 1.4 HELA 12.5 HELB 173.3 HELC DNB HELD 24.2 HELE 0.3 HELF 1.5 DNB means "did not bind"
[0178] These data indicate considerable variation of EC50 between the 30 humanized antibodies tested with HBLB and HELE showing at least two fold better binding that the next humanized antibody HBLF and larger margins over most of the humanized antibodies. The binding curves of FIG. 2 show that both HBLB and HELE had stronger binding than the original mouse antibody.
[0179] The HBLB antibody was selected as the best of the humanized antibodies because it has (together with HELE) the strongest binding but has fewer backmutations versus HELE, there being four back mutations in HBLB and twelve in HELE.
[0180] The EC50s for the humanized LIV-1 mAb which bound human LIV-1 expressed on CHO cells were determined for human LIV-1 expressed as a native protein in an MCF7 cell line (FIG. 3). Again, LIV-1 mAb HBLB and HELE were determined to be the tightest binders.
[0181] The Kd for HBLB to human LIV-1 on the MCF7 cell line was determined from the average of several saturation binding curves as 1.5 nM whereas that for the mouse antibody is 2.9 nM. In other words, the HBLB antibody has about twice the affinity for native human LIV-1 as the mouse antibody. The saturation binding curve shown in FIG. 4 is a representative example.
[0182] Two forms of the HBLB were compared for binding to human LIV-1 recombinantly expressed from CHO cells. One form was expressed with wildtype human IgG1 and kappa constant regions. The other form was the same except for an S239C mutation (EU numbering) in the IgG1 heavy chain (referred to as LIV-14d or HBLB S239C), which reduces binding of the antibody to Fc gamma receptors. The binding curves and EC50's of these antibodies compared with the mouse donor antibody are shown in FIG. 5. The EC50's of both forms of HBLB were similar to one another (within the error of the study), and both were stronger than the mouse antibody.
[0183] The EC50s for the humanized LIV-1 mAb HBLB and HBLB S239C were also determined for cyno LIV-1 expressed as a recombinant protein in a CHO cell line. Both antibodies bound with equal affinity (better than murine LIV-1 mAb).
Expression Data for LIV-1
[0184] Murine LIV-1 mAbs (at least 2 for concordance) were used for immunohistochemical analysis of various tumor types using formalin-fixed paraffin embedded tissues.
TABLE-US-00004 TABLE 4 Summary of the expression data for LIV-1 in tumor samples Origin Type LIV-1+ # cases % Breast Primary & metastatic 28-46 (TMA) Primary tumors 12 12 100 Metastatic tumors 17 19 89 Post-hormone 19 22 86 treatment Triple Negative 13 20 65 Prostate Metastatic hormone 15 25 60 refractory: bone mets soft tissue mets 21 25 84 Ovarian Primary (TMA) 9 72 13 Metastatic (TMA) 4 11 36 Post-chemo treated 5 17 29 Endometrial 7 56 12 Squamous cell Primary tumors 8 114 7 carcinoma (uterine and multiple organs) Pancreatic Primary tumors 9 95 9 Lung Primary tumors (TMA) 3 192 2
[0185] We observed lower LIV-1 IHC positivity in studies done using tissue microarrays compared to large tissue sections. The difference in expression is highly significant suggesting analysis of LIV-1 expression in larger tissue sections is preferred. There was good concordance of expression using at least 2 different anti-LIV-1 mAbs. FIGS. 6 and 7 show a high level of LIV-1 expression in post-hormone (tamoxifen or aromatase inhibitors) treated breast and prostate tumors providing a strong rationale to target these tumors using a LIV-1 ADC. FIG. 8 shows detectable LIV-1 expression in triple negative (ER-, PgR-, Her2-) breast cancer tissues. The LIV-1 level of expression in triple negative breast cancer by immunohistochemistry staining was comparable to the level in the PC3 animal model, where we demonstrated anti-tumor activity of LIV-1 ADC. Triple negative breast cancers are therefore a potential target population, particularly triple negative breast cancers which have been found to express LIV-1.
In Vitro Anti-Tumor Activity of hLIV-14 mAb as ADC and Effector Function Enhanced mAb (SEA)
[0186] Anti-tumor activity of LIV-1 ADCs in vitro was measured using both cytotoxicity assays (FIG. 9) and antibody dependent cell cytotoxicity (ADCC) (FIGS. 10 and 11). First, we performed a survey of LIV-1 expression in various cell lines by quantitative FACS analysis. The breast cancer cell line MCF-7 from ATCC had the highest level of LIV-1 binding sites/cell, as compared to the MCF-7 cell line from other sources (data not shown). We used this cell line for both assays in vitro. Referring to FIG. 9, various hLIV-14 ADCs (the HBLB antibody conjugated with vcMMAE (referred to as 1006) or mcMMAF (referred to as 1269) (both small molecules and/or linkers described in US20050238649)) were highly effective in killing MCF-7 cells, as compared with the nonbinding and murine control conjugates (mIgG-1006, mIgG-1269, hIgG-1006 and hIgG-1269). In addition, cysteine mutant LIV-14d ADCs, having an average of two drug linkers per antibody were also highly effective in killing MCF-7 cells as measured by the cytotoxic assay. Referring to FIGS. 10 and 11, in ADCC assays the activity of the fucosylated/wild-type (WT) mAb and ADCs were compared with the effector-function enhanced versions (non-fucosylated mAbs and ADCs, referred to as SEA). The results demonstrated that effector function enhanced LIV-1 mAbs and ADCs have good ADCC activity against MCF-7 cells, as compared to non-effector function enhanced mAbs or ADCs (compare, for example, FIG. 10 hLIV-1 SEA vcMMAE with hLIV-1 vcMMAE). Referring again to FIG. 9, an effector function enhanced LIV-1 ADC (indicated as SEA) also had a similar level of cytotoxic activity as wildtype (non-fucosylated) ADCs (compare hLIV-1 SEA 1006 (vcMMAE) with hLIV-1 1006 (vcMMAE)). Thus cytotoxicity can be affected by both effector function and conjugate action.
In Vivo Anti-Tumor Activity of hLIV-14 ADC
[0187] Using breast cancer (MCF-7) and prostate cancer (PC-3) models, we determined the anti-tumor activity of LIV-1 ADCs (chimeric and humanized (HBLB) mAbs with an average of 4 drugs per antibody) in vivo (FIGS. 12-15). LIV-1 ADCs conjugated to vcMMAE showed significant tumor delay compared to untreated and control ADCs. At least one complete regression (CR) was observed in all the studies using LIV-1-vcMMAE at 3 mg/kg with a number of animals having tumors that were static or grew slowly compared to controls. Referring to FIG. 12, a chimeric form of the parental murine antibody conjugated to vcMMAE resulted in complete regressions in 3 out of 7 mice. Referring to FIG. 13, the same chimeric ADC produced a complete regression in 1 out of 8 mice. Referring to FIG. 14, a humanized ADC (HBLB) conjugated to vcMMAE (hLIV-14-vcMMAE(4)) produced a complete regression in 1 out of 8 mice. In addition, a cysteine mutant form of the HBLB antibody, a vcMMAE drug tinker conjugated to each heavy chain at position 239, producing a conjugate with an average drug load of 2 drug linkers per antibody; designated hLIV-14d-vcMMAE(2)) exhibited similar activity as the 4-loaded form. Referring to FIG. 15, the humanized ADC (HBLB) conjugated to vcMMAE (hLIV-14-vcMMAE(4)) produced a complete regression in 1 out of 8 mice in a prostate carcinoma model. In contrast, the activity of the two loaded cysteine mutants was not as pronounced in this model (compare hLIV-14-vcMMAE(4) with hLIV-14d-vcMMAE(2), and hLIV-14-mcMMAF(4) with hLIV-14d-mcMMAF(2). In summary, these studies demonstrate that LIV-1 ADC can stop or delay growth of LIV-1 expressing cancers including breast and prostate.
II. Humanization of BR2-22a
[0188] BR2-22a, sometimes also referred to as mAb2, is a mouse monoclonal antibody of isotype IgG1 Kappa.
Methodologies:
[0189] Unless otherwise stated below, methods described for humanization and testing of BR2-14a are also applicable to BR2-22.
Saturation Binding Assays
[0190] 1.times.10.sup.5 antigen expressing cells (either MCF7 cells expressing human LIV-1, 293F cells, a transfected CHO cell line expressing human LIV-1 or a transfected CHO cell line expressing cyno LIV-1) were aliquoted per well of a 96-well v-bottom plates. AlexaFluor-647 labeled murine BR2-22a was added in concentrations ranging from 0.66 pM to 690 nM and incubated on ice for 30 minutes. Cells were pelleted and washed 3.times. with PBS/BSA. The cells were then pelleted and resuspended in 125 .mu.L of PBS/BSA. Fluorescence was analyzed by flow cytometery, using percent of saturated fluorescent signal to determine percent bound and to subsequently calculate apparent Kd.
Competition Binding Assays
[0191] 1.times.10.sup.5 CHO cells expressing recombinant LIV-1 in PBS were aliquoted into each well of a 96-well v-bottom plates on ice. The cells were incubated for 1 hour with 5 nM AlexaFluor-647 (AF) labeled parental BR2-22a and increasing concentrations (from 0.038 nM to 600 nM) of unlabeled humanized BR2-22a antibody in all combinations of humanized light Chains LA-LG and humanized heavy chains HA-HG. Cells were pelleted and washed 3 times with PBS. The cells were then pelleted and resuspended in 125 .mu.L of PBS/BSA. Fluorescence was analyzed by flow cytometery, using percent of saturated fluorescent signal to determine percent labeled humanized BR2-22a antibody bound and to subsequently extrapolate the EC50 by fitting the data to a sigmoidal dose-response curve with variable slope.
In Vivo Activity Study
[0192] Nude (nu/nu) mice (7-8 animals/group) were implanted with tumor cells grown in culture: MCF-7 (NCI) at 5.times.10.sup.6 in 25% matrigel, PC3 from ATCC (2.5.times.10.sup.6 cells in 25% matrigel), and PC3 from DSMZ (5.times.10.sup.5 in 25% matrigel). For in vivo growth of MCF-7 cells, female mice also received estrogen supplementation by implanting a slow-release estrogen pellet (90 day release). Dosing with either chimeric or humanized LIV-1 ADC or nonbinding control ADC (3 mg/kg) started when tumors reached 100 mm.sup.3 (q4d.times.4 intraperitoneal injections). Tumor volumes were monitored using calipers and animals were euthanized when tumor volume reached .about.800 mm.sup.3. Median tumor volume plots were continued for each group until one or more animals were euthanized. All animal procedures were performed under a protocol approved by the Institutional Animal Care and Use Committee in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care.
Summary of Results and Discussion
Saturation Binding
[0193] BR2-22a shows 94% identity to BR2-14a in the mature heavy chain variable region and 91% identity in the mature light chain variable region. The KD for the murine Liv1 of BR2-22a (Table 5) was determined for human LIV-1 expressed as an endogenous protein in a human breast cancer cell line, in 293F cells or as a recombinant protein in a CHO cell line. The KD for BR2-22a was also determined for cyno LIV-1 expressed as a recombinant protein in a CHO cell line.
TABLE-US-00005 TABLE 5 Affinity measurements of BR2-22a for human (hLIV-1) and cyno LIV-1 (cyLIV-1). Cell line Antigen Kd (nM) MCF7 (ATCC) hLIV-1 1.1 293F (hLIV-1) hLIV-1 0.5 Cho hLIV-1 hLIV-1 1.5 Cho cyLIV-1 cLIV-1 4.2
Humanization Strategy
[0194] The BR2-22a antibody was humanized using a VH1-02 JH5 germline acceptor sequence for the heavy chain and a VK2-30 JK4acceptor sequence for the light chain. These acceptor sequences were chosen based on their having the highest sequence identity to the mature variable region frameworks of BR2-22A heavy and light chains. Initially five variant heavy chains were constructed. Each included the three Kabat CDRs from the heavy chain of BR2-22a, the chains differing in having from zero (VA) to 11 (VE) backmutations. Initially six variant light chains were constructed. Each included the three Kabat CDRs from the light chain of BR2-22a and from zero (LA) to four backmutations (LF). These backmutations were chosen as a result of modeling the BR2-22A antibody to identify positions with potential to interact with antigen directly, affect CDR conformation or affect the interface between heavy and light chains and based on prior experience in humanizing BR2-14a because of the high sequence identity between BR2-14a and BR2-22a. In fact, the same eleven positions in the heavy chain and same four positions in the light chain were considered for backmutation in both BR2-14a and BR2-22a (L39 was not considered in BR2-22a because the mouse residue is the same as the human residue). The back mutations present in each variant of humanized BR2-22a are shown in Tables 6 and 7 below.
TABLE-US-00006 TABLE 6 VH exon V.sub.H variant acceptor sequence donor framework residues hV.sub.H A VH1-02 None hV.sub.H B VH1-02 H29, H30, H76 hV.sub.H C VH1-02 H66, H67, H71 hV.sub.H D VH1-02 H27, H93, H94 hV.sub.H E VH1-02 H27, H28, H29, H30, H48, H66, H67, H71, H76, H93, H94 hV.sub.H F VH1-02 H27, H29, H30, H94 hV.sub.H G VH1-02 H27, H29, H30, H76, H94
TABLE-US-00007 TABLE 7 VL exon V.sub.L variant acceptor sequence donor framework residues hV.sub.K A VK2-30 None hV.sub.K B VK2-30 L36 hV.sub.K C VK2-30 L37 hV.sub.K D VK2-30 L45 hV.sub.K E VK2-30 L46 hV.sub.K F VK2-30 L36, L37, L45, L46 hV.sub.K G VK2-30 L36, L46
[0195] The full sequence of the mature variable region of each variant is shown in FIGS. 16A and 16B.
[0196] All permutations of these five heavy chains and six light chains were then tested in a competition assay compared with BR2-22a (see FIG. 17). Surprisingly, in view of the experience with the BR2-14a antibody in which improved binding relative to the mouse antibody was obtained with only four backmutations and further backmutations did not necessarily improve binding affinity, the only combination of humanized chains that showed binding affinity approximating that of BR2-22a was HELF with 15 backmutations. The other permutations showed poor or no significant binding to LIV-1. The EC50s of the different permutations are shown in Table 8 below.
TABLE-US-00008 TABLE 8 EC50s for humanized BR2-22a antibodies Ab EC50 (.mu.g/mL) HALA DNB HALB DNB HALC DNB HALD DNB HALE DNB HALF 33.2 HBLA DNB HBLB 4.9 HBLC DNB HBLD DNB HBLE DNB HBLF 6.5 HCLA DNB HCLB >100 HCLC DNB HCLD DNB HCLE DNB HCLF >100 HDLA DNB HDLB DNB HDLC DNB HDLD DNB HDLE DNB HDLF 14.4 HELA 68.2 HELB >100 HELC 65.7 HELD >100 HELE 25.1 HELF 0.3 HELG 0.2 HFLF 0.8 HFLG 0.8 HGLF 0.4 HGLG 0.5
DNB means did not bind
[0197] Although HELF shows satisfactory binding, the antibody contains a total of 15 backmutations, a number larger than ideal with respect to potential immunogenicity. Therefore, the HE and LF chains were systematically varied to test the effect of removing individual backmutations. FIG. 18 shows the variants tested. LF-1 through LF-4 differ from LF in each lacking a different backmutation present in LF. Similarly, HE-1 through HE-11 lack one of the backmutations present in HE. FIG. 19 compares LF-1 through LF-4 (each paired with HE). FIG. 19 shows that LF-2 and LF-3 lose substantial binding affinity relative to LF (indicated as HELF historic control in the graph), whereas LF-1 and LF-4 do not. It is concluded that backmutations L36 and L46 contribute substantially to retention of binding affinity, while backmutations at positions L37 and L45 can be dispensed without significant effect on binding. FIG. 20 shows similar binding curves for the HE variants. FIG. 20 shows that HE-11 lost most of its binding indicating that backmutation at position H94 has the greatest effect on binding affinity of the backmutations tested. Loss of backmutations at positions H27, H29 and H30 also caused significant loss of affinity. The role of H30 can be rationalized by the mouse residue being the result of somatic mutation. Loss of a back mutation at position H76 caused some loss of affinity. The other back mutations at positions H28, H48, H66, H67, H71 and H93 could be dispensed with little or no effect on binding affinity.
[0198] In light of these experiments, heavy chains HF and HG were constructed as was light chain LG. HF included backmutations at H27, H29, H30 and H94 and HG included these mutations and a backmutation at H76. LG contains backmutations at L36 and L46. Several permutations of HF, HG, LE and LF were tested for competition binding as shown in FIG. 21 and all showed binding within a factor of three of that of mouse BR2-22a.
[0199] In light of this experiment, HGLG was selected for further experiments as representing the best combination of binding affinity and fewest backmutations. This antibody is hereafter referred to as hLIV22. The saturation binding affinity of hLIV22 for human and cyno LIV-1 expressed from CHO cells is shown in FIG. 22 compared with that of hLIV14. FIG. 22 shows that hLIV22 has about four fold higher affinity (inverse of dissociation constant) for human LIV-1 than does hLIV14. Furthermore, the affinity of hLIV22 for human LIV-1 is the same within experimental error as its affinity for cynomolgus LIV-1, whereas hLIV14 shows twice the affinity for human LIV-1 as for cynomolgus LIV-1. The affinity of hLIV22 for human LIV-1 is the same within experimental error as that of the parent mouse antibody, BR2-22a.
In Vitro Anti-Tumor Activity of hLIV22 ADCs
[0200] Anti-tumor activity of hLIV22 ADC in vitro was measured using cytotoxicity assays. First, we performed a survey of LIV-1 expression in various cell lines by quantitative FACS analysis. The breast cancer cell line MCF-7 from ATCC had the highest level of LIV-1 binding sites/cell, as compared to the MCF-7 cell line from other sources (data not shown). We used this cell line for in vitro assays. We observed that various hLIV22 ADCs (conjugated with vcMMAE (referred to as 1006) or mcMMAF (referred to as 1269) (both small molecules described in US 2005-0238649)) were highly effective in killing MCF-7 cells as measured by the in vitro cytotoxic assay. FIGS. 23 and 24 compare hLIV22-conjugated to 1006 or 1269 with a nonbinding control antibody conjugated to 1006 or 1269.
In Vivo Anti-Tumor Activity of LIV-1 ADC
[0201] Using prostate cancer (PC-3) and breast cancer (MCF-7) models as shown in FIGS. 25 and 26, we determined the anti-tumor activity of hLIV22 ADCs (with an average of 4 drugs per antibody) in vivo. hLIV22 ADCs conjugated to vcMMAE showed significant tumor delay compared to untreated and control ADCs. There were multiple complete regressions was observed in the MCF-7 study using hLIV22-vcMMAE at 3 mg/kg. Additionally, in all studies there were a number of animals that had tumors that were static or grew slowly compared to controls. These studies demonstrate that hLIV22 ADC can stop or delay growth of LIV-1 expressing cancers, including breast and prostate. FIG. 27 compares the activity of hLIV22 and hLIV14 ADCs in the MCF-7 model. Although both antibodies were effective, hLIV22 was slightly more effective. hLIV22 ADCs were also tested in a model of cervical cancer. A HeLA cell xenograft model was used for the assay. After tumors grew to an appropriate sixe, hLIV22 conjugated to vcMMAE was administered to animals at 3 mg/kg and 1 mg/kg. A control antibody conjugate was administered at 3 mg/kg. Complete and partial regression were observed in animals that received 3 mg/kg hLIV22 vc MMAE conjugate. (Data not shown.) Thus, LIV-1 antibodies and antibody drug conjugates can be used to treat LIV-expressing cervical cancers.
III. Treatment of Skin Cancer Using Anti-LIV-1 Antibodies
Expression of LIV-1 Protein on Melanoma Tumor Samples
[0202] Melanoma samples from patients were assessed for LIV-1 expression, using IHC staining. FFPE slides were de-paraffinized using Bond.TM. Dewax solution (Leica, cat # AR9222) at 72.degree. C. Antigen retrieval was performed using EDTA based Bond.TM. Epitope Retrieval Solution 2 (Leica, cat # AR9640) for 20 min at 100.degree. C. For IHC staining we used alkaline phosphatase based detection kit: Bond.TM. Polymer Refine Red Detection kit (Leica, cat # DS9390). Slides were incubated with murine monoclonal primary antibodies against LIV-1 (BR2-14a) for 45 min at 1 .mu.g/ml with preliminary 30 min protein block (DAKO cat # X0909). Mouse IgG (Sigma, cat # M5284) was used as negative control. After chromogen development, sections were counterstained with hematoxylin and coverslipped. Slides were evaluated and scored by pathologist.
[0203] Results are shown in FIG. 28. Seventy-two percent of the tested melanoma patient samples (21/29) were positive for LIV-1 expression. This indicates that LIV-1 inhibitors, e.g., anti-LIV-1 antibodies, can be used to treat melanoma cancers.
In Vive Anti-Melanoma Activity of LIV-1 ADC
[0204] Nude (nu/nu) mice (7-8 animals/group) are implanted with 10.times.10.sup.6 SK-MEL-5 cells (a melanoma tumor-derived cell line) grown in culture. Tumors are allowed to grow in vivo until they are 100 mm.sup.3, as measured using a caliper. Humanized LIV-ADCs, e.g., hLIV14 or hLIV22, are administered at 3 mg/kg. Drug conjugates are, e.g., vcMMAE or mcMMAF. Control ADC's are also administered to control animals at 3 mg/kg. ADC's are given as q4d.times.4 intraperitoneal injections. Tumor volumes are monitored using calipers and animals are euthanized when tumor volume reaches .about.800 mm.sup.3. Administration of hLIV14 ADC or hLIV22 ADC greatly reduces tumor growth in animals as compared to those animals that received control ADC's.
TABLE-US-00009 Sequence listing <LIV-1 mAb light chain leader; PRT/1; mus musculus> SEQ ID NO: 1 MKLPVRLLVLMFWIPVSTS <LIV-1 mAb heavy chain leader; PRT/1; mus musculus> SEQ ID NO: 2 MKCSWVIFFLMAVVLGINS <replacement heavy chain leader sequence; PRT/1; mus musculus> SEQ ID NO: 3 MAWVWTLLFLMAAAQSAQA <Light chain constant region; PRT 1; homo sapiens> SEQ ID NO: 4 TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN RGEC <CH1-CH3; PRT/1; homo sapiens> SEQ ID NO: 5 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLGGPSVFLEPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF YPSDIAVEWESNWPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK <heavy chain CH1-CH3 (no c-term K); PRT/1; homo sapiens> SEQ ID NO: 6 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF YPSDIAVEWESNWPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPG <S239C heavy chain CH1-CH3; PRT/1; homo sapiens> SEQ ID NO: 7 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHICPSNTKVDKKVEPKS CDKTHTCPPCPAPELLGGPCVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK <S239C heavy chain CH1-CH3 (no c-term K); PRT/1; homo sapiens> SEQ ID NO: 8 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLGGPCVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPG <hLIV-1 mAb HA; PRT/1; artificial> SEQ ID NO: 9 QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGWI DPENGDTEYAPTFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARHDAH YGTWFAYWGQGTLVTVSS <hLIV-1 mAb HB; PRT/1; artificial> SEQ ID NO: 10 QVQLVQSGAEVKKPGASVKVSCKASGYTIEDYYMHWVRQAPGQGLEWMGWI DPENGDTEYAPTFQGRVTMTRDTSINTAYMELSRLRSDDTAVYYCARHDAH YGTWFAYWGQGTLVTVSS <hLIV-1 mAb HC; PRT/1; artificial> SEQ ID NO: 11 QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGWI DPENGDTEYAPTFQGKATMTADTSISTAYMELSRLRSDDTAVYYCARHDAH YGTWFAYWGQGTLVTVSS <hLIV-1 mAb HD; PRT/1; artificial> SEQ ID NO: 12 QVQLVQSGAEVKKPGASVKVSCKASGFTFTDYYMHWVRQAPGQGLEWMGWI DPENGDTEYAPTFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCNVHDAH YGTWFAYWGQGTLVTVSS <hLIV-1 mAb HE; PRT/1; artificial> SEQ ID NO: 13 QVQLVQSGAEVKKPGASVKVSCKASGFNIEDYYMHWVRQAPGQGLEWIGWI DPENGDTEYAPTFQGKATMTADTSINTAYMELSRLRSDDTAVYYCNVHDAH YGTWFAYWGQGTLVTVSS <hLIV-1 mAb LA; PRT/1; artificial SEQ ID NO: 14 DVVMTQSPLSLPVTLGQPASISCRSSQSIIRNDGNTYLEWFQQRPGQSPRR LIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYT FGGGTKVEIKR <hLIV-1 mAb LB; PRT/1; artificial> SEQ ID NO: 15 DVVMTQSPLSLPVTLGQPASISCRSSQSIIRNDGNTYLEWYQQRPGQSPRR LIYRVSNRFSGVPDRFGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYT FGGGTKVEIKR <hLIV-1 mAb LC; PRT/1; artificial> SEQ ID NO: 16 DVVMTQSPLSLPVTLGQPASISCRSSQSIIRNDGNTYLEWFLQRPGQSPRR LIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYT FGGGTKVEIKR <hLIV-1 mAb LD; PRT/1; artificial> SEQ ID NO: 17 DVVMTQSPLSLPVTLGQPASISCRSSQSIIRNDGNTYLEWFQQRPGQSPKR LIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYT FGGGTKVEIKR <hLIV-1 mAb LE; PRT/1; artificial> SEQ ID NO: 18 DVVMTQSPLSLPVTLGQPASISCRSSQSIIRNDGNTYLEWFQQRPGQSPRL LIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYT FGGGTKVEIKR <hLIV-1 mAb LF; PRT/1; artificial> SEQ ID NO: 19 DVVMTQSPLSLPVTLGQPASISCRSSQSIIRNDGNTYLEWYLQKPGQSPKL LIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYT FGGGTKVEIKR DNA sequences: <LIV-1 mAb heavy chain leader; DNA; mus musculus> SEQ ID NO: 20 atgaaatgcagctgggtcatcttnttcctgatggcagtggttctaggaatc aattca <LIV-1 mAb light chain leader; DNA; mus musculus> SEQ ID NO: 21 atgaagttgcctgttaggctgttggtgctgatgttctggattcctgtttct accagt <replacement heavy chain leader sequence; DNA; mus musculus> SEQ ID NO: 22 atggcttgggtgtggaccttgctattcctgatggcagctgcccaaagtgcc caagca <light chain constant region; DNA; mus musculus> SEQ ID NO: 23 acggtggctgcaccatctgtcttcatcttcccgccatctgatgagcagttg aaatctggaactgcctctgttgtgtgcctgctgaataacttctatcccaga gaggccaaagtacagtggaaggtggataacgccctccaatcgggtaactcc caggagagtgtcacagagcaggacagcaaggacagcacctacagcctcagc agcaccctgacgctgagcaaagcagactacgagaaacacaaagtctacgcc tgcgaagtcacccatcagggcctgagctcgcccgtcacaaagagcttcaac aggggagagtgt <CH1-CH3; DNA; homo sapiens> SEQ ID NO: 24 gctagcaccaagggcccatctgtcttccccctggcaccctcctccaagagc acctctgggggcacagctgccctgggctgcctggtcaaggactacttccct gaacctgtgacagtgtcctggaactcaggcgccctgaccagcggcgtgcac accttcccggctgtcctacagtcctcaggactctactccctcagcagcgtg gtgaccgtgccctccagcagcttgggcacccagacctacatctgcaacgtg aatcacaagcccagcaacaccaaggtggacaagaaagttgagcccaaatct tgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctgggg ggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatc tcccggacccctgaggtcacacgcgtggtggtggacgtgagccacgaagac cctgaggtcaagttcaactggtacgtggacggcgtagaggtgcataatgcc aagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagc gtcctcaccgtectgcaccaggactggctgaatggcaaggagtacaagtgc aaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaa gccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgg gatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttc tatcccagcgacatcgccgtggagtgggagagcaatgggcagccagagaac
aactacaagaccacgcctcccgtgctggactccgacggctccttcttcctc tacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttc tcatgctccgtgatgcatgaggctctgcacaaccactacacacagaagagc ctctccctgtctccgggtaaa <CH1-CH3 (w/o c-term K); DNA; homo sapiens> SEQ ID NO: 25 gctagcaccaagggcccatctgtcttccccctggcaccctcctccaagagc acctctgggggcacagctgccctgggctgcctggtcaaagactacttccct gaacctgtgacagtgtcctggaactcaggcgccctgaccagcggcatgcac accttcccggctgtcctacagtcctcaggactctactccctcagcagcgtg gtgaccgtgccctccagcagcttgggcacccagacctacatctgcaacgtg aatcacaagcccagcaacaccaaggtggacaagaaagttgagcccaaatct tgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctgggg ggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatc tcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagac cctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgcc aagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagc gtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgc aaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaa gccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgg gatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttc tatcccagcgacatcgccgtggagtaggagagcaatgggcagccggagaac aactacaagaccacgcctcccgtgctggactccgacggctccttcttcctc tacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttc tcatgctccgtgatgcatgaggctctgcacaaccactacacacagaagagc ctctccctgtctccgggt <S239C CH1-CH3; DNA; artificial> SEQ ID NO: 26 gctagcaccaagggcccatctgtcttccccctggcaccctcctccaagagc acctctgggggcacagctgccctgggctgcctggtcaaggactacttccct gaacctgtgacagtgtcctggaactcaggcgccctgaccagcggcgtgcac accttcccggctgtcctacagtcctcaggactctactccctcagcagcgtg gtgaccgtgccctccagcagcttgggcacccagacctacatctgcaacgtg aatcacaagcccagcaacaccaaggtggacaagaaagttgagcccaaatct tgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctgggg ggaccgtgtgtcttcctcttccccccaaaacccaaggacaccctcatgatc tcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagac cctgaggtcaagttcaactggtacgtagacggcgtggaggtgcataatgcc aagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagc gtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgc aaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaa gccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgg gatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttc tatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaac aactacaagaccacgcctcccgtgctggactccgacggctccttcttcctc tacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttc tcatgctccgtgatgcatgaggctctgcacaaccactacacacagaagagc ctctccctgtctccgggtaaa <S239C CH1-CH3 (w/o c-term K); DNA; artificial> SEQ ID NO: 27 gctagcaccaagggcccatctgtcttccccctggcaccctcctccaagagc acctctgggggcacagctgccctgggctgcctggtcaaggactacttccct gaacctgtgacagtgtcctggaactcaggcgccctgaccagcggcgtgcac accttcccggctgtcctacagtcctcaggactctactccctcagcagcgtg gtgaccgtgccctccagcagcttgggcacccagacctacatctgcaacgtg aatcacaagcccagcaacaccaaggtggacaagaaagttgagcccaaatct tgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctgggg ggaccgtgtgtcttcctcttccccccaaaacccaaggacaccctcatgatc tcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagac cctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgcc aagacaaagccgcgggaggagcagtacaacagcacgtaccgtatggtcagc gtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgc aaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaa gccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgg gatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttc tatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaac aactacaagaccacgcctcccgtgctggactccgacgggtccttcttcctc tacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttc tcatgctccgtgatgcatgaggctctgcacaaccactacacacagaagagc ctctccctgtctcgggt <hLIV-1 mAb HA; DNA; artificial> SEQ ID NO: 28 caggtgcagctggtgcagtctggggctgaggtgaagaagcctggggcctca gtgaaggtctcctgcaaggcttctggatacaccttcacagactactatatg cactgggtgaggcaggcccctggacaagggcttgagtggatgggatggatt gatcctgagaatggtgatactgaatatgcccccaccttccaggacagggtc accatgaccagggacacctccatcagcacagcctacatggagctgagcagg ctgagatctgatgacacagctgtgtattactgtgccagacatgatgctcac tatgggacctggtttgcttactggggccaaggaaccctggtcacagtctcc tca <hLIV-1 mAb HB; DNA; artificial> SEQ ID NO: 29 caggtgcagctggtgcagtctggggctgaggtgaagaagcctggggcctca gtgaaggtctcctgcaaggcttctggatacaccattgaagactactatatg cactgggtgaggcaggcccctggacaagggcttgagtggatgggatggatt gatcctgagaatggtgatactgaatatgcccccaccttccagggcagggtc accatgaccagggacacctccatcaacacagcctacatggagctgagcagg ctgagatctgatgacacagctgtgtattactgtgccagacatgatgctcac tatgggacctggtttgcttactggggccaaggaaccctggtcacagtctcc tca <hLIV-1 mAb HC; DNA; artificial> SEQ ID NO: 30 caggtgcagctggtgcagtctggggctgaggtgaagaagcctggggcctca gtgaaggtctcctgcaaggcttctggatacaccttcacagactactatatg cactgggtgaggcaggcccctggacaagggcttgagtggatgggatggatt gatcctgagaatggtgatactgaatatgcccccaccttccagggcaaggcc actatgactgcagacacctccatcagcacagcctacatagagctgagcagg ctgagatctgatgacacagctgtgtattactgtgccagacatgatgctcac tatgggacctggtttgcttactggggccaaggaaccctggtcacagtctcc tca <hLIV-1 mAb HD; DNA; artificial> SEQ ID NO: 31 caggtgcagctggtgcagtctggggctgaggtgaagaagcctggggcctca gtgaaggtctcctgcaaggcttctggattcaccttcacagactactatatg cactgggtgaggcaggcccctggacaagggcttgagtggatgggatggatt gatcctgagaatggtgatactgaatatgcccccaccttccagggcagggtc accatgaccagggacacctccatcagcacagcctacatggagctgagcagg ctgagatctgatgacacagctgtgtattactgtgccagacatgatgctcac tatgggacctggtttgcttactggggccaaggaaccctggtcacagtctcc tca <hLIV-1 mAb HE; DNA; artificial> SEQ ID NO: 32 Caggtgcagctggtgcagtctggggctgaggtgaagaagcctggggcctca gtgaaggtctcctgcaaggcttctggattcaacattgaagactactatatg cactgggtgaggcaggcccctggacaagggcttgagtgaattggatggatt gatcctgagaatggtgatactgaatatgcccccaccttccagggcaaggcc actatgactgcagacacctccatcaacacagcctacatggagctaagcagg ctgagatctgatgacacagctgtgtattactgtaatgtccatgatgctcac tatgggacctggtttgcttactggggccaaggaaccctggtcacagtctcc tca <hLIV-1 mAb LA; DNA; artificial> SEQ ID NO: 33 gatgttgtgatgactcagtctccactctccctgcctgtcacccttggacag cctgcctccatctcctgcagatctagtcagagcattataaggaatgatgga aacacctatttggaatggtttcagcagaggccaggccaatctccaaggagg ctaatttatagagtttccaacaggttttctggggtcccagacagattctct ggcagtgggtcaggcactgatttcacactgaaaatcagcagggtggaggct gaggatgttggggtttattactgctttcaaggttcacatuttccctacacc tttggaggagggaccaaggtggagatcaaacgt <hLIV-1 mAb LB; DNA; artificial> SEQ ID NO: 34 gatgttgtgatgactcagtctccactctccctgcctgtcacccttggacag cctgcctccatctectgcagatctagtcagagcattataaggaatgatgga aacacctatttggaatggtaccagcagaggccaggccaatctccaaggagg ctaatttatagagtttccaacaggttttctggggtcccagacagattctct
ggcagtgggtcaggcactgatttcacactgaaaatcagcagggtggaggct gaggatgttggggtttattactgetttcaaggttcacatgttccctacacc tttggaggagggaccaaggtggagatcaaacgt <hLIV-1 mAb LC; DNA; artificial> SEQ ID NO: 35 gatgttgtgatgactcagtctccactctecctgcctgtcaccettggacag cctgcctccatctcctgcagatctagtcagagcattataaggaatgatgga aacacctatttggaatggtttctgcagaggccaggccaatctccaaggagg ctaatttatagagtttccaacaggttttctggggtcccagacagattctct ggcagtgggtcaggcactgatttcacactgaaaatcagcagggtggaggct gaggatgttggggtttattactgctttcaaggttcacatgttccctacacc tttggaggagggaccaaggtggagatcaaacgt <hLIV-1 mAb LD; DNA; artificial> SEQ ID NO: 36 gatgttgtgatgactcagtctccactctccctgcctgtcacccttggacag cctgcctccatctcctgcagatctagtcagagcattataaggaatgatgga aacacctatttggaatggtttcagcagaggccaggccaatctccaaagagg ctaatttatagagtttccaacaggttttctggggtcccagacagattctct ggcagtgggtcaggcactgatttcacactgaaaatcagcagggtggaggct gaggatgttggggtttattactgctttcaaggttcacatgttccctacacc tttggaggagggaccaaggtggagatcaaacgt <hLIV-1 mAb LE; DNA; artificial> SEQ ID NO: 37 gatgttgtgatgactcagtctccactctccctgcctgtcacccttggacag cctgcctccatctcctgcagatctagtcagagcattataaggaatgatgga aacacctatttggaatggtttcagcagaggccaggccaatctccaaggctc ctaatttatagagtttccaacaggttttctggggtcccagacagattctct ggcagtgggtcaggcactgatttcacactgaaaatcagcagggtggaggct gaggatgttgggatttattactgctttcaaggttcacatattccctacacc tttgaaggagggaccaaggtggagatcaaacgt <hLIV-1 mAb LF; DNA; artificial> SEQ ID NO: 38 gatgttgtgatgactcagtctccactctccctgcctgtcacccttggacag cctgcctccatctcctgcagatctagtcagagcattataaggaatgatgga aacacctatttggaatggtacctgcagaaaccaggccaatctccaaagctc ctaatttatagagtttccaacaggttttctggggtcccagacagattctct ggcagtgggtcaggcactgatttcacactgaaaatcagcagggtggaggct gaggatgttggggtttattactgctttcaaggttcacatgttccctacacc tttggaggagggaccaaggtggagatcaaacgt <Liv1 mAb2 light chain leader; PRT/1; mus musculus> SEQ ID NO: 39 MKLPVRLLVLMFWIPVATSS <Liv1 mAb2 heavy chain leader; PRT/1; mus musculus> SEQ ID NO: 40 MKCSWVIFFLMAVVIGINS <replacement heavy chain leader sequence; PRT/1; mus musculus> SEQ ID NO: 41 MAWVWTLLFLMAAAQSAQA <Light chain constantregion; PRT/1; homo sapiens> SEQ ID NO: 42 TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN RGEC <CH1-CH3; PRT/1; homo sapiens> SEQ ID NO: 43 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK* <heavy chain CH1-CH3 (no c-term K); PRT/1; homo sapiens> SEQ ID NO: 44 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPG <S239C heavy chain CH1-CH3; PRT/1; homo sapiens> SEQ ID NO: 45 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLGGPCVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK <S239C heavy chain CH1-CH3 (no c-term K); PRT/1; homo sapiens> SEQ ID NO: 46 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSQVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLGGPCVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPG <hLiv1 mAb2 HA; PRT/1;artificial> SEQ ID NO: 47 QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGWI DPENGDTEYGPKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARHNAH YGTWFAYWGQGTLVTVSS <hLiv1 mAb2 HB; PRT/1; artificial> SEQ ID NO: 48 QVQLVQSGAEVKKPGASVKVSCKASGYTIEDYYMHWVRQAPGQGLEWMGWI DPENGDTEYGPKFQGRVTMTRDTSINTAYMELSRLRSDDTAVYYCARHNAH YGTWFAYWGQGTLVTVSS <hLiv1 mAb2 HC; PRT/1; artificial> SEQ ID NO: 49 QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGWI DPENGDTEYGPKFQGKATMTADTSISTAYMELSRLRSDDTAVYYCARHNAH YGTWFAYWGQGTLVTVSS <hLiv1 mAb2 HD; PRT/1; artificial> SEQ ID NO: 50 QVQLVQSGAEVKKPGASVKVSCKASGLTFTDYYMHWVRQAPGQGLEWMGWI DPENGDTEYGPKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCTVHNAH YGTWFAYWGQGTLVTVSS <hLiv1 mAb2 HE; PRT/1; artificial> SEQ ID NO: 51 QVQLVQSGAEVKKPGASVKVSCKASGLNIEDYYMHWVRQAPGQGLEWIGWI DPENGDTEYGPKFQGKATMTADTSINTAYMELSRLRSDDTAVYYCTVHNAH YGTWFAYWGQGTLVTVSS <hLiv1 mAb2 HF; PRT/1 artificial> SEQ ID NO: 52 QVQLVQSGAEVKKPGASVKVSCKASGLTIEDYYMHWVRQAPGQGLEWMGWI DPENGDTEYGPKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAVHNAH YGTWFAYWGQGTLVTVSS <hLiv1 mAb2 HG; PRT/1; artificial> SEQ ID NO: 53 QVQLVQSGAEVKKPGASVKVSCKASGLTIEDYYMHWVRQAPGQGLEWMGWI DPENGDTEYGPKFQGRVTMTRDTSINTAYMELSRLRSDDTAVYYCAVHNAH YGTWFAYWGQGTLVTVSS <hLiv1 mAb2 LA; PRT/1; artificial> SEQ ID NO: 54 DVVMTQSPLSLPVTLGQPASISCRSSQSLLHSSGNTYLEWFQQRPGQSPRR LIYKISTRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYT FGGGTKVEIKR <hLiv1 mAb2 LB; PRT/1; artificial> SEQ ID NO: 55 DVVMTQSPLSLPVTLGQPASISCRSSQSLLHSSGNTYLEWYQQRPGQSPRR LIYKISTRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYT FGGGTKVEIKR <hLiv1 mAb2 LC; PRT/1; artificial> SEQ ID NO: 56 DVVMTQSPLSLPVTLGQPASISCRSSQSLLHSSGNTYLEWFLQRPGQSPRR LIYKISTRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYT FGGGTKVEIKR <hLiv1 mAb2 LD; PRT/1; artificial> SEQ ID NO:57 DVVMTQSPLSLPVTLGQPASISCRSSQSLLHSSGNTYLEWFQQRPGQSPKR LIYKISTRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYT FGGGTKVEIKR <hLiv1 mAb2 LE; PRT/1; artificial> SEQ ID NO: 58 DVVMTQSPLSLPVTLGQPASISCRSSQSLLHSSGNTYLEWFQQRPGQSPRP LIYKISTRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYT FGGGTKVEIKR
<hLiv1 mAb2 LF; PRT/1; artificial> SEQ ID NO: 59 DVVMTQSPLSLPVTLGQPASISGRSSQSLLHSSGNTYLEWYLQRPGQSPKP LIYKISTRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYT FGGGTKVEIKR <hLiv1 mAb2 LG; PRT/1; artificial> SEQ ID NO: 60 DVVMTQSPLSLPVTLGQPASISCRSSQSLLHSSGNTYLEWYQQRPGQSPRP LIYKISTRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYT FGGGTKVEIKR DNA seguences: <Liv1 mAb2 heavy chain leader; DNA; mus musculus> SEQ ID NO: 61 atgaaatgcagctgggtcatattcttcctgatggcgtggttataggaatc aattca <Liv1 mAb2 light chain leader; DNA; mus musculus> SEQ ID NO: 62 atgaagttgcctgttaggctgttggtgctgatgttcgatttgctacc agcagt <replacement heavy chain leader seguence; DNA; mus musculus> SEQ ID NO: 63 atggcttgggtgtggaccttgctattcctgatggcagctgcccaaagtgcc caagca <light chain constant region; DNA; homo sapiens> SEQ ID NO: 64 acgacggtggctgcaccatctgtcttcatcttcccgccatctgatgagcag ttgaaatctggaactgcctctgttgtgtgcctgctgaataacttctatccc agagaggccaaagtacagtggaaggtggataacgccctccaatcgggtaac tcccaggagagtgtcacagagcaggacagcaaggacagcacctacagcctc agcagcaccctgacgctgagcaaagcagactacgagaaacacaaagtctac gcctgcgaagtcacccatcagggcctgagctcgcccgtcacaaagagcttc aacaggggagagtgttag <CH1-CH3; DNA; homo sapiens> SEQ ID NO: 65 gctagcaccaagggcccatctgtcttccccctggcaccctcctccaagagc acctctgggggcacagctgccctgggctgcctggtcaaggactacttccct gaacctgtgacagtgtcctggaactcaggcgccctgaccagcggcgtgcac accttcccggctgtcctacagtcctcaggactctactccctcagcagcgtg gtgaccgtgccctccagcagcttgggcacccagacctacatctgcaacgtg aatcacaagcccagcaacaccaaggtggacaagaaagttgagcccaaatct tgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctgggg ggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatc tcccggacccctgaggtcacatucgtggtggtggacgtgagccacgaagac cctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgcc aagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagc gtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgc aaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaa gccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgg gatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttc tatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaac aactacaagaccacgcctcccgtgctggactccgacggctccttcttcctc tacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttc tcatgctccgtgatgcatgaggctctgcacaaccactacacacagaagagc cttccctgtctccgggtaaa <CH1-CH3 (w/o c-term K); DNA; homo sapiens> SEQ ID NO: 66 gctagcaccaagggcccatctgtcttccccctggcaccctcctccaagagc acctctgggggcacagctaccctgggctgcctggtcaagcractacttcct gaacctgtgacagtgtcctggaactcaggcgccctgaccagcggcgtgcac accttcccggctgtcctacagtcctcaggactctactccctcagcagcgtg gtgaccgtgccctccagcagcttgggcacccagacctacatctgcaacgtg aatcacaagcccagcaacaccaaggtggacaagaaagttgagcccaaatct tgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctgggg ggaccgtcagtcttcctcttccccccaaaacccaagaacaccctcatgatc tcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagac cctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgcc aagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagc gtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgc aaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaa gccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgg gatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttc tatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaac aactacaagaccacgcctcccgtgctggactccgacggctccttcttcctc tacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttc tcatgctccgtgatgcatgaggctctgcacaaccactacacacagaagagc ctctccctgtctccgggt <S239C CH1-CH3; DNA; artificial> SEQ ID NO: 67 gctagcaccaagggcccatctgtcttccccctggcaccctcctccaagagc acctctgggggcacagctgccctgggctgcctggtcaaggactacttccct gaacctgtgacagtgtcctggaactcaggcgccctgaccagcggcgtgcac accttcccggctgtcctacagtcctcaggactctactccctcagcagcgtg gtgaccgtgccctccagcagcttgggcacccagacctacatctgcaacgtg aatcacaagcccagcaacaccaaggtggacaagaaagttgagcccaaatct tgtgacaaaactcacacatgcccaccgtgcccaacacctgaactcctgggg ggaccgtgtgtcttcctcttccccccaaaacccaaggacaccctcatgatc tcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagac cctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgcc aagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagc gtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgc aaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaa gccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgg gatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttc tatcccagcgacatcgccgtggagtgggagagcaatgagcagccggagaac aactataagaccacgcctcccgtgctggactccgacggctccttcttcctc tacagcaagctcaccgtggacaagagcaggtggcagcaagggaacgtcttc tcatgctccgtgatgcatgaggctctgcacaaccactacacacagaagagc ctctccctgtctccgggtaaa <S239C CH1-CH3 (w/o c-term K); DNA; artificial> SEQ ID NO: 68 gctagcaccaagggcccatctgtcttccccctggcaccctcctccaagagc acctctgggggcacagctgccctgggctgcctggtcaaggactacttccct gaacctgtgacagtgtcctggaactcaggcgccctgaccagcggcgtgcac accttcccggctgtcctacagtcctcaggactctactccctcagcagcgtg gtgaccgtgccctccagcagcttgggcacccagacctacatctgcaacgtg aatcacaagcccagcaacaccaaggtggacaagaaagttgagcccaaatct tgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctgggg ggaccgtgtgtcttcctcttccccccaaaacccaaggacaccctcatgatc tcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagac cctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgcc aagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagc gtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgc aaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaa gccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgg gatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttc tatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaac aactacaagaccacgcctcccgtgctggactccgacggctccttcttcctc tacagcaagctcaccgtggacaagagcaggtggcagcaggggaacatcttc tcatgctccgtgatgcatgaggctctgcacaaccactacacacagaagagc ctctccctgtctccgggt <hLiv1 mAb2 HA; DNA; artificial> SEQ ID NO: 69 caggtgcagctggtgcagtctggggctgaggtgaagaagcctggggcctca gtgaaggtctcctgcaaggcttctggatacaccttcacagactactatatg cactgggtgaggcaggcccctggacaagggcttgagtggatgggatggatt gatcctgaaaatggtgatactgaatatggcccgaagttccagggcagggtc accatgaccagggacacctccatcagcacagcctacatggagctgagcagg ctgagatctgatgacacagctgtgtattactgtgccagacataatgctcac tacgggacctggtttgcttactggggccaaggaaccctggtcacagtctcc tca <hLiv1 mAb2 HB; DNA; artificial> SEQ ID NO: 70 caggtgcagctggtgcagtctggggctgaggtaaagaagcctggggcctca gtgaaggtctcctgcaaggcttctggatacaccattgaagactactatatg cactgggtgaggcaggcccctggacaagggcttgagtggatgggatggatt gatcctgaaaatggtgatactgaatatggcccgaagttccagggcagggtc accatgaccagggacacctccatcaacacagcctacatggagctgagcagg ctgagatctgatgacacagctgtgtattactgtgccagacataatgctcac
tacgggacctggtttgcttactggggccaaggaaccctggtcacagtctcc tca <hLiv1 mAb2 HC; DNA; artificial> SEQ ID NO: 71 caggtgcaactggtgcagtctggggctgaggtgaagaagcctggggcctca gtgaaggtctcctgcaaggcttctggatacaccttcacagactactatatg cactgggtgaggcaggcccctggacaagggcttgagtggatgggatggatt gatcctgaaaatggtgatactgaatatggcccgaagttccagggcaaggcc accatgaccgcagacacctccatcagcacagcctacatggagctgagcagg ctgagatctgatgacacagctgtgtattactgtgccagacataatgctcac tacgggacctggtttgcttactggggccaaagaaccctggtcacagtctcc tca <hLiv1 mAb2 HD; DNA; artificial> SEQ ID NO: 72 Caggtgcaactggtgcagtctggggctgaggtgaagaagcctggggcctca gtgaaggtctcctgcaaggcttctggactcaccttcacagactactatatg cactgggtgaggcaggcccctggacaagggcttgagtggatgggatggatt gatcctgaaaatggtgatactgaatatggcccgaagttccagggcagggtc accatgaccagggacacctccatcagcacagcctacatggagctgagcagg ctgagatctgatgacacagctgtgtattactgtactgtccataatgctcac tacggaacctggtttgcttactggggccaaggaaccctggtcacagtctcc tca <hLiv1 mAb2 HE; DNA; artificial> SEQ ID NO: 73 caggtgcagctggtgcagtctggggctgaggtgaagaagcctggggcctca gtgaaggtctcctgcaaggcttctggactcaacattgaagactactatatg cactgggtgaggcaggcccctggacaagggcttgagtggattgaatggatt gatcctgaaaatggtgatactgaatatggcccgaagttccagggcaaggcc accatgaccgcagacacctccatcaacacagcctacatggagctgagcagg ctgagatctgatgacacagctgtgtattactgtactgtccataatgctcac tacgggacctggtttgcttactggggccaaggaaccctggtcacagtctcc tca <hLiv1 mAb2 HF; DNA; artificial> SEQ ID NO: 74 caggtgcagctggtgcagtctggggctgaggtgaagaagcctggggcctca gtgaaggtctcctgcaaggcttctggactcaccattgaagactactatatg cactgggtgaggcaggcccctggacaagggcttgagtggatgggatggatt gatcctgaaaatggtgatactgaatatggcccaaagttccagggcagggtc accatgaccagggacacctccatcagcacagcctacatggagctgagcagg ctgagatctgatgacacagctgtgtattactgtgccgtccataatgctcac tacgggacctggtttgcttactggggccaaggaaccctggtcacagtctcc tca <hLiv1 mAb2 HG; DNA; artificial> SEQ ID NO: 75 caggtgcagctggtgcagtctggggctgaggtgaagaagcctggggcctca gtgaaggtctcctgcaaggcttctagactcaccattgaagactactatatg cactgggtgaggcaggcccctggacaagggcttgagtggatgggatggatt gatcctgaaaatggtgatactgaatatggcccgaagttccagggcagggtc accatgaccaggaacacctccatcaacacagccLacatggagctgagcagg ctgagatctgatgacacagctgtgtattactgtgccgtccataatgctcac tacaggacctggtttgcttactggggccaaggaaccctggtcacagtctcc tca <hLiv1 mAb2 LA; DNA; artificial> SEQ ID NO: 76 gatgttctggattcctactaccagcagtgatgttgtgatgactcagtctcc actctccctgcctgtcacccttggacagcctgcctccatctcctacagatc tagtcagagccttttacacagtagtggaaacacctatttagaatagtttca gcagaggccaggccaatctccaaggaggctaatttataaaatttccacccg attttctggggccccaaacagattctctggcagtgggtcaggcactgattt cacactgaaaatcagcagggtggaggctgaggatgttagggtttattactg ctttcaaggttcacatgttccctacacctttggaggaaggaccaaggtgga gatcaaacgtacg <hLiv1 mAb2 LB; DNA; artificial> SEQ ID NO: 77 gatgttctggattcctgctaccagcagtgatgttgtgatgactcagtctcc actctccctgcctgtcacccttggacagcctgcctccatctcctgcagatc tagtcagagccttttacacagtagtggaaacacctatttagaatggtacca gcagaggccaggccaatctccaaggaggctaatttataaaatttccacccg attttctggggtcccagacagattctctggcagtgggtcaggcactgattt cacactgaaaatcagcagggtggaggctgaggatgttggggtttattactg ctttcaaggttcacatgttccctacacctttggaggagggaccaaggtgga gatcaaacgtacg <hLiv1 mAb2 LC; DNA; artificial> SEQ ID NO: 78 gatgttctggattcctgctaccagcagtgatgttgtgatgactcagtctcc actctccctgcctgtcacccttggacagcctgcctccatctcctgcagatc tagtcagagccttttacacagtagtggaaacacctatttagaatggtttct gcagaggccaggccaatctccaaggaggctaatttataaaatttccacccg attttctggggtcccagacagattctctggcagtgggtcaggcactgattt cacactgaaaatcagcagggtggaggctgaggatgttggggtttattactg ctttcaaggttcacatgttccctacacctttggaggagggaccaaggtgga gatcaaacgtacg <hLiv1 mAb2 LD; DNA; artificial> SEQ ID NO: 79 gatgttctggattcctgctaccagcagtgatgttgtgatgactcagtctcc actctccctgcctgtcacccttggacagcctgcctccatctcctgcagatc tagtcagagccttttacacagtagtggaaacacctatttagaatggtttca gcagaggccaggccaatctccaaagaggctaatttataaaatttccacccg attttctggggtcccagacagattctctggcagtgggtcaagcactgattt cacactgaaaatcagcagggtggaggctgaggatgttggggtttattactg ctttcaaggttcacatgttccctacacctttggaggagggaccaaggtgga gatcaaacgtacg <hLiv1 mAb2 LE; DNA; artificial> SEQ ID NO: 80 gatgttctggattcctgctaccagcagtgatgttgtgatgactcagtctcc actctccctgcctgtcacccttggacagcctgcctccatctcctgcagatc tagtcagagccttttacacagtagtggaaacacctatttagaatggtttca gcagaggccaggccaatctccaaggcccctaatttataaaatttccacccg attttctggggtcccagacagattctctggcagtgggtcaggcactgattt cacactgaaaatcagcagggtggaggctgaggatgttggggtttattactg ctttcaaggttcacatgttccctacacctttggaggagggaccaaggtgga gatcaaacgtacg <hLiv1 mAb2 LF; DNA; artificial> SEQ ID NO: 81 gatgttgtgatgactcagtctccactctccctgcctgtcacccttggacag cctgcctccatctcctgcagatctagtcagagccttttacacagtagtgga aacacctatttagaatggtacctgcagaggccaggccaatctccaaagccc ctaatttataaaatttccacccgattttctggggtcccaaacagattctct ggcagtgggtcaggcactgatttcacactgaaaatcagcagggtggaggct gaggatgttggggtttattactgctttcaaggttcacatgttccctacacc tttggaggagggaccaaggtggagatcaaacgt <hLiv1 BR2-22a LG; DNA; artificial> SEQ ID NO: 82 gatgttgtgatgactcagtctccactctccctgcctgtcacccttggacag cctgcctccatctcctgcagatctagtcagagccttttacacagtagtgga aacacctatttagaatggtaccagcagaggccaggccaatctccaaggccc ctaatttataaaatttccacccgattttctggggtcccagacagattctct ggcagtgggtcaggcactgatttcacactgaaaatcagcagggtggaggct gaggatgttggggtttattactgctttcaaggttcacatgttccctacacc tttggaggagggaccaaggtggagatcaaacgt <Q13433; protein SEQ ID NO: 83 MARKLSVILI LTFALSVTNP LHELKAAAFP QTTEKISPNW ESGINVDLAI STRQYHLQQL FYRYGENNSL SVEGFRKLLQ NIGIDKIKRI HIHHDHDHHS DHEHHSDHER HSDHEHHSEH EHHSDHDHHS HHNHAASGKN KRKALCPDHD SDSSGKDPRN SQGKGAHRPE HASGRRNVKD SVSASEVTST VYNTVSEGTH FLETIETPRP GKLFPKDVSS STPPSVTSKS RVSRLAGRKT NESVSEPRKG FMYSRNTNEN PQECFNASKL LTSHGMGIQV PLNATEFNYL CPAIINQIDA RSCLIHTSEK KAEIPPKTYS LQIAWVGGFI AISIISFLSL LGVILVPLMN RVFFKFLLSF LVALAVGTLS GDAFLHLLPH SHASHHHSHS HEEPAMEMKR GPLFSHLSSQ NIEESAYFDS TWKGLTALGG LYFMFLVEHV LTLIKQFKDK KKKNQKKPEN DDDVEIKKQL SKYESQLSTN EEKVDTDDRT EGYLRAPSQE PSHFDSQQPA VLEEEEVMIA HAHPQEVYNE YVPRGCKNKC HSHFHDTLGQ SDDLIHHHHD YHHILHHHHH QNHHPHSHSQ RYSREELKDA GVATLAWMVI MGDGLHNFSD GLAIGAAFTE GLSSGLSTSV AVFCHELPHE
LGDFAVLLKA GMTVKQAVLY NALSAMLAYL GMATGIFIGH YAENVSMWIF ALTAGLFMYV ALVDMVPEML HNDASDHGCS RWGYFFLQNA GMLLGFGIML LISIFEHKIV FRINF <AAA96258.2; protein SEQ ID NO: 84 MARKLSVILI LTFALSVTNP LHELKAAAFP QTTEKISPNW ESGINVDLAI STRQYHLQQL FYRYGENNSL SVEGFRKLLQ NIGIDKIKRI HIHHDHDHHS DHEHHSDHER HSDHEHHSDH EHHSDHNHAA SGKNKRKALC PDHDSDSSGK DPRNSQGKGA HRPEHASGRR NVKDSVSASE VTSTVYNTVS EGTHFLETIE TPRPGKLFPK DVSSSTPPSV TSKSRVSRLA GRKTNESVSE PRKGFMYSRN TNENPQECFN ASKLLTSHGM GIQVPLNATE FNYLCPAIIN QIDARSCLIH TSEKKAEIPP KTYSLQIAWV GGFIAISIIS FLSLLGVILV PLMNRVFFKF LLSFLVALAV GTLSGDAFLH LLPHSHASHH HSHSHEEPAM EMKRGPLFSH LSSQNIEESA YFDSTWKGLT ALGGLYFMFL VEHVLTLIKQ FKDKKKKNQK KPENDDDVEI KKQLSKYESQ LSTNEEKVDT DDRTEGYLRA DSQEPSHFDS QQPAVLEEEE VMIAHAHPQE VYNEYVPRGC KNKCHSHFHD TLGQSDDLIH HHHDYHHILH HHHHQNHHPH SHSQRYSREE LKDAGVATLA WMVIMGDGLH NFSDGLAIGA AFTEGLSSGL STSVAVFCHE LPHELGDFAV LLKAGMTVKQ AVLYNALSAM LAYLGMATGI FIGHYAENVS MWTFALTAGL FMYVALVDMV PEMLHNDASD HGCSRWGYFF LQNAGMLLGF GIMLLISIFE HKIVFRINF >Cyno LIV-1 SEQ ID NO: 85 MARKLSVILILTFTLSVTNPLHELKSAAAFPQTTEKISPNWESGINVDLAI TTRQYHLQQLFYRYGENNSLSVEGFRKLLQNIGIDKIKRIHIHHDHDHHSD HEHHSDHEHHSDHEHHSHRNHAASGKNKRKALCPEHDSDSSGKDPRNSQGK GAHRPEHANGRRNVKDSVSTSEVTSTVYNTVSEGTHFLETIETPKLFPKDV SSSTPPSVTEKSLVSRLAGRKTNESMSEPRKGFMYSRNTNENPQECFNASK LLTSHGMGIQVPLNATEFNYLCPAIINQIDARSCLIHTSEKKAEIPPKTYS LQIAWVGGFIAISIISFLSLLGVILVPLMNRVFFKFLLSFLVALAVGTLSG DAFLHLLPHSHASHHHSHSHEEPAMEMKRGPLFSHLSSQNIEESAYFDSTW KGLTALGGLYFMFLVEHVLTLIKQFKDKKKKNQKKPENDDDVEIKKQLSKY ESQLSTNEEKVDTDDRTEGYLRADSQEPSHFDSQQPAILEEEEVMIAHAHP QEVYNEYVPRGCKNKCHSHFHDTLGQSDDLIHHHHDYHHILHHHHHQNHHP HSHSQRYSREELKDAGIATLAWMVIMGDGLHNFSDGLAIGAAFTEGLSSGL STSVAVFCHELPHELGDFAVLLKAGMTVKQAVLYNALSAMLAYLGMATGIF IGHYAENVSMWIFALTAGLFMYVALVDMVPEMLHNDASDHGCSRWGYFFLQ NAGMLLGFGIMLLISIFEHKIVFRINF
Sequence CWU
1
1
90119PRTMus musculus 1Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp
Ile Pro Val1 5 10 15Ser
Thr Ser219PRTMus musculus 2Met Lys Cys Ser Trp Val Ile Phe Phe Leu Met
Ala Val Val Leu Gly1 5 10
15Ile Asn Ser319PRTMus musculus 3Met Ala Trp Val Trp Thr Leu Leu Phe Leu
Met Ala Ala Ala Gln Ser1 5 10
15Ala Gln Ala4106PRTHomo sapiens 4Thr Val Ala Ala Pro Ser Val Phe
Ile Phe Pro Pro Ser Asp Glu Gln1 5 10
15Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn
Phe Tyr 20 25 30Pro Arg Glu
Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 35
40 45Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp
Ser Lys Asp Ser Thr 50 55 60Tyr Ser
Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys65
70 75 80His Lys Val Tyr Ala Cys Glu
Val Thr His Gln Gly Leu Ser Ser Pro 85 90
95Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100
1055330PRTHomo sapiens 5Ala Ser Thr Lys Gly Pro Ser Val
Phe Pro Leu Ala Pro Ser Ser Lys1 5 10
15Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
Asp Tyr 20 25 30Phe Pro Glu
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35
40 45Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
Ser Gly Leu Tyr Ser 50 55 60Leu Ser
Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr65
70 75 80Tyr Ile Cys Asn Val Asn His
Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90
95Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys
Pro Pro Cys 100 105 110Pro Ala
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115
120 125Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
Thr Pro Glu Val Thr Cys 130 135 140Val
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp145
150 155 160Tyr Val Asp Gly Val Glu
Val His Asn Ala Lys Thr Lys Pro Arg Glu 165
170 175Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
Leu Thr Val Leu 180 185 190His
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195
200 205Lys Ala Leu Pro Ala Pro Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly 210 215
220Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu225
230 235 240Leu Thr Lys Asn
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245
250 255Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
Asn Gly Gln Pro Glu Asn 260 265
270Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285Leu Tyr Ser Lys Leu Thr Val
Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295
300Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
Thr305 310 315 320Gln Lys
Ser Leu Ser Leu Ser Pro Gly Lys 325
3306329PRTHomo sapiens 6Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
Pro Ser Ser Lys1 5 10
15Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30Phe Pro Glu Pro Val Thr Val
Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40
45Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr
Ser 50 55 60Leu Ser Ser Val Val Thr
Val Pro Ser Ser Ser Leu Gly Thr Gln Thr65 70
75 80Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
Thr Lys Val Asp Lys 85 90
95Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110Pro Ala Pro Glu Leu Leu
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120
125Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
Thr Cys 130 135 140Val Val Val Asp Val
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp145 150
155 160Tyr Val Asp Gly Val Glu Val His Asn Ala
Lys Thr Lys Pro Arg Glu 165 170
175Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190His Gln Asp Trp Leu
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195
200 205Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
Lys Ala Lys Gly 210 215 220Gln Pro Arg
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu225
230 235 240Leu Thr Lys Asn Gln Val Ser
Leu Thr Cys Leu Val Lys Gly Phe Tyr 245
250 255Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
Gln Pro Glu Asn 260 265 270Asn
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275
280 285Leu Tyr Ser Lys Leu Thr Val Asp Lys
Ser Arg Trp Gln Gln Gly Asn 290 295
300Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr305
310 315 320Gln Lys Ser Leu
Ser Leu Ser Pro Gly 3257330PRTHomo sapiens 7Ala Ser Thr
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys1 5
10 15Ser Thr Ser Gly Gly Thr Ala Ala Leu
Gly Cys Leu Val Lys Asp Tyr 20 25
30Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45Gly Val His Thr Phe Pro Ala
Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55
60Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr65
70 75 80Tyr Ile Cys Asn
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85
90 95Lys Val Glu Pro Lys Ser Cys Asp Lys Thr
His Thr Cys Pro Pro Cys 100 105
110Pro Ala Pro Glu Leu Leu Gly Gly Pro Cys Val Phe Leu Phe Pro Pro
115 120 125Lys Pro Lys Asp Thr Leu Met
Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135
140Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn
Trp145 150 155 160Tyr Val
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175Glu Gln Tyr Asn Ser Thr Tyr
Arg Val Val Ser Val Leu Thr Val Leu 180 185
190His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
Ser Asn 195 200 205Lys Ala Leu Pro
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210
215 220Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
Ser Arg Asp Glu225 230 235
240Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255Pro Ser Asp Ile Ala
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260
265 270Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
Gly Ser Phe Phe 275 280 285Leu Tyr
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290
295 300Val Phe Ser Cys Ser Val Met His Glu Ala Leu
His Asn His Tyr Thr305 310 315
320Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325
3308329PRTHomo sapiens 8Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
Leu Ala Pro Ser Ser Lys1 5 10
15Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30Phe Pro Glu Pro Val Thr
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40
45Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu
Tyr Ser 50 55 60Leu Ser Ser Val Val
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr65 70
75 80Tyr Ile Cys Asn Val Asn His Lys Pro Ser
Asn Thr Lys Val Asp Lys 85 90
95Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110Pro Ala Pro Glu Leu
Leu Gly Gly Pro Cys Val Phe Leu Phe Pro Pro 115
120 125Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
Glu Val Thr Cys 130 135 140Val Val Val
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp145
150 155 160Tyr Val Asp Gly Val Glu Val
His Asn Ala Lys Thr Lys Pro Arg Glu 165
170 175Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
Leu Thr Val Leu 180 185 190His
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195
200 205Lys Ala Leu Pro Ala Pro Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly 210 215
220Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu225
230 235 240Leu Thr Lys Asn
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245
250 255Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
Asn Gly Gln Pro Glu Asn 260 265
270Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285Leu Tyr Ser Lys Leu Thr Val
Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295
300Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
Thr305 310 315 320Gln Lys
Ser Leu Ser Leu Ser Pro Gly 3259120PRTArtificial
SequenceSynthesized 9Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
Pro Gly Ala1 5 10 15Ser
Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20
25 30Tyr Met His Trp Val Arg Gln Ala
Pro Gly Gln Gly Leu Glu Trp Met 35 40
45Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Pro Thr Phe
50 55 60Gln Gly Arg Val Thr Met Thr Arg
Asp Thr Ser Ile Ser Thr Ala Tyr65 70 75
80Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val
Tyr Tyr Cys 85 90 95Ala
Arg His Asp Ala His Tyr Gly Thr Trp Phe Ala Tyr Trp Gly Gln
100 105 110Gly Thr Leu Val Thr Val Ser
Ser 115 12010120PRTArtificial SequenceSynthesized
10Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1
5 10 15Ser Val Lys Val Ser Cys
Lys Ala Ser Gly Tyr Thr Ile Glu Asp Tyr 20 25
30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
Glu Trp Met 35 40 45Gly Trp Ile
Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Pro Thr Phe 50
55 60Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile
Asn Thr Ala Tyr65 70 75
80Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ala Arg His Asp Ala His
Tyr Gly Thr Trp Phe Ala Tyr Trp Gly Gln 100
105 110Gly Thr Leu Val Thr Val Ser Ser 115
12011120PRTArtificial SequenceSynthesized 11Gln Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5
10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr
Thr Phe Thr Asp Tyr 20 25
30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45Gly Trp Ile Asp Pro Glu Asn Gly
Asp Thr Glu Tyr Ala Pro Thr Phe 50 55
60Gln Gly Lys Ala Thr Met Thr Ala Asp Thr Ser Ile Ser Thr Ala Tyr65
70 75 80Met Glu Leu Ser Arg
Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85
90 95Ala Arg His Asp Ala His Tyr Gly Thr Trp Phe
Ala Tyr Trp Gly Gln 100 105
110Gly Thr Leu Val Thr Val Ser Ser 115
12012120PRTArtificial SequenceSynthesized 12Gln Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10
15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe
Thr Asp Tyr 20 25 30Tyr Met
His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35
40 45Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr
Glu Tyr Ala Pro Thr Phe 50 55 60Gln
Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr65
70 75 80Met Glu Leu Ser Arg Leu
Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85
90 95Asn Val His Asp Ala His Tyr Gly Thr Trp Phe Ala
Tyr Trp Gly Gln 100 105 110Gly
Thr Leu Val Thr Val Ser Ser 115
12013120PRTArtificial SequenceSynthesized 13Gln Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10
15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile
Glu Asp Tyr 20 25 30Tyr Met
His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr
Glu Tyr Ala Pro Thr Phe 50 55 60Gln
Gly Lys Ala Thr Met Thr Ala Asp Thr Ser Ile Asn Thr Ala Tyr65
70 75 80Met Glu Leu Ser Arg Leu
Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85
90 95Asn Val His Asp Ala His Tyr Gly Thr Trp Phe Ala
Tyr Trp Gly Gln 100 105 110Gly
Thr Leu Val Thr Val Ser Ser 115
12014113PRTArtificial SequenceSynthesized 14Asp Val Val Met Thr Gln Ser
Pro Leu Ser Leu Pro Val Thr Leu Gly1 5 10
15Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile
Ile Arg Asn 20 25 30Asp Gly
Asn Thr Tyr Leu Glu Trp Phe Gln Gln Arg Pro Gly Gln Ser 35
40 45Pro Arg Arg Leu Ile Tyr Arg Val Ser Asn
Arg Phe Ser Gly Val Pro 50 55 60Asp
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65
70 75 80Ser Arg Val Glu Ala Glu
Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85
90 95Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys
Val Glu Ile Lys 100 105
110Arg15113PRTArtificial SequenceSynthesized 15Asp Val Val Met Thr Gln
Ser Pro Leu Ser Leu Pro Val Thr Leu Gly1 5
10 15Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser
Ile Ile Arg Asn 20 25 30Asp
Gly Asn Thr Tyr Leu Glu Trp Tyr Gln Gln Arg Pro Gly Gln Ser 35
40 45Pro Arg Arg Leu Ile Tyr Arg Val Ser
Asn Arg Phe Ser Gly Val Pro 50 55
60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65
70 75 80Ser Arg Val Glu Ala
Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85
90 95Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr
Lys Val Glu Ile Lys 100 105
110Arg16113PRTArtificial SequenceSynthesized 16Asp Val Val Met Thr Gln
Ser Pro Leu Ser Leu Pro Val Thr Leu Gly1 5
10 15Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser
Ile Ile Arg Asn 20 25 30Asp
Gly Asn Thr Tyr Leu Glu Trp Phe Leu Gln Arg Pro Gly Gln Ser 35
40 45Pro Arg Arg Leu Ile Tyr Arg Val Ser
Asn Arg Phe Ser Gly Val Pro 50 55
60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65
70 75 80Ser Arg Val Glu Ala
Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85
90 95Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr
Lys Val Glu Ile Lys 100 105
110Arg17113PRTArtificial SequenceSynthesized 17Asp Val Val Met Thr Gln
Ser Pro Leu Ser Leu Pro Val Thr Leu Gly1 5
10 15Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser
Ile Ile Arg Asn 20 25 30Asp
Gly Asn Thr Tyr Leu Glu Trp Phe Gln Gln Arg Pro Gly Gln Ser 35
40 45Pro Lys Arg Leu Ile Tyr Arg Val Ser
Asn Arg Phe Ser Gly Val Pro 50 55
60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65
70 75 80Ser Arg Val Glu Ala
Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85
90 95Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr
Lys Val Glu Ile Lys 100 105
110Arg18113PRTArtificial SequenceSynthesized 18Asp Val Val Met Thr Gln
Ser Pro Leu Ser Leu Pro Val Thr Leu Gly1 5
10 15Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser
Ile Ile Arg Asn 20 25 30Asp
Gly Asn Thr Tyr Leu Glu Trp Phe Gln Gln Arg Pro Gly Gln Ser 35
40 45Pro Arg Leu Leu Ile Tyr Arg Val Ser
Asn Arg Phe Ser Gly Val Pro 50 55
60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65
70 75 80Ser Arg Val Glu Ala
Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85
90 95Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr
Lys Val Glu Ile Lys 100 105
110Arg19113PRTArtificial SequenceSynthesized 19Asp Val Val Met Thr Gln
Ser Pro Leu Ser Leu Pro Val Thr Leu Gly1 5
10 15Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser
Ile Ile Arg Asn 20 25 30Asp
Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35
40 45Pro Lys Leu Leu Ile Tyr Arg Val Ser
Asn Arg Phe Ser Gly Val Pro 50 55
60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65
70 75 80Ser Arg Val Glu Ala
Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85
90 95Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr
Lys Val Glu Ile Lys 100 105
110Arg2057DNAMus musculus 20atgaaatgca gctgggtcat cttcttcctg atggcagtgg
ttctaggaat caattca 572157DNAMus musculus 21atgaagttgc ctgttaggct
gttggtgctg atgttctgga ttcctgtttc taccagt 572257DNAMus musculus
22atggcttggg tgtggacctt gctattcctg atggcagctg cccaaagtgc ccaagca
5723318DNAMus musculus 23acggtggctg caccatctgt cttcatcttc ccgccatctg
atgagcagtt gaaatctgga 60actgcctctg ttgtgtgcct gctgaataac ttctatccca
gagaggccaa agtacagtgg 120aaggtggata acgccctcca atcgggtaac tcccaggaga
gtgtcacaga gcaggacagc 180aaggacagca cctacagcct cagcagcacc ctgacgctga
gcaaagcaga ctacgagaaa 240cacaaagtct acgcctgcga agtcacccat cagggcctga
gctcgcccgt cacaaagagc 300ttcaacaggg gagagtgt
31824990DNAHomo sapiens 24gctagcacca agggcccatc
tgtcttcccc ctggcaccct cctccaagag cacctctggg 60ggcacagctg ccctgggctg
cctggtcaag gactacttcc ctgaacctgt gacagtgtcc 120tggaactcag gcgccctgac
cagcggcgtg cacaccttcc cggctgtcct acagtcctca 180ggactctact ccctcagcag
cgtggtgacc gtgccctcca gcagcttggg cacccagacc 240tacatctgca acgtgaatca
caagcccagc aacaccaagg tggacaagaa agttgagccc 300aaatcttgtg acaaaactca
cacatgccca ccgtgcccag cacctgaact cctgggggga 360ccgtcagtct tcctcttccc
cccaaaaccc aaggacaccc tcatgatctc ccggacccct 420gaggtcacat gcgtggtggt
ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg 480tacgtggacg gcgtggaggt
gcataatgcc aagacaaagc cgcgggagga gcagtacaac 540agcacgtacc gtgtggtcag
cgtcctcacc gtcctgcacc aggactggct gaatggcaag 600gagtacaagt gcaaggtctc
caacaaagcc ctcccagccc ccatcgagaa aaccatctcc 660aaagccaaag ggcagccccg
agaaccacag gtgtacaccc tgcccccatc ccgggatgag 720ctgaccaaga accaggtcag
cctgacctgc ctggtcaaag gcttctatcc cagcgacatc 780gccgtggagt gggagagcaa
tgggcagccg gagaacaact acaagaccac gcctcccgtg 840ctggactccg acggctcctt
cttcctctac agcaagctca ccgtggacaa gagcaggtgg 900cagcagggga acgtcttctc
atgctccgtg atgcatgagg ctctgcacaa ccactacaca 960cagaagagcc tctccctgtc
tccgggtaaa 99025987DNAHomo sapiens
25gctagcacca agggcccatc tgtcttcccc ctggcaccct cctccaagag cacctctggg
60ggcacagctg ccctgggctg cctggtcaag gactacttcc ctgaacctgt gacagtgtcc
120tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca
180ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacccagacc
240tacatctgca acgtgaatca caagcccagc aacaccaagg tggacaagaa agttgagccc
300aaatcttgtg acaaaactca cacatgccca ccgtgcccag cacctgaact cctgggggga
360ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct
420gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg
480tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacaac
540agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag
600gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc
660aaagccaaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggatgag
720ctgaccaaga accaggtcag cctgacctgc ctggtcaaag gcttctatcc cagcgacatc
780gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccgtg
840ctggactccg acggctcctt cttcctctac agcaagctca ccgtggacaa gagcaggtgg
900cagcagggga acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacaca
960cagaagagcc tctccctgtc tccgggt
98726990DNAArtificial SequenceSynthesized 26gctagcacca agggcccatc
tgtcttcccc ctggcaccct cctccaagag cacctctggg 60ggcacagctg ccctgggctg
cctggtcaag gactacttcc ctgaacctgt gacagtgtcc 120tggaactcag gcgccctgac
cagcggcgtg cacaccttcc cggctgtcct acagtcctca 180ggactctact ccctcagcag
cgtggtgacc gtgccctcca gcagcttggg cacccagacc 240tacatctgca acgtgaatca
caagcccagc aacaccaagg tggacaagaa agttgagccc 300aaatcttgtg acaaaactca
cacatgccca ccgtgcccag cacctgaact cctgggggga 360ccgtgtgtct tcctcttccc
cccaaaaccc aaggacaccc tcatgatctc ccggacccct 420gaggtcacat gcgtggtggt
ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg 480tacgtggacg gcgtggaggt
gcataatgcc aagacaaagc cgcgggagga gcagtacaac 540agcacgtacc gtgtggtcag
cgtcctcacc gtcctgcacc aggactggct gaatggcaag 600gagtacaagt gcaaggtctc
caacaaagcc ctcccagccc ccatcgagaa aaccatctcc 660aaagccaaag ggcagccccg
agaaccacag gtgtacaccc tgcccccatc ccgggatgag 720ctgaccaaga accaggtcag
cctgacctgc ctggtcaaag gcttctatcc cagcgacatc 780gccgtggagt gggagagcaa
tgggcagccg gagaacaact acaagaccac gcctcccgtg 840ctggactccg acggctcctt
cttcctctac agcaagctca ccgtggacaa gagcaggtgg 900cagcagggga acgtcttctc
atgctccgtg atgcatgagg ctctgcacaa ccactacaca 960cagaagagcc tctccctgtc
tccgggtaaa 99027987DNAArtificial
SequenceSynthesized 27gctagcacca agggcccatc tgtcttcccc ctggcaccct
cctccaagag cacctctggg 60ggcacagctg ccctgggctg cctggtcaag gactacttcc
ctgaacctgt gacagtgtcc 120tggaactcag gcgccctgac cagcggcgtg cacaccttcc
cggctgtcct acagtcctca 180ggactctact ccctcagcag cgtggtgacc gtgccctcca
gcagcttggg cacccagacc 240tacatctgca acgtgaatca caagcccagc aacaccaagg
tggacaagaa agttgagccc 300aaatcttgtg acaaaactca cacatgccca ccgtgcccag
cacctgaact cctgggggga 360ccgtgtgtct tcctcttccc cccaaaaccc aaggacaccc
tcatgatctc ccggacccct 420gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc
ctgaggtcaa gttcaactgg 480tacgtggacg gcgtggaggt gcataatgcc aagacaaagc
cgcgggagga gcagtacaac 540agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc
aggactggct gaatggcaag 600gagtacaagt gcaaggtctc caacaaagcc ctcccagccc
ccatcgagaa aaccatctcc 660aaagccaaag ggcagccccg agaaccacag gtgtacaccc
tgcccccatc ccgggatgag 720ctgaccaaga accaggtcag cctgacctgc ctggtcaaag
gcttctatcc cagcgacatc 780gccgtggagt gggagagcaa tgggcagccg gagaacaact
acaagaccac gcctcccgtg 840ctggactccg acggctcctt cttcctctac agcaagctca
ccgtggacaa gagcaggtgg 900cagcagggga acgtcttctc atgctccgtg atgcatgagg
ctctgcacaa ccactacaca 960cagaagagcc tctccctgtc tccgggt
98728360DNAArtificial SequenceSynthesized
28caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc
60tcctgcaagg cttctggata caccttcaca gactactata tgcactgggt gaggcaggcc
120cctggacaag ggcttgagtg gatgggatgg attgatcctg agaatggtga tactgaatat
180gcccccacct tccagggcag ggtcaccatg accagggaca cctccatcag cacagcctac
240atggagctga gcaggctgag atctgatgac acagctgtgt attactgtgc cagacatgat
300gctcactatg ggacctggtt tgcttactgg ggccaaggaa ccctggtcac agtctcctca
36029360DNAArtificial SequenceSynthesized 29caggtgcagc tggtgcagtc
tggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60tcctgcaagg cttctggata
caccattgaa gactactata tgcactgggt gaggcaggcc 120cctggacaag ggcttgagtg
gatgggatgg attgatcctg agaatggtga tactgaatat 180gcccccacct tccagggcag
ggtcaccatg accagggaca cctccatcaa cacagcctac 240atggagctga gcaggctgag
atctgatgac acagctgtgt attactgtgc cagacatgat 300gctcactatg ggacctggtt
tgcttactgg ggccaaggaa ccctggtcac agtctcctca 36030360DNAArtificial
SequenceSynthesized 30caggtgcagc tggtgcagtc tggggctgag gtgaagaagc
ctggggcctc agtgaaggtc 60tcctgcaagg cttctggata caccttcaca gactactata
tgcactgggt gaggcaggcc 120cctggacaag ggcttgagtg gatgggatgg attgatcctg
agaatggtga tactgaatat 180gcccccacct tccagggcaa ggccactatg actgcagaca
cctccatcag cacagcctac 240atggagctga gcaggctgag atctgatgac acagctgtgt
attactgtgc cagacatgat 300gctcactatg ggacctggtt tgcttactgg ggccaaggaa
ccctggtcac agtctcctca 36031360DNAArtificial SequenceSynthesized
31caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc
60tcctgcaagg cttctggatt caccttcaca gactactata tgcactgggt gaggcaggcc
120cctggacaag ggcttgagtg gatgggatgg attgatcctg agaatggtga tactgaatat
180gcccccacct tccagggcag ggtcaccatg accagggaca cctccatcag cacagcctac
240atggagctga gcaggctgag atctgatgac acagctgtgt attactgtgc cagacatgat
300gctcactatg ggacctggtt tgcttactgg ggccaaggaa ccctggtcac agtctcctca
36032360DNAArtificial SequenceSynthesized 32caggtgcagc tggtgcagtc
tggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60tcctgcaagg cttctggatt
caacattgaa gactactata tgcactgggt gaggcaggcc 120cctggacaag ggcttgagtg
gattggatgg attgatcctg agaatggtga tactgaatat 180gcccccacct tccagggcaa
ggccactatg actgcagaca cctccatcaa cacagcctac 240atggagctga gcaggctgag
atctgatgac acagctgtgt attactgtaa tgtccatgat 300gctcactatg ggacctggtt
tgcttactgg ggccaaggaa ccctggtcac agtctcctca 36033339DNAArtificial
SequenceSynthesized 33gatgttgtga tgactcagtc tccactctcc ctgcctgtca
cccttggaca gcctgcctcc 60atctcctgca gatctagtca gagcattata aggaatgatg
gaaacaccta tttggaatgg 120tttcagcaga ggccaggcca atctccaagg aggctaattt
atagagtttc caacaggttt 180tctggggtcc cagacagatt ctctggcagt gggtcaggca
ctgatttcac actgaaaatc 240agcagggtgg aggctgagga tgttggggtt tattactgct
ttcaaggttc acatgttccc 300tacacctttg gaggagggac caaggtggag atcaaacgt
33934339DNAArtificial SequenceSynthesized
34gatgttgtga tgactcagtc tccactctcc ctgcctgtca cccttggaca gcctgcctcc
60atctcctgca gatctagtca gagcattata aggaatgatg gaaacaccta tttggaatgg
120taccagcaga ggccaggcca atctccaagg aggctaattt atagagtttc caacaggttt
180tctggggtcc cagacagatt ctctggcagt gggtcaggca ctgatttcac actgaaaatc
240agcagggtgg aggctgagga tgttggggtt tattactgct ttcaaggttc acatgttccc
300tacacctttg gaggagggac caaggtggag atcaaacgt
33935339DNAArtificial SequenceSynthesized 35gatgttgtga tgactcagtc
tccactctcc ctgcctgtca cccttggaca gcctgcctcc 60atctcctgca gatctagtca
gagcattata aggaatgatg gaaacaccta tttggaatgg 120tttctgcaga ggccaggcca
atctccaagg aggctaattt atagagtttc caacaggttt 180tctggggtcc cagacagatt
ctctggcagt gggtcaggca ctgatttcac actgaaaatc 240agcagggtgg aggctgagga
tgttggggtt tattactgct ttcaaggttc acatgttccc 300tacacctttg gaggagggac
caaggtggag atcaaacgt 33936339DNAArtificial
SequenceSynthesized 36gatgttgtga tgactcagtc tccactctcc ctgcctgtca
cccttggaca gcctgcctcc 60atctcctgca gatctagtca gagcattata aggaatgatg
gaaacaccta tttggaatgg 120tttcagcaga ggccaggcca atctccaaag aggctaattt
atagagtttc caacaggttt 180tctggggtcc cagacagatt ctctggcagt gggtcaggca
ctgatttcac actgaaaatc 240agcagggtgg aggctgagga tgttggggtt tattactgct
ttcaaggttc acatgttccc 300tacacctttg gaggagggac caaggtggag atcaaacgt
33937339DNAArtificial SequenceSynthesized
37gatgttgtga tgactcagtc tccactctcc ctgcctgtca cccttggaca gcctgcctcc
60atctcctgca gatctagtca gagcattata aggaatgatg gaaacaccta tttggaatgg
120tttcagcaga ggccaggcca atctccaagg ctcctaattt atagagtttc caacaggttt
180tctggggtcc cagacagatt ctctggcagt gggtcaggca ctgatttcac actgaaaatc
240agcagggtgg aggctgagga tgttggggtt tattactgct ttcaaggttc acatgttccc
300tacacctttg gaggagggac caaggtggag atcaaacgt
33938339DNAArtificial SequenceSynthesized 38gatgttgtga tgactcagtc
tccactctcc ctgcctgtca cccttggaca gcctgcctcc 60atctcctgca gatctagtca
gagcattata aggaatgatg gaaacaccta tttggaatgg 120tacctgcaga aaccaggcca
atctccaaag ctcctaattt atagagtttc caacaggttt 180tctggggtcc cagacagatt
ctctggcagt gggtcaggca ctgatttcac actgaaaatc 240agcagggtgg aggctgagga
tgttggggtt tattactgct ttcaaggttc acatgttccc 300tacacctttg gaggagggac
caaggtggag atcaaacgt 3393920PRTMus musculus
39Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Val1
5 10 15Ala Thr Ser Ser
204019PRTMus musculus 40Met Lys Cys Ser Trp Val Ile Phe Phe Leu Met Ala
Val Val Ile Gly1 5 10
15Ile Asn Ser4119PRTMus musculus 41Met Ala Trp Val Trp Thr Leu Leu Phe
Leu Met Ala Ala Ala Gln Ser1 5 10
15Ala Gln Ala42106PRTHomo sapiens 42Thr Val Ala Ala Pro Ser Val
Phe Ile Phe Pro Pro Ser Asp Glu Gln1 5 10
15Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn
Asn Phe Tyr 20 25 30Pro Arg
Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 35
40 45Gly Asn Ser Gln Glu Ser Val Thr Glu Gln
Asp Ser Lys Asp Ser Thr 50 55 60Tyr
Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys65
70 75 80His Lys Val Tyr Ala Cys
Glu Val Thr His Gln Gly Leu Ser Ser Pro 85
90 95Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 10543330PRTHomo sapiens 43Ala Ser Thr Lys Gly Pro Ser
Val Phe Pro Leu Ala Pro Ser Ser Lys1 5 10
15Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val
Lys Asp Tyr 20 25 30Phe Pro
Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35
40 45Gly Val His Thr Phe Pro Ala Val Leu Gln
Ser Ser Gly Leu Tyr Ser 50 55 60Leu
Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr65
70 75 80Tyr Ile Cys Asn Val Asn
His Lys Pro Ser Asn Thr Lys Val Asp Lys 85
90 95Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
Cys Pro Pro Cys 100 105 110Pro
Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115
120 125Lys Pro Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro Glu Val Thr Cys 130 135
140Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp145
150 155 160Tyr Val Asp Gly
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165
170 175Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
Ser Val Leu Thr Val Leu 180 185
190His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205Lys Ala Leu Pro Ala Pro Ile
Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215
220Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp
Glu225 230 235 240Leu Thr
Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255Pro Ser Asp Ile Ala Val Glu
Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265
270Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
Phe Phe 275 280 285Leu Tyr Ser Lys
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290
295 300Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
Asn His Tyr Thr305 310 315
320Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325
33044329PRTHomo sapiens 44Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
Leu Ala Pro Ser Ser Lys1 5 10
15Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30Phe Pro Glu Pro Val Thr
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40
45Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu
Tyr Ser 50 55 60Leu Ser Ser Val Val
Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr65 70
75 80Tyr Ile Cys Asn Val Asn His Lys Pro Ser
Asn Thr Lys Val Asp Lys 85 90
95Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110Pro Ala Pro Glu Leu
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115
120 125Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
Glu Val Thr Cys 130 135 140Val Val Val
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp145
150 155 160Tyr Val Asp Gly Val Glu Val
His Asn Ala Lys Thr Lys Pro Arg Glu 165
170 175Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
Leu Thr Val Leu 180 185 190His
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195
200 205Lys Ala Leu Pro Ala Pro Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly 210 215
220Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu225
230 235 240Leu Thr Lys Asn
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245
250 255Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
Asn Gly Gln Pro Glu Asn 260 265
270Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285Leu Tyr Ser Lys Leu Thr Val
Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295
300Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
Thr305 310 315 320Gln Lys
Ser Leu Ser Leu Ser Pro Gly 32545330PRTHomo sapiens 45Ala
Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys1
5 10 15Ser Thr Ser Gly Gly Thr Ala
Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25
30Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
Thr Ser 35 40 45Gly Val His Thr
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55
60Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly
Thr Gln Thr65 70 75
80Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95Lys Val Glu Pro Lys Ser
Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100
105 110Pro Ala Pro Glu Leu Leu Gly Gly Pro Cys Val Phe
Leu Phe Pro Pro 115 120 125Lys Pro
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130
135 140Val Val Val Asp Val Ser His Glu Asp Pro Glu
Val Lys Phe Asn Trp145 150 155
160Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175Glu Gln Tyr Asn
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180
185 190His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
Cys Lys Val Ser Asn 195 200 205Lys
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210
215 220Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
Pro Pro Ser Arg Asp Glu225 230 235
240Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
Tyr 245 250 255Pro Ser Asp
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260
265 270Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
Ser Asp Gly Ser Phe Phe 275 280
285Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290
295 300Val Phe Ser Cys Ser Val Met His
Glu Ala Leu His Asn His Tyr Thr305 310
315 320Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 33046329PRTHomo sapiens 46Ala Ser Thr Lys Gly Pro
Ser Val Phe Pro Leu Ala Pro Ser Ser Lys1 5
10 15Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
Val Lys Asp Tyr 20 25 30Phe
Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35
40 45Gly Val His Thr Phe Pro Ala Val Leu
Gln Ser Ser Gly Leu Tyr Ser 50 55
60Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr65
70 75 80Tyr Ile Cys Asn Val
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85
90 95Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His
Thr Cys Pro Pro Cys 100 105
110Pro Ala Pro Glu Leu Leu Gly Gly Pro Cys Val Phe Leu Phe Pro Pro
115 120 125Lys Pro Lys Asp Thr Leu Met
Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135
140Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn
Trp145 150 155 160Tyr Val
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175Glu Gln Tyr Asn Ser Thr Tyr
Arg Val Val Ser Val Leu Thr Val Leu 180 185
190His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
Ser Asn 195 200 205Lys Ala Leu Pro
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210
215 220Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
Ser Arg Asp Glu225 230 235
240Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255Pro Ser Asp Ile Ala
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260
265 270Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
Gly Ser Phe Phe 275 280 285Leu Tyr
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290
295 300Val Phe Ser Cys Ser Val Met His Glu Ala Leu
His Asn His Tyr Thr305 310 315
320Gln Lys Ser Leu Ser Leu Ser Pro Gly
32547120PRTArtificial SequenceSynthesized 47Gln Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10
15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
Thr Asp Tyr 20 25 30Tyr Met
His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35
40 45Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr
Glu Tyr Gly Pro Lys Phe 50 55 60Gln
Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr65
70 75 80Met Glu Leu Ser Arg Leu
Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85
90 95Ala Arg His Asn Ala His Tyr Gly Thr Trp Phe Ala
Tyr Trp Gly Gln 100 105 110Gly
Thr Leu Val Thr Val Ser Ser 115
12048120PRTArtificial SequenceSynthesized 48Gln Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10
15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Ile
Glu Asp Tyr 20 25 30Tyr Met
His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35
40 45Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr
Glu Tyr Gly Pro Lys Phe 50 55 60Gln
Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Asn Thr Ala Tyr65
70 75 80Met Glu Leu Ser Arg Leu
Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85
90 95Ala Arg His Asn Ala His Tyr Gly Thr Trp Phe Ala
Tyr Trp Gly Gln 100 105 110Gly
Thr Leu Val Thr Val Ser Ser 115
12049120PRTArtificial SequenceSynthesized 49Gln Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10
15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
Thr Asp Tyr 20 25 30Tyr Met
His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35
40 45Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr
Glu Tyr Gly Pro Lys Phe 50 55 60Gln
Gly Lys Ala Thr Met Thr Ala Asp Thr Ser Ile Ser Thr Ala Tyr65
70 75 80Met Glu Leu Ser Arg Leu
Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85
90 95Ala Arg His Asn Ala His Tyr Gly Thr Trp Phe Ala
Tyr Trp Gly Gln 100 105 110Gly
Thr Leu Val Thr Val Ser Ser 115
12050120PRTArtificial SequenceSynthesized 50Gln Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10
15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Leu Thr Phe
Thr Asp Tyr 20 25 30Tyr Met
His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35
40 45Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr
Glu Tyr Gly Pro Lys Phe 50 55 60Gln
Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr65
70 75 80Met Glu Leu Ser Arg Leu
Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85
90 95Thr Val His Asn Ala His Tyr Gly Thr Trp Phe Ala
Tyr Trp Gly Gln 100 105 110Gly
Thr Leu Val Thr Val Ser Ser 115
12051120PRTArtificial SequenceSynthesized 51Gln Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10
15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Leu Asn Ile
Glu Asp Tyr 20 25 30Tyr Met
His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35
40 45Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr
Glu Tyr Gly Pro Lys Phe 50 55 60Gln
Gly Lys Ala Thr Met Thr Ala Asp Thr Ser Ile Asn Thr Ala Tyr65
70 75 80Met Glu Leu Ser Arg Leu
Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85
90 95Thr Val His Asn Ala His Tyr Gly Thr Trp Phe Ala
Tyr Trp Gly Gln 100 105 110Gly
Thr Leu Val Thr Val Ser Ser 115
12052120PRTArtificial SequenceSynthesized 52Gln Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10
15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Leu Thr Ile
Glu Asp Tyr 20 25 30Tyr Met
His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35
40 45Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr
Glu Tyr Gly Pro Lys Phe 50 55 60Gln
Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr65
70 75 80Met Glu Leu Ser Arg Leu
Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85
90 95Ala Val His Asn Ala His Tyr Gly Thr Trp Phe Ala
Tyr Trp Gly Gln 100 105 110Gly
Thr Leu Val Thr Val Ser Ser 115
12053120PRTArtificial SequenceSynthesized 53Gln Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10
15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Leu Thr Ile
Glu Asp Tyr 20 25 30Tyr Met
His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35
40 45Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr
Glu Tyr Gly Pro Lys Phe 50 55 60Gln
Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Asn Thr Ala Tyr65
70 75 80Met Glu Leu Ser Arg Leu
Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85
90 95Ala Val His Asn Ala His Tyr Gly Thr Trp Phe Ala
Tyr Trp Gly Gln 100 105 110Gly
Thr Leu Val Thr Val Ser Ser 115
12054113PRTArtificial SequenceSynthesized 54Asp Val Val Met Thr Gln Ser
Pro Leu Ser Leu Pro Val Thr Leu Gly1 5 10
15Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu
Leu His Ser 20 25 30Ser Gly
Asn Thr Tyr Leu Glu Trp Phe Gln Gln Arg Pro Gly Gln Ser 35
40 45Pro Arg Arg Leu Ile Tyr Lys Ile Ser Thr
Arg Phe Ser Gly Val Pro 50 55 60Asp
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65
70 75 80Ser Arg Val Glu Ala Glu
Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85
90 95Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys
Val Glu Ile Lys 100 105
110Arg55113PRTArtificial SequenceSynthesized 55Asp Val Val Met Thr Gln
Ser Pro Leu Ser Leu Pro Val Thr Leu Gly1 5
10 15Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser
Leu Leu His Ser 20 25 30Ser
Gly Asn Thr Tyr Leu Glu Trp Tyr Gln Gln Arg Pro Gly Gln Ser 35
40 45Pro Arg Arg Leu Ile Tyr Lys Ile Ser
Thr Arg Phe Ser Gly Val Pro 50 55
60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65
70 75 80Ser Arg Val Glu Ala
Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85
90 95Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr
Lys Val Glu Ile Lys 100 105
110Arg56113PRTArtificial SequenceSynthesized 56Asp Val Val Met Thr Gln
Ser Pro Leu Ser Leu Pro Val Thr Leu Gly1 5
10 15Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser
Leu Leu His Ser 20 25 30Ser
Gly Asn Thr Tyr Leu Glu Trp Phe Leu Gln Arg Pro Gly Gln Ser 35
40 45Pro Arg Arg Leu Ile Tyr Lys Ile Ser
Thr Arg Phe Ser Gly Val Pro 50 55
60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65
70 75 80Ser Arg Val Glu Ala
Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85
90 95Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr
Lys Val Glu Ile Lys 100 105
110Arg57113PRTArtificial SequenceSynthesized 57Asp Val Val Met Thr Gln
Ser Pro Leu Ser Leu Pro Val Thr Leu Gly1 5
10 15Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser
Leu Leu His Ser 20 25 30Ser
Gly Asn Thr Tyr Leu Glu Trp Phe Gln Gln Arg Pro Gly Gln Ser 35
40 45Pro Lys Arg Leu Ile Tyr Lys Ile Ser
Thr Arg Phe Ser Gly Val Pro 50 55
60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65
70 75 80Ser Arg Val Glu Ala
Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85
90 95Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr
Lys Val Glu Ile Lys 100 105
110Arg58113PRTArtificial SequenceSynthesized 58Asp Val Val Met Thr Gln
Ser Pro Leu Ser Leu Pro Val Thr Leu Gly1 5
10 15Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser
Leu Leu His Ser 20 25 30Ser
Gly Asn Thr Tyr Leu Glu Trp Phe Gln Gln Arg Pro Gly Gln Ser 35
40 45Pro Arg Pro Leu Ile Tyr Lys Ile Ser
Thr Arg Phe Ser Gly Val Pro 50 55
60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65
70 75 80Ser Arg Val Glu Ala
Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85
90 95Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr
Lys Val Glu Ile Lys 100 105
110Arg59113PRTArtificial SequenceSynthesized 59Asp Val Val Met Thr Gln
Ser Pro Leu Ser Leu Pro Val Thr Leu Gly1 5
10 15Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser
Leu Leu His Ser 20 25 30Ser
Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Arg Pro Gly Gln Ser 35
40 45Pro Lys Pro Leu Ile Tyr Lys Ile Ser
Thr Arg Phe Ser Gly Val Pro 50 55
60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65
70 75 80Ser Arg Val Glu Ala
Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85
90 95Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr
Lys Val Glu Ile Lys 100 105
110Arg60113PRTArtificial SequenceSynthesized 60Asp Val Val Met Thr Gln
Ser Pro Leu Ser Leu Pro Val Thr Leu Gly1 5
10 15Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser
Leu Leu His Ser 20 25 30Ser
Gly Asn Thr Tyr Leu Glu Trp Tyr Gln Gln Arg Pro Gly Gln Ser 35
40 45Pro Arg Pro Leu Ile Tyr Lys Ile Ser
Thr Arg Phe Ser Gly Val Pro 50 55
60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65
70 75 80Ser Arg Val Glu Ala
Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85
90 95Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr
Lys Val Glu Ile Lys 100 105
110Arg6157DNAMus musculus 61atgaaatgca gctgggtcat cttcttcctg atggcagtgg
ttataggaat caattca 576257DNAMus musculus 62atgaagttgc ctgttaggct
gttggtgctg atgttctgga ttcctgctac cagcagt 576357DNAMus musculus
63atggcttggg tgtggacctt gctattcctg atggcagctg cccaaagtgc ccaagca
5764324DNAHomo sapiens 64acgacggtgg ctgcaccatc tgtcttcatc ttcccgccat
ctgatgagca gttgaaatct 60ggaactgcct ctgttgtgtg cctgctgaat aacttctatc
ccagagaggc caaagtacag 120tggaaggtgg ataacgccct ccaatcgggt aactcccagg
agagtgtcac agagcaggac 180agcaaggaca gcacctacag cctcagcagc accctgacgc
tgagcaaagc agactacgag 240aaacacaaag tctacgcctg cgaagtcacc catcagggcc
tgagctcgcc cgtcacaaag 300agcttcaaca ggggagagtg ttag
32465990DNAHomo sapiens 65gctagcacca agggcccatc
tgtcttcccc ctggcaccct cctccaagag cacctctggg 60ggcacagctg ccctgggctg
cctggtcaag gactacttcc ctgaacctgt gacagtgtcc 120tggaactcag gcgccctgac
cagcggcgtg cacaccttcc cggctgtcct acagtcctca 180ggactctact ccctcagcag
cgtggtgacc gtgccctcca gcagcttggg cacccagacc 240tacatctgca acgtgaatca
caagcccagc aacaccaagg tggacaagaa agttgagccc 300aaatcttgtg acaaaactca
cacatgccca ccgtgcccag cacctgaact cctgggggga 360ccgtcagtct tcctcttccc
cccaaaaccc aaggacaccc tcatgatctc ccggacccct 420gaggtcacat gcgtggtggt
ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg 480tacgtggacg gcgtggaggt
gcataatgcc aagacaaagc cgcgggagga gcagtacaac 540agcacgtacc gtgtggtcag
cgtcctcacc gtcctgcacc aggactggct gaatggcaag 600gagtacaagt gcaaggtctc
caacaaagcc ctcccagccc ccatcgagaa aaccatctcc 660aaagccaaag ggcagccccg
agaaccacag gtgtacaccc tgcccccatc ccgggatgag 720ctgaccaaga accaggtcag
cctgacctgc ctggtcaaag gcttctatcc cagcgacatc 780gccgtggagt gggagagcaa
tgggcagccg gagaacaact acaagaccac gcctcccgtg 840ctggactccg acggctcctt
cttcctctac agcaagctca ccgtggacaa gagcaggtgg 900cagcagggga acgtcttctc
atgctccgtg atgcatgagg ctctgcacaa ccactacaca 960cagaagagcc tctccctgtc
tccgggtaaa 99066987DNAHomo sapiens
66gctagcacca agggcccatc tgtcttcccc ctggcaccct cctccaagag cacctctggg
60ggcacagctg ccctgggctg cctggtcaag gactacttcc ctgaacctgt gacagtgtcc
120tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca
180ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacccagacc
240tacatctgca acgtgaatca caagcccagc aacaccaagg tggacaagaa agttgagccc
300aaatcttgtg acaaaactca cacatgccca ccgtgcccag cacctgaact cctgggggga
360ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct
420gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg
480tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacaac
540agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag
600gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc
660aaagccaaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggatgag
720ctgaccaaga accaggtcag cctgacctgc ctggtcaaag gcttctatcc cagcgacatc
780gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccgtg
840ctggactccg acggctcctt cttcctctac agcaagctca ccgtggacaa gagcaggtgg
900cagcagggga acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacaca
960cagaagagcc tctccctgtc tccgggt
98767990DNAArtificial SequenceSynthesized 67gctagcacca agggcccatc
tgtcttcccc ctggcaccct cctccaagag cacctctggg 60ggcacagctg ccctgggctg
cctggtcaag gactacttcc ctgaacctgt gacagtgtcc 120tggaactcag gcgccctgac
cagcggcgtg cacaccttcc cggctgtcct acagtcctca 180ggactctact ccctcagcag
cgtggtgacc gtgccctcca gcagcttggg cacccagacc 240tacatctgca acgtgaatca
caagcccagc aacaccaagg tggacaagaa agttgagccc 300aaatcttgtg acaaaactca
cacatgccca ccgtgcccag cacctgaact cctgggggga 360ccgtgtgtct tcctcttccc
cccaaaaccc aaggacaccc tcatgatctc ccggacccct 420gaggtcacat gcgtggtggt
ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg 480tacgtggacg gcgtggaggt
gcataatgcc aagacaaagc cgcgggagga gcagtacaac 540agcacgtacc gtgtggtcag
cgtcctcacc gtcctgcacc aggactggct gaatggcaag 600gagtacaagt gcaaggtctc
caacaaagcc ctcccagccc ccatcgagaa aaccatctcc 660aaagccaaag ggcagccccg
agaaccacag gtgtacaccc tgcccccatc ccgggatgag 720ctgaccaaga accaggtcag
cctgacctgc ctggtcaaag gcttctatcc cagcgacatc 780gccgtggagt gggagagcaa
tgggcagccg gagaacaact acaagaccac gcctcccgtg 840ctggactccg acggctcctt
cttcctctac agcaagctca ccgtggacaa gagcaggtgg 900cagcagggga acgtcttctc
atgctccgtg atgcatgagg ctctgcacaa ccactacaca 960cagaagagcc tctccctgtc
tccgggtaaa 99068987DNAArtificial
SequenceSynthesized 68gctagcacca agggcccatc tgtcttcccc ctggcaccct
cctccaagag cacctctggg 60ggcacagctg ccctgggctg cctggtcaag gactacttcc
ctgaacctgt gacagtgtcc 120tggaactcag gcgccctgac cagcggcgtg cacaccttcc
cggctgtcct acagtcctca 180ggactctact ccctcagcag cgtggtgacc gtgccctcca
gcagcttggg cacccagacc 240tacatctgca acgtgaatca caagcccagc aacaccaagg
tggacaagaa agttgagccc 300aaatcttgtg acaaaactca cacatgccca ccgtgcccag
cacctgaact cctgggggga 360ccgtgtgtct tcctcttccc cccaaaaccc aaggacaccc
tcatgatctc ccggacccct 420gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc
ctgaggtcaa gttcaactgg 480tacgtggacg gcgtggaggt gcataatgcc aagacaaagc
cgcgggagga gcagtacaac 540agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc
aggactggct gaatggcaag 600gagtacaagt gcaaggtctc caacaaagcc ctcccagccc
ccatcgagaa aaccatctcc 660aaagccaaag ggcagccccg agaaccacag gtgtacaccc
tgcccccatc ccgggatgag 720ctgaccaaga accaggtcag cctgacctgc ctggtcaaag
gcttctatcc cagcgacatc 780gccgtggagt gggagagcaa tgggcagccg gagaacaact
acaagaccac gcctcccgtg 840ctggactccg acggctcctt cttcctctac agcaagctca
ccgtggacaa gagcaggtgg 900cagcagggga acgtcttctc atgctccgtg atgcatgagg
ctctgcacaa ccactacaca 960cagaagagcc tctccctgtc tccgggt
98769360DNAArtificial SequenceSynthesized
69caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc
60tcctgcaagg cttctggata caccttcaca gactactata tgcactgggt gaggcaggcc
120cctggacaag ggcttgagtg gatgggatgg attgatcctg aaaatggtga tactgaatat
180ggcccgaagt tccagggcag ggtcaccatg accagggaca cctccatcag cacagcctac
240atggagctga gcaggctgag atctgatgac acagctgtgt attactgtgc cagacataat
300gctcactacg ggacctggtt tgcttactgg ggccaaggaa ccctggtcac agtctcctca
36070360DNAArtificial SequenceSynthesized 70caggtgcagc tggtgcagtc
tggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60tcctgcaagg cttctggata
caccattgaa gactactata tgcactgggt gaggcaggcc 120cctggacaag ggcttgagtg
gatgggatgg attgatcctg aaaatggtga tactgaatat 180ggcccgaagt tccagggcag
ggtcaccatg accagggaca cctccatcaa cacagcctac 240atggagctga gcaggctgag
atctgatgac acagctgtgt attactgtgc cagacataat 300gctcactacg ggacctggtt
tgcttactgg ggccaaggaa ccctggtcac agtctcctca 36071360DNAArtificial
SequenceSynthesized 71caggtgcagc tggtgcagtc tggggctgag gtgaagaagc
ctggggcctc agtgaaggtc 60tcctgcaagg cttctggata caccttcaca gactactata
tgcactgggt gaggcaggcc 120cctggacaag ggcttgagtg gatgggatgg attgatcctg
aaaatggtga tactgaatat 180ggcccgaagt tccagggcaa ggccaccatg accgcagaca
cctccatcag cacagcctac 240atggagctga gcaggctgag atctgatgac acagctgtgt
attactgtgc cagacataat 300gctcactacg ggacctggtt tgcttactgg ggccaaggaa
ccctggtcac agtctcctca 36072360DNAArtificial SequenceSynthesized
72caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc
60tcctgcaagg cttctggact caccttcaca gactactata tgcactgggt gaggcaggcc
120cctggacaag ggcttgagtg gatgggatgg attgatcctg aaaatggtga tactgaatat
180ggcccgaagt tccagggcag ggtcaccatg accagggaca cctccatcag cacagcctac
240atggagctga gcaggctgag atctgatgac acagctgtgt attactgtac tgtccataat
300gctcactacg ggacctggtt tgcttactgg ggccaaggaa ccctggtcac agtctcctca
36073360DNAArtificial SequenceSynthesized 73caggtgcagc tggtgcagtc
tggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60tcctgcaagg cttctggact
caacattgaa gactactata tgcactgggt gaggcaggcc 120cctggacaag ggcttgagtg
gattggatgg attgatcctg aaaatggtga tactgaatat 180ggcccgaagt tccagggcaa
ggccaccatg accgcagaca cctccatcaa cacagcctac 240atggagctga gcaggctgag
atctgatgac acagctgtgt attactgtac tgtccataat 300gctcactacg ggacctggtt
tgcttactgg ggccaaggaa ccctggtcac agtctcctca 36074360DNAArtificial
SequenceSynthesized 74caggtgcagc tggtgcagtc tggggctgag gtgaagaagc
ctggggcctc agtgaaggtc 60tcctgcaagg cttctggact caccattgaa gactactata
tgcactgggt gaggcaggcc 120cctggacaag ggcttgagtg gatgggatgg attgatcctg
aaaatggtga tactgaatat 180ggcccgaagt tccagggcag ggtcaccatg accagggaca
cctccatcag cacagcctac 240atggagctga gcaggctgag atctgatgac acagctgtgt
attactgtgc cgtccataat 300gctcactacg ggacctggtt tgcttactgg ggccaaggaa
ccctggtcac agtctcctca 36075360DNAArtificial SequenceSynthesized
75caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc
60tcctgcaagg cttctggact caccattgaa gactactata tgcactgggt gaggcaggcc
120cctggacaag ggcttgagtg gatgggatgg attgatcctg aaaatggtga tactgaatat
180ggcccgaagt tccagggcag ggtcaccatg accagggaca cctccatcaa cacagcctac
240atggagctga gcaggctgag atctgatgac acagctgtgt attactgtgc cgtccataat
300gctcactacg ggacctggtt tgcttactgg ggccaaggaa ccctggtcac agtctcctca
36076370DNAArtificial SequenceSynthesized 76gatgttctgg attcctgcta
ccagcagtga tgttgtgatg actcagtctc cactctccct 60gcctgtcacc cttggacagc
ctgcctccat ctcctgcaga tctagtcaga gccttttaca 120cagtagtgga aacacctatt
tagaatggtt tcagcagagg ccaggccaat ctccaaggag 180gctaatttat aaaatttcca
cccgattttc tggggtccca gacagattct ctggcagtgg 240gtcaggcact gatttcacac
tgaaaatcag cagggtggag gctgaggatg ttggggttta 300ttactgcttt caaggttcac
atgttcccta cacctttgga ggagggacca aggtggagat 360caaacgtacg
37077370DNAArtificial
SequenceSynthesized 77gatgttctgg attcctgcta ccagcagtga tgttgtgatg
actcagtctc cactctccct 60gcctgtcacc cttggacagc ctgcctccat ctcctgcaga
tctagtcaga gccttttaca 120cagtagtgga aacacctatt tagaatggta ccagcagagg
ccaggccaat ctccaaggag 180gctaatttat aaaatttcca cccgattttc tggggtccca
gacagattct ctggcagtgg 240gtcaggcact gatttcacac tgaaaatcag cagggtggag
gctgaggatg ttggggttta 300ttactgcttt caaggttcac atgttcccta cacctttgga
ggagggacca aggtggagat 360caaacgtacg
37078370DNAArtificial SequenceSynthesized
78gatgttctgg attcctgcta ccagcagtga tgttgtgatg actcagtctc cactctccct
60gcctgtcacc cttggacagc ctgcctccat ctcctgcaga tctagtcaga gccttttaca
120cagtagtgga aacacctatt tagaatggtt tctgcagagg ccaggccaat ctccaaggag
180gctaatttat aaaatttcca cccgattttc tggggtccca gacagattct ctggcagtgg
240gtcaggcact gatttcacac tgaaaatcag cagggtggag gctgaggatg ttggggttta
300ttactgcttt caaggttcac atgttcccta cacctttgga ggagggacca aggtggagat
360caaacgtacg
37079370DNAArtificial SequenceSynthesized 79gatgttctgg attcctgcta
ccagcagtga tgttgtgatg actcagtctc cactctccct 60gcctgtcacc cttggacagc
ctgcctccat ctcctgcaga tctagtcaga gccttttaca 120cagtagtgga aacacctatt
tagaatggtt tcagcagagg ccaggccaat ctccaaagag 180gctaatttat aaaatttcca
cccgattttc tggggtccca gacagattct ctggcagtgg 240gtcaggcact gatttcacac
tgaaaatcag cagggtggag gctgaggatg ttggggttta 300ttactgcttt caaggttcac
atgttcccta cacctttgga ggagggacca aggtggagat 360caaacgtacg
37080370DNAArtificial
SequenceSynthesized 80gatgttctgg attcctgcta ccagcagtga tgttgtgatg
actcagtctc cactctccct 60gcctgtcacc cttggacagc ctgcctccat ctcctgcaga
tctagtcaga gccttttaca 120cagtagtgga aacacctatt tagaatggtt tcagcagagg
ccaggccaat ctccaaggcc 180cctaatttat aaaatttcca cccgattttc tggggtccca
gacagattct ctggcagtgg 240gtcaggcact gatttcacac tgaaaatcag cagggtggag
gctgaggatg ttggggttta 300ttactgcttt caaggttcac atgttcccta cacctttgga
ggagggacca aggtggagat 360caaacgtacg
37081339DNAArtificial SequenceSynthesized
81gatgttgtga tgactcagtc tccactctcc ctgcctgtca cccttggaca gcctgcctcc
60atctcctgca gatctagtca gagcctttta cacagtagtg gaaacaccta tttagaatgg
120tacctgcaga ggccaggcca atctccaaag cccctaattt ataaaatttc cacccgattt
180tctggggtcc cagacagatt ctctggcagt gggtcaggca ctgatttcac actgaaaatc
240agcagggtgg aggctgagga tgttggggtt tattactgct ttcaaggttc acatgttccc
300tacacctttg gaggagggac caaggtggag atcaaacgt
33982339DNAArtificial SequenceSynthesized 82gatgttgtga tgactcagtc
tccactctcc ctgcctgtca cccttggaca gcctgcctcc 60atctcctgca gatctagtca
gagcctttta cacagtagtg gaaacaccta tttagaatgg 120taccagcaga ggccaggcca
atctccaagg cccctaattt ataaaatttc cacccgattt 180tctggggtcc cagacagatt
ctctggcagt gggtcaggca ctgatttcac actgaaaatc 240agcagggtgg aggctgagga
tgttggggtt tattactgct ttcaaggttc acatgttccc 300tacacctttg gaggagggac
caaggtggag atcaaacgt 33983755PRTHomo sapiens
83Met Ala Arg Lys Leu Ser Val Ile Leu Ile Leu Thr Phe Ala Leu Ser1
5 10 15Val Thr Asn Pro Leu His
Glu Leu Lys Ala Ala Ala Phe Pro Gln Thr 20 25
30Thr Glu Lys Ile Ser Pro Asn Trp Glu Ser Gly Ile Asn
Val Asp Leu 35 40 45Ala Ile Ser
Thr Arg Gln Tyr His Leu Gln Gln Leu Phe Tyr Arg Tyr 50
55 60Gly Glu Asn Asn Ser Leu Ser Val Glu Gly Phe Arg
Lys Leu Leu Gln65 70 75
80Asn Ile Gly Ile Asp Lys Ile Lys Arg Ile His Ile His His Asp His
85 90 95Asp His His Ser Asp His
Glu His His Ser Asp His Glu Arg His Ser 100
105 110Asp His Glu His His Ser Glu His Glu His His Ser
Asp His Asp His 115 120 125His Ser
His His Asn His Ala Ala Ser Gly Lys Asn Lys Arg Lys Ala 130
135 140Leu Cys Pro Asp His Asp Ser Asp Ser Ser Gly
Lys Asp Pro Arg Asn145 150 155
160Ser Gln Gly Lys Gly Ala His Arg Pro Glu His Ala Ser Gly Arg Arg
165 170 175Asn Val Lys Asp
Ser Val Ser Ala Ser Glu Val Thr Ser Thr Val Tyr 180
185 190Asn Thr Val Ser Glu Gly Thr His Phe Leu Glu
Thr Ile Glu Thr Pro 195 200 205Arg
Pro Gly Lys Leu Phe Pro Lys Asp Val Ser Ser Ser Thr Pro Pro 210
215 220Ser Val Thr Ser Lys Ser Arg Val Ser Arg
Leu Ala Gly Arg Lys Thr225 230 235
240Asn Glu Ser Val Ser Glu Pro Arg Lys Gly Phe Met Tyr Ser Arg
Asn 245 250 255Thr Asn Glu
Asn Pro Gln Glu Cys Phe Asn Ala Ser Lys Leu Leu Thr 260
265 270Ser His Gly Met Gly Ile Gln Val Pro Leu
Asn Ala Thr Glu Phe Asn 275 280
285Tyr Leu Cys Pro Ala Ile Ile Asn Gln Ile Asp Ala Arg Ser Cys Leu 290
295 300Ile His Thr Ser Glu Lys Lys Ala
Glu Ile Pro Pro Lys Thr Tyr Ser305 310
315 320Leu Gln Ile Ala Trp Val Gly Gly Phe Ile Ala Ile
Ser Ile Ile Ser 325 330
335Phe Leu Ser Leu Leu Gly Val Ile Leu Val Pro Leu Met Asn Arg Val
340 345 350Phe Phe Lys Phe Leu Leu
Ser Phe Leu Val Ala Leu Ala Val Gly Thr 355 360
365Leu Ser Gly Asp Ala Phe Leu His Leu Leu Pro His Ser His
Ala Ser 370 375 380His His His Ser His
Ser His Glu Glu Pro Ala Met Glu Met Lys Arg385 390
395 400Gly Pro Leu Phe Ser His Leu Ser Ser Gln
Asn Ile Glu Glu Ser Ala 405 410
415Tyr Phe Asp Ser Thr Trp Lys Gly Leu Thr Ala Leu Gly Gly Leu Tyr
420 425 430Phe Met Phe Leu Val
Glu His Val Leu Thr Leu Ile Lys Gln Phe Lys 435
440 445Asp Lys Lys Lys Lys Asn Gln Lys Lys Pro Glu Asn
Asp Asp Asp Val 450 455 460Glu Ile Lys
Lys Gln Leu Ser Lys Tyr Glu Ser Gln Leu Ser Thr Asn465
470 475 480Glu Glu Lys Val Asp Thr Asp
Asp Arg Thr Glu Gly Tyr Leu Arg Ala 485
490 495Asp Ser Gln Glu Pro Ser His Phe Asp Ser Gln Gln
Pro Ala Val Leu 500 505 510Glu
Glu Glu Glu Val Met Ile Ala His Ala His Pro Gln Glu Val Tyr 515
520 525Asn Glu Tyr Val Pro Arg Gly Cys Lys
Asn Lys Cys His Ser His Phe 530 535
540His Asp Thr Leu Gly Gln Ser Asp Asp Leu Ile His His His His Asp545
550 555 560Tyr His His Ile
Leu His His His His His Gln Asn His His Pro His 565
570 575Ser His Ser Gln Arg Tyr Ser Arg Glu Glu
Leu Lys Asp Ala Gly Val 580 585
590Ala Thr Leu Ala Trp Met Val Ile Met Gly Asp Gly Leu His Asn Phe
595 600 605Ser Asp Gly Leu Ala Ile Gly
Ala Ala Phe Thr Glu Gly Leu Ser Ser 610 615
620Gly Leu Ser Thr Ser Val Ala Val Phe Cys His Glu Leu Pro His
Glu625 630 635 640Leu Gly
Asp Phe Ala Val Leu Leu Lys Ala Gly Met Thr Val Lys Gln
645 650 655Ala Val Leu Tyr Asn Ala Leu
Ser Ala Met Leu Ala Tyr Leu Gly Met 660 665
670Ala Thr Gly Ile Phe Ile Gly His Tyr Ala Glu Asn Val Ser
Met Trp 675 680 685Ile Phe Ala Leu
Thr Ala Gly Leu Phe Met Tyr Val Ala Leu Val Asp 690
695 700Met Val Pro Glu Met Leu His Asn Asp Ala Ser Asp
His Gly Cys Ser705 710 715
720Arg Trp Gly Tyr Phe Phe Leu Gln Asn Ala Gly Met Leu Leu Gly Phe
725 730 735Gly Ile Met Leu Leu
Ile Ser Ile Phe Glu His Lys Ile Val Phe Arg 740
745 750Ile Asn Phe 75584749PRTHomo sapiens 84Met
Ala Arg Lys Leu Ser Val Ile Leu Ile Leu Thr Phe Ala Leu Ser1
5 10 15Val Thr Asn Pro Leu His Glu
Leu Lys Ala Ala Ala Phe Pro Gln Thr 20 25
30Thr Glu Lys Ile Ser Pro Asn Trp Glu Ser Gly Ile Asn Val
Asp Leu 35 40 45Ala Ile Ser Thr
Arg Gln Tyr His Leu Gln Gln Leu Phe Tyr Arg Tyr 50 55
60Gly Glu Asn Asn Ser Leu Ser Val Glu Gly Phe Arg Lys
Leu Leu Gln65 70 75
80Asn Ile Gly Ile Asp Lys Ile Lys Arg Ile His Ile His His Asp His
85 90 95Asp His His Ser Asp His
Glu His His Ser Asp His Glu Arg His Ser 100
105 110Asp His Glu His His Ser Asp His Glu His His Ser
Asp His Asn His 115 120 125Ala Ala
Ser Gly Lys Asn Lys Arg Lys Ala Leu Cys Pro Asp His Asp 130
135 140Ser Asp Ser Ser Gly Lys Asp Pro Arg Asn Ser
Gln Gly Lys Gly Ala145 150 155
160His Arg Pro Glu His Ala Ser Gly Arg Arg Asn Val Lys Asp Ser Val
165 170 175Ser Ala Ser Glu
Val Thr Ser Thr Val Tyr Asn Thr Val Ser Glu Gly 180
185 190Thr His Phe Leu Glu Thr Ile Glu Thr Pro Arg
Pro Gly Lys Leu Phe 195 200 205Pro
Lys Asp Val Ser Ser Ser Thr Pro Pro Ser Val Thr Ser Lys Ser 210
215 220Arg Val Ser Arg Leu Ala Gly Arg Lys Thr
Asn Glu Ser Val Ser Glu225 230 235
240Pro Arg Lys Gly Phe Met Tyr Ser Arg Asn Thr Asn Glu Asn Pro
Gln 245 250 255Glu Cys Phe
Asn Ala Ser Lys Leu Leu Thr Ser His Gly Met Gly Ile 260
265 270Gln Val Pro Leu Asn Ala Thr Glu Phe Asn
Tyr Leu Cys Pro Ala Ile 275 280
285Ile Asn Gln Ile Asp Ala Arg Ser Cys Leu Ile His Thr Ser Glu Lys 290
295 300Lys Ala Glu Ile Pro Pro Lys Thr
Tyr Ser Leu Gln Ile Ala Trp Val305 310
315 320Gly Gly Phe Ile Ala Ile Ser Ile Ile Ser Phe Leu
Ser Leu Leu Gly 325 330
335Val Ile Leu Val Pro Leu Met Asn Arg Val Phe Phe Lys Phe Leu Leu
340 345 350Ser Phe Leu Val Ala Leu
Ala Val Gly Thr Leu Ser Gly Asp Ala Phe 355 360
365Leu His Leu Leu Pro His Ser His Ala Ser His His His Ser
His Ser 370 375 380His Glu Glu Pro Ala
Met Glu Met Lys Arg Gly Pro Leu Phe Ser His385 390
395 400Leu Ser Ser Gln Asn Ile Glu Glu Ser Ala
Tyr Phe Asp Ser Thr Trp 405 410
415Lys Gly Leu Thr Ala Leu Gly Gly Leu Tyr Phe Met Phe Leu Val Glu
420 425 430His Val Leu Thr Leu
Ile Lys Gln Phe Lys Asp Lys Lys Lys Lys Asn 435
440 445Gln Lys Lys Pro Glu Asn Asp Asp Asp Val Glu Ile
Lys Lys Gln Leu 450 455 460Ser Lys Tyr
Glu Ser Gln Leu Ser Thr Asn Glu Glu Lys Val Asp Thr465
470 475 480Asp Asp Arg Thr Glu Gly Tyr
Leu Arg Ala Asp Ser Gln Glu Pro Ser 485
490 495His Phe Asp Ser Gln Gln Pro Ala Val Leu Glu Glu
Glu Glu Val Met 500 505 510Ile
Ala His Ala His Pro Gln Glu Val Tyr Asn Glu Tyr Val Pro Arg 515
520 525Gly Cys Lys Asn Lys Cys His Ser His
Phe His Asp Thr Leu Gly Gln 530 535
540Ser Asp Asp Leu Ile His His His His Asp Tyr His His Ile Leu His545
550 555 560His His His His
Gln Asn His His Pro His Ser His Ser Gln Arg Tyr 565
570 575Ser Arg Glu Glu Leu Lys Asp Ala Gly Val
Ala Thr Leu Ala Trp Met 580 585
590Val Ile Met Gly Asp Gly Leu His Asn Phe Ser Asp Gly Leu Ala Ile
595 600 605Gly Ala Ala Phe Thr Glu Gly
Leu Ser Ser Gly Leu Ser Thr Ser Val 610 615
620Ala Val Phe Cys His Glu Leu Pro His Glu Leu Gly Asp Phe Ala
Val625 630 635 640Leu Leu
Lys Ala Gly Met Thr Val Lys Gln Ala Val Leu Tyr Asn Ala
645 650 655Leu Ser Ala Met Leu Ala Tyr
Leu Gly Met Ala Thr Gly Ile Phe Ile 660 665
670Gly His Tyr Ala Glu Asn Val Ser Met Trp Ile Phe Ala Leu
Thr Ala 675 680 685Gly Leu Phe Met
Tyr Val Ala Leu Val Asp Met Val Pro Glu Met Leu 690
695 700His Asn Asp Ala Ser Asp His Gly Cys Ser Arg Trp
Gly Tyr Phe Phe705 710 715
720Leu Gln Asn Ala Gly Met Leu Leu Gly Phe Gly Ile Met Leu Leu Ile
725 730 735Ser Ile Phe Glu His
Lys Ile Val Phe Arg Ile Asn Phe 740
74585741PRTCynomolgous sp. 85Met Ala Arg Lys Leu Ser Val Ile Leu Ile Leu
Thr Phe Thr Leu Ser1 5 10
15Val Thr Asn Pro Leu His Glu Leu Lys Ser Ala Ala Ala Phe Pro Gln
20 25 30Thr Thr Glu Lys Ile Ser Pro
Asn Trp Glu Ser Gly Ile Asn Val Asp 35 40
45Leu Ala Ile Thr Thr Arg Gln Tyr His Leu Gln Gln Leu Phe Tyr
Arg 50 55 60Tyr Gly Glu Asn Asn Ser
Leu Ser Val Glu Gly Phe Arg Lys Leu Leu65 70
75 80Gln Asn Ile Gly Ile Asp Lys Ile Lys Arg Ile
His Ile His His Asp 85 90
95His Asp His His Ser Asp His Glu His His Ser Asp His Glu His His
100 105 110Ser Asp His Glu His His
Ser His Arg Asn His Ala Ala Ser Gly Lys 115 120
125Asn Lys Arg Lys Ala Leu Cys Pro Glu His Asp Ser Asp Ser
Ser Gly 130 135 140Lys Asp Pro Arg Asn
Ser Gln Gly Lys Gly Ala His Arg Pro Glu His145 150
155 160Ala Asn Gly Arg Arg Asn Val Lys Asp Ser
Val Ser Thr Ser Glu Val 165 170
175Thr Ser Thr Val Tyr Asn Thr Val Ser Glu Gly Thr His Phe Leu Glu
180 185 190Thr Ile Glu Thr Pro
Lys Leu Phe Pro Lys Asp Val Ser Ser Ser Thr 195
200 205Pro Pro Ser Val Thr Glu Lys Ser Leu Val Ser Arg
Leu Ala Gly Arg 210 215 220Lys Thr Asn
Glu Ser Met Ser Glu Pro Arg Lys Gly Phe Met Tyr Ser225
230 235 240Arg Asn Thr Asn Glu Asn Pro
Gln Glu Cys Phe Asn Ala Ser Lys Leu 245
250 255Leu Thr Ser His Gly Met Gly Ile Gln Val Pro Leu
Asn Ala Thr Glu 260 265 270Phe
Asn Tyr Leu Cys Pro Ala Ile Ile Asn Gln Ile Asp Ala Arg Ser 275
280 285Cys Leu Ile His Thr Ser Glu Lys Lys
Ala Glu Ile Pro Pro Lys Thr 290 295
300Tyr Ser Leu Gln Ile Ala Trp Val Gly Gly Phe Ile Ala Ile Ser Ile305
310 315 320Ile Ser Phe Leu
Ser Leu Leu Gly Val Ile Leu Val Pro Leu Met Asn 325
330 335Arg Val Phe Phe Lys Phe Leu Leu Ser Phe
Leu Val Ala Leu Ala Val 340 345
350Gly Thr Leu Ser Gly Asp Ala Phe Leu His Leu Leu Pro His Ser His
355 360 365Ala Ser His His His Ser His
Ser His Glu Glu Pro Ala Met Glu Met 370 375
380Lys Arg Gly Pro Leu Phe Ser His Leu Ser Ser Gln Asn Ile Glu
Glu385 390 395 400Ser Ala
Tyr Phe Asp Ser Thr Trp Lys Gly Leu Thr Ala Leu Gly Gly
405 410 415Leu Tyr Phe Met Phe Leu Val
Glu His Val Leu Thr Leu Ile Lys Gln 420 425
430Phe Lys Asp Lys Lys Lys Lys Asn Gln Lys Lys Pro Glu Asn
Asp Asp 435 440 445Asp Val Glu Ile
Lys Lys Gln Leu Ser Lys Tyr Glu Ser Gln Leu Ser 450
455 460Thr Asn Glu Glu Lys Val Asp Thr Asp Asp Arg Thr
Glu Gly Tyr Leu465 470 475
480Arg Ala Asp Ser Gln Glu Pro Ser His Phe Asp Ser Gln Gln Pro Ala
485 490 495Ile Leu Glu Glu Glu
Glu Val Met Ile Ala His Ala His Pro Gln Glu 500
505 510Val Tyr Asn Glu Tyr Val Pro Arg Gly Cys Lys Asn
Lys Cys His Ser 515 520 525His Phe
His Asp Thr Leu Gly Gln Ser Asp Asp Leu Ile His His His 530
535 540His Asp Tyr His His Ile Leu His His His His
His Gln Asn His His545 550 555
560Pro His Ser His Ser Gln Arg Tyr Ser Arg Glu Glu Leu Lys Asp Ala
565 570 575Gly Ile Ala Thr
Leu Ala Trp Met Val Ile Met Gly Asp Gly Leu His 580
585 590Asn Phe Ser Asp Gly Leu Ala Ile Gly Ala Ala
Phe Thr Glu Gly Leu 595 600 605Ser
Ser Gly Leu Ser Thr Ser Val Ala Val Phe Cys His Glu Leu Pro 610
615 620His Glu Leu Gly Asp Phe Ala Val Leu Leu
Lys Ala Gly Met Thr Val625 630 635
640Lys Gln Ala Val Leu Tyr Asn Ala Leu Ser Ala Met Leu Ala Tyr
Leu 645 650 655Gly Met Ala
Thr Gly Ile Phe Ile Gly His Tyr Ala Glu Asn Val Ser 660
665 670Met Trp Ile Phe Ala Leu Thr Ala Gly Leu
Phe Met Tyr Val Ala Leu 675 680
685Val Asp Met Val Pro Glu Met Leu His Asn Asp Ala Ser Asp His Gly 690
695 700Cys Ser Arg Trp Gly Tyr Phe Phe
Leu Gln Asn Ala Gly Met Leu Leu705 710
715 720Gly Phe Gly Ile Met Leu Leu Ile Ser Ile Phe Glu
His Lys Ile Val 725 730
735Phe Arg Ile Asn Phe 74086120PRTArtificial
SequenceSynthesized 86Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg
Ser Gly Ala1 5 10 15Ser
Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Glu Asp Tyr 20
25 30Tyr Met His Trp Val Lys Gln Arg
Pro Lys Gln Gly Leu Glu Trp Ile 35 40
45Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Pro Thr Phe
50 55 60Gln Gly Lys Ala Thr Met Thr Ala
Asp Thr Ser Ser Asn Thr Ala Tyr65 70 75
80Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95Asn
Val His Asp Ala His Tyr Gly Thr Trp Phe Ala Tyr Trp Gly Gln
100 105 110Gly Thr Leu Val Thr Val Ser
Ala 115 12087113PRTArtificial SequenceSynthesized
87Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly1
5 10 15Asp Gln Ala Ser Ile Ser
Cys Arg Ser Ser Gln Ser Ile Ile Arg Asn 20 25
30Asp Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro
Gly Gln Ser 35 40 45Pro Lys Leu
Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro 50
55 60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
Thr Leu Lys Ile65 70 75
80Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly
85 90 95Ser His Val Pro Tyr Thr
Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100
105 110Arg88120PRTArtificial SequenceSynthesized 88Glu
Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Ser Gly Ala1
5 10 15Ser Val Lys Leu Ser Cys Thr
Ala Ser Gly Leu Asn Ile Glu Asp Tyr 20 25
30Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu
Trp Ile 35 40 45Gly Trp Ile Asp
Pro Glu Asn Gly Asp Thr Glu Tyr Gly Pro Lys Phe 50 55
60Gln Gly Lys Ala Thr Met Thr Ala Asp Thr Ser Ser Asn
Thr Ala Tyr65 70 75
80Leu Gln Leu Ser Ser Leu Thr Ser Gly Asp Thr Ala Val Tyr Tyr Cys
85 90 95Thr Val His Asn Ala His
Tyr Gly Thr Trp Phe Ala Tyr Trp Gly Gln 100
105 110Gly Thr Leu Val Thr Val Ser Ala 115
12089113PRTArtificial SequenceSynthesized 89Asp Val Leu Met Thr
Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly1 5
10 15Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln
Ser Leu Leu His Ser 20 25
30Ser Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Arg Pro Gly Gln Ser
35 40 45Pro Lys Pro Leu Ile Tyr Lys Ile
Ser Thr Arg Phe Ser Gly Val Pro 50 55
60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65
70 75 80Ser Arg Val Glu Ala
Glu Asp Leu Gly Leu Tyr Tyr Cys Phe Gln Gly 85
90 95Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr
Lys Leu Glu Ile Lys 100 105
110Arg904PRTArtificial SequenceSynthesized 90Gly Phe Leu Gly1
User Contributions:
Comment about this patent or add new information about this topic: